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SUMMARY
This thesis is concerned with the development of a 
marketing decision support system (MDSS) assisting in 
the allocation of the marketing budget to market 
segments, products, and promotional tools. The concept 
is illustrated using a case example of a US company 
operating in the UK ethical pharmaceuticals market with 
emphasis on marketing to general practitioners.
The thesis is testing approaches to segmenting the GP 
market, which subsequently lead to the identification 
of seven market segments. The response to sales force 
effort, advertising and direct mail is then 
subjectively estimated for each product and market 
segment. When the estimates are transformed into a 
mathematical expression, a model is developed which, 
when optimised, leads to the allocation of the 
marketing budget.
This thesis aims to contribute to the marketing 
literature in two ways. Firstly, it attempts to extend 
work by Doyle and Saunders (1985) to link segmentation 
and implementation - allocation of the marketing budget 
in this case. Secondly, it aims to add to the body of 
decision support research by including the allocation 
of resources not only to products and promotional tools 
but also to market segments.
1Chapter 1 INTRODUCTION
Marketing decision making has become much more 
sophisticated since availability of data for decision 
making is ever increasing in the late 1980s. Not the 
lack, but the utilisation of the wealth of data will be 
a problem as Little (1987, p.25) observed.
Consequently, growth of model assisted decision making 
in the marketing area can be observed, for which Lilien 
and Kotler (1983, p.xv) stated five reasons:
1. The increased development of marketing decision 
support systems. These combine models with 
increasingly more accurate data.
2. Many more quantitative MBAs are becoming managers. 
They have the skills and desire to use such 
models.
3. Marketing theory is improving in its ability to 
explain the phenomena observed.
4. Implementation of marketing models is more widely 
reported and lessons may be learnt from their 
application.
5. Marketing budgets continue to rise, so that models 
support the manager's desire for increased 
productivity.
While the last point is not necessarily true across 
industries, one important factor for the increased 
utilisation of models needs to be added. The 
penetration of personal computers has made the use of 
marketing models much more convenient for the decision 
maker (Little and Cassettari 1984, p.46). The 
application of software such as Lotus 1-2-3 has eased 
the barrier by making managers hands-on users of 
computers. This increases their desire to use or even 
to develop models.
This thesis aims to link the opportunities presented in 
the availability of data and the advances in model 
building with the development of a marketing strategy. 
It is aimed to develop further the work conducted by 
Doyle and Saunders (1985), who developed a model 
describing the strategic marketing process (figure 
1.1). They linked market segmentation, targeting, 
positioning and the resource allocation problem.
Market segmentation was defined by Kotler (1984, p.252) 
as the act of dividing a market into distinct groups of 
buyers who might require separate products and/or 
marketing mixes, market targeting as the act of 
evaluating and selecting one or more of the market
segments to enter, and product positioning as the act 
of formulating a competitive positioning for the 
product and a detailed marketing mix, including the 
allocation of resources of the marketing budget.
In their previous work Doyle and Saunders (1985) 
implemented the model to the stage of target segment 
identification. It is here intended to develop this 
model further, to include resource allocation to the 
target segments identified.
In consumer markets it is possible to segment markets 
based upon market research studies conducted on quota 
samples (Wind 1978, p.325) of a given population.
Within well defined statistical boundaries it is then 
possible to assume that certain segments in the market 
exist. Following this step the implementation of such 
a segmentation study into proper targeting is very 
difficult indeed. Where are the members of the target 
market and how can they be successfully approached?
Based on the access to a comprehensive commercial 
database - which was compiled to allow accurate 
targeting in the British Pharmaceutical Industry - this 
inherent problem of segmentation in consumer markets 
can be overcome. Since it is feasible to relate the 
findings of a segmentation study based on the database 
back to the other information held on the database.
valuable information on how to approach members in 
certain segments can be extracted. This is even more 
important when, as in the case described here, the 
database covers large parts of the population.
The database available for this work can be treated as 
an example of many new databases which will become 
available in the not too distant future. Developments 
in the credit card area and, at the retail-level, 
developments regarding EPOS or EFTPOS demonstrate the 
likely potential of powerful databases. Availability 
of this kind of data will bring an important link 
between market segmentation, market targeting and 
targeting of the individual buyer in a target market 
segment.
This thesis aims at linking segmentation and targeting 
with the implementation of a marketing strategy. This 
is the allocation of the marketing resources 
(manifested in the marketing budget) to products, media 
and segments. Thus, the work reported in this thesis 
intends to bridge the gap between model building and 
implementation.
Based on a case study in the pharmaceutical industry 
the following hypotheses will be tested.
HI Seq»ent«tion can be used to allocate sales effort
Mind (1978) in his discussion of approaches to 
segmentation refers to a number of bases for 
segmentation and reports a number of applications of 
segmentation as displayed in table 1.1. No reference 
is made to sales applications. This negligence is 
typical of segmentation research. By testing this 
hypothesis it is hoped to contribute to segmentation 
research in discussing the relevance of sales force 
allocation in the context of segmentation.
H2 Such segmentation procedures can be impleawnted in 
practice
The implementation of a successful segmentation 
procedure will often lead to a change in decision 
making (Schulz and Henry 1981). However, the 
implementation of segmentation is neglected in the 
literature (Saunders and Maier 1988), thus it is 
important to report on issues related to 
implementation.
H3 It is possible to define market segments on the 
basis of response to marketing stimuli
Market segmentation aims at identifying groups of 
customers within the market which behave similarly
relative to their buying behaviour. Marketing 
expenditure aims at changing this very buying 
behaviour. In order to allocate the marketing budget 
effectively, groups of customers with similar response 
to marketing stimuli need to be identified. As far as 
the allocation of the marketing budget is concerned, 
the ultimate basis for segmenting a market is dynamic 
behaviour - the response to marketing stimuli.
H4 It is possible to define static segments which 
reflect dynamic behaviour
In terms of implementation, it is rather difficult to 
measure dynamic behaviour. Consequently, a particular 
problem is the availability of data since it obviously 
does require a fairly long time horizon to compile the 
relevant information. Therefore it is often not 
practical to use dynamic behaviour as a direct basis 
for segmentation. This thesis aims at testing whether 
static bases, i.e. based on data collected at only one 
particular moment in time, can be used as a proxy for 
dynamic behaviour and thus can function as a meaningful 
basis for segmenting markets.
7H5 A Model can be used to support the optim u m 
allocation of the Marketing budget across 
products# segments and promotional tools
Budget allocation problems are usually addressed in 
terms of allocation across products and/or promotional 
tools such as advertising, sales force expenditure and 
direct mail. This hypothesis aims at testing whether a 
model can be developed to assist in the allocation of 
resources across previously identified segments, 
products, and promotional tools.
The thesis is divided into ten chapters. Since this 
work is concerned with improving decision making, 
contributions made by research into decision support 
systems form an important foundation for achieving this 
objective. Therefore chapter two reviews marketing 
decision support systems. Particular emphasis is given 
to the components of a marketing decision support 
system and its development process.
Chapter three describes the specific situation upon 
which the hypotheses are tested. The pharmaceutical 
industry is described, the role of the doctor as the 
'buyer' in the prescribing process discussed, and the 
tools highlighted which are available to pharmaceutical 
companies to influence the prescribing process, 
including advertising, sales force and direct mail.
Within this framework a specific case is illustrated 
and the data upon which the subsequent analyses are 
based are described.
Chapter four provides a brief review of the literature 
on market segmentation. Due to the hybrid situation in 
the market under examination, approaches to 
segmentation in industrial and consumer markets are 
illustrated.
Chapter five reports the results of an approach to 
dynamic, or response based, segmentation. It is 
explained to segment the market according to similarity 
in response to marketing stimuli over time. Based on an 
outline of the methodology, the results of the approach 
to response based segmentation are discussed.
Chapter six reports the results of an approach to 
static market segmentation. Based on the outline of 
the methodology, results of what are called macro­
analysis and micro-analysis are reported and validated.
Chapter seven creates the foundation for developing a 
model allocating resources to products, segments and 
promotional tools. The literature on marketing 
decision models is reviewed to identify approaches to 
solving the problem identified in this case.
Chapter eight presents the application of a model 
allocating resources - the marketing budget - to 
segments identified previously, to products and to 
promotional tools. Based on the model specification, 
parameterisation and optimisation are explained. The 
findings are displayed and discussed.
In chapter nine, issues related to implementing the 
findings are addressed. Implementation is discussed 
according to the three main streams of this thesis: 
market segmentation, targeting and budget allocation.
The role of chapter ten is to summarise and to conclude 
on the findings presented in this thesis. Primarily 
the findings are discussed in the light of the five 
hypotheses tested. However, the limitations of this 
thesis are highlighted and areas for further research
identified.
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Figure 1.1 The components of strategic marketing 
(as presented in Saunders and Wong, 1985)
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1
Media Usage 1
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Hybrid ! / •
Table 1.1 Preferred bases for segmentation 
(based on Wind. 1978)
Chapter 2 MARKETING DECISION SUPPORT SYSTEMS (MDSS)
2.1 Introduction
This thesis intends to test the hypothesis H5 which 
states that a model can be used to support the optimum 
allocation of the marketing budget across products, 
segments, and promotional tools.
The decision to allocate the marketing budget in an 
organisation usually lies with the Marketing Director 
or the Marketing Manager. In testing the above 
mentioned hypothesis HS it is important to understand 
the tools currently available to the decision maker.
Increasingly popular in application and academic 
literature have been decision support systems (DSS).
DSS are systems developed to support managers' decision 
making processes in complex and ill-structured decision 
situations (Keen and Scott Morton 1978). Considering 
the complexities of a budget allocation process, a DSS 
could be of considerable value to the Marketing 
Manager.
The function of this chapter is to review the 
literature on decision support systems and, more 
specifically, those related to marketing, marketing 
decision support systems (MDSS). The objective is to
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demonstrate how the work reported here fits in with the 
literature on decision support systems.
The first section is aimed at reviewing the literature 
on OSS. The second section is more specifically 
concerned with the various components of an MDSS and 
how an MDSS is a special form of a decision support 
system.
In the third section some comments are made about the 
importance of more recent developments in the adoption 
of microcomputers in relation to MDSS acceptance. The 
fourth section then discusses development processes 
with the view to a successful implementation of an 
MDSS.
Finally, the conclusions drawn from the literature 
review are summarised and an outlook for future 
development is provided.
2.2 Decision Support Systems (DSS)
Since Gory and Scott Morton (1971) introduced the term 
'decision support system' not much progress has been 
made in ultimately defining what a DSS actually is (Sol 
1987, Keen 1987). However, it is claimed that the DSS 
'movement' has made a major contribution to improve the
performance of information workers through the 
application of information technology during the past 
decade with an even more promising role in the next 
(Sprague 1987).
An important influence to the DSS thinking was Little's 
(1970) introduction of the decision calculus concept.
He defined a decision calculus as a model-based set of 
procedures for processing data and judgements to assist 
a manager in his decision-making. Sprague (1980, p.8) 
called a DSS an interactive computer-based system which 
helps decision makers utilise data and models to solve 
unstructured problems. Keen and Scott Morton (1978) 
developed a widely accepted definition in which they 
emphasised the assistance for managers in semi- 
structured tasks in order to improve the effectiveness 
of decision-making. Alter (1980, p.xi) pointed out the 
importance of a quick response to the changing needs of 
decision-makers.
Numerous authors have contributed their ideas. An 
overview was given by Ginzberg and Stohr (1982). These 
additions have led to the inclusion in the definition 
of a DSS of any system that makes some contribution to 
decision-making with the consequence that the term can 
be applied to all but transaction processing (Sprague 
and Carlson 1982, p.4). This is demonstrated by a 
definition brought forward by Freyenfeld (1984, p.10)
14
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who wanted to apply this term to all decision-making 
and hence excluded the phrase "manager" and replaced it 
by "decision-maker". The majority of authors, however, 
places the decision level at a high level in the 
hierarchy; some put it as high as the chief executive. 
Therefore, it seems to be reasonable to include the 
term "manager" in the definition. The discussion has 
led to some rather critical comments which pointed out 
that DSS is a redundant term and which criticised the 
missing conceptual framework for DSS (Naylor 1982).
In order to attempt a useful definition it is helpful 
to describe the role of DSS in the light of conceptual 
frameworks which preceded the developments of DSS 
namely. Management Information Systems (MIS) and 
Operational Research/Management Science (OR/MS).
Keen and Scott Morton (1978, p.1-2) contributed the 
following distinction:
(a) MIS
The main impact has been on structured tasks, 
where standard operating procedures, decision 
rules and information flows can be reliably pre­
defined. Data are typically used in the context 
of repetitive, routine transport and report 
generation (Bonczek et al 1982). The main payoff 
has been in improving efficiency by reducing costs
(Kleijnen 1984; Carter 1984) and replacing 
clerical personnel.
The relevance tor managers' decision-making has 
mainly been indirect. Cor example by providing 
reports and access to data. Thus the MIS is 
designed to deal with the "overload of 
information" (Holzhauer 1984) and the "management" 
or administration of information (Sizer 1983).
(b) OR/MS
The impact has mostly been on structured problems 
(rather than tasks) where the objectives, data and 
constraints can be pre-specified. The payoff has 
been in better solutions for given types of 
problems. The relevance for managers has been the 
provision of detailed recommendations and new 
methodologies for handling complex problems.
(c) DSS
The impact is on decisions in which there is a 
sufficient structure for computer and analytic 
aids to be of value but where managers' judgement 
is essential. The payoff is in extending the 
range and capabilities of managers' decision 
processes to help them improve their 
effectiveness. The relevance for managers is the 
creation of a supportive tool under their own
16
control, which does not attempt to automate the 
decision process, pre-define objectives or impose 
solutions.
In the absence of a clearly defined conceptual 
framework, with the exception of a trial undertaken by 
Sprague and Carlson (1982, Chapter.2), the term 
decision support system (DSS) shall be used in this 
work to include the following aspects:
- when the objective is to improve the effectiveness
and productivity of managers
- where in an interactive process it assists rather
than replaces managerial judgement
- where it supports decision processes in semi-
structured tasks without automating the process
- when tasks to be solved have several features (Keen
1981, p.3):
- they are non-routine and involve frequent ad hoc
analysis
- they often address "what-if" questions
- they have no correct answers.
With Bennet (1983, p.3) it can be concluded that the 
purpose of a DSS cannot be achieved without impact on 
the process of decision-making and on the behaviour of 
the decision-maker. Recent contributions (Henderson 
1987, Wang and Yu 1987) draw the attention to synergy
between DSS research and the development of expert 
systems.
Stabell (1987) in an attempt to structure the various 
'DSS schools' distinguished four approaches to DSS 
research. Firstly, decision analysis with the focus on 
how to make decisions. Secondly, the decision calculus 
approach with the focus on the decision situation and 
the goal of better decisions through better models of 
the decision situation. Thirdly, decision research 
with the focus on the decision process and the decision 
maker. Fourthly, the school of implementation process 
with its obvious emphasis on implementation issues. 
Stabell (1987, p.250) acknowledged the existence of a 
further, different approach to DSS research with its 
emphasis on DSS technology, including DSS generators 
and design methods.
Table 2.1. summarises the different approaches of the 
various schools and highlights the important aspects 
for the decision calculus approach including repetitive 
decisions and the reference discipline of operations 
research.
These distinctions between the various schools are of 
relevance in the context of this thesis in that Stabell 
(1987, p.246) pointed out for marketing problems the 
particular relevance of the decision calculus approach.
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Consequently, as far as decision support systems are 
concerned, the focus of this thesis shall follow very 
much the 'school' of decision calculus.
To meet the purposes outlined above certain 
requirements for an evaluation (Armstrong and Shapiro 
1974) need to be met. The requirements for a DSS have 
been formulated by Little (1970, p.B-470). He 
suggested that a DSS should be simple, robust, easy to 
control, adaptive, as complete as possible and easy to 
communicate with. By simple is meant easy to 
understand; by robust, hard to get absurd answers from; 
by easy to control, that the user knows what input data 
would be required to produce desired output answers; 
adaptive means that the model can be adjusted as new 
information is acquired; completeness Implies that 
important phenomena will be included even if they 
require judgemental estimates of their effect; easy to 
communicate with means that the manager can quickly and 
easily change inputs and obtain and understand the 
outputs. The importance of the DSS language used is 
stressed by Meador and Mezger (1984).
DSS were introduced in various fields and for various 
applications. An overview was given by Keen (1981). 
First applications occurred in financial planning and 
in marketing, as well as in non-commercial applications
such as police beats and urban planning (Sprague and 
Carlson 1982, p.22).
It is rather difficult to assess the benefits of using 
a DSS. Keen (1981) suggested the use of a value 
analysis rather than the common cost-benefit approach 
since the latter requires an accuracy which can by 
definition not be present at semi-structured tasks. 
However, he cites a few benefits some of which are 
difficult to measure or difficult to quantify: 
increase in number of choices examined 
better understanding of the business 
fast response to unexpected situations 
ability to carry out ad hoc analysis 
- new insights and learning 
improved communication 
control 
cost savings 
better decisions
more effective teamwork; development of group 
decision support systems (Huber, 1984) 
time savings
making better use of data resources.
There is still a discussion whether the use of a DSS 
really leads to "better” decisions. An evaluation of 
judgement-based marketing models was undertaken by
McIntyre (1982) and by McIntyre and Currim (1982, 
p .204 ) . Their findings include that a decision 
calculus model does not improve the ability to estimate 
response functions and that a decision improvement 
(when there is one) is due to a better integration of 
judgements. They concluded that, although that the 
model clearly helped on average, it certainly did not 
help every user to perform better than every non-user.
In a study Fudge and Lodish (1977, p.104) determined 
that a group of employees using a DSS achieved 8.1% 
higher sales than a control group not using it. The 
same authors report other successful implementations 
(Lodish 1981). Other studies (Chakravarti, Mitchell 
and Staelin 1979, 1981) pointed out the limitation of 
ADBUDG, a DSS for advertising budgeting. They 
concluded that decision-making was not improved. In a 
reply. Little and Lodish (1981), pointed out the 
limitations of the study, but agreed that ADBUDG is not 
robust.
There is no final conclusion to this topic but there 
are indications that an improvement in decision-making 
can be achieved mainly due to the benefits gained 
during the model building process, giving decision 
makers insights which are often non-quantifiable.
21
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Therefore, it is no surprise that the market for DSS 
has expanded (Maher 1984). Today's DSS have evolved 
either from financial modelling systems or from 
database management systems (Seils 1982). Systems are 
becoming more sophisticated and are able to handle 
multi-dimensional problems (e.g. systems in the UK 
supplied by Comshare). The lack of a clear DSS 
definition is reflected in the type of DSS packages 
offered on the market. Briggs (1982) counted more than 
70 packages with the spectrum ranging from Visicalc for 
$200 to more sophisticated systems exceeding $200,000.
Keen (1987) was concerned about the balance within the 
term 'decision support system'. He claimed that too 
much effort is actually put on 'support' without 
addressing its strategic implications or on 'systems'. 
For the latter emerging technologies such as document 
based DSS, expert systems, and telecommunications 
should, however, should not be overlooked to avoid 
possible bottlenecks in the progress of DSS 
development.
Keen (1987, p.259) stated that 'decision' defined as 
the nontechnical functional and analytical aspects of 
DSS and the criteria for selecting applications, are 
currently the bottleneck.
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2.3 Marketing Decision Support Systems as DSS
Little (1979a, p.l) defined a marketing decision 
support system as a co-ordinated collection of data, 
systems, tools and techniques with supporting software 
and hardware by which an organisation gathers and 
interprets relevant information from business and the 
environment and turns it into a basis for marketing 
action.
He described a data bank, models, statistics, 
optimisation and communication as the elements of an 
MDSS. In the data bank, the data on major marketing 
variables such as sales, advertising, price and 
promotion in a sufficient detailed form are provided. 
Models represent the behaviour of the real world 
phenomena. Those of interest here find explicit 
mathematical and computational representation. A 
classification of different models was provided by 
Zoltners (1981). He distinguished descriptive models, 
which attempt to provide detailed and accurate 
representation of the marketing phenomena under 
investigation; predictive models, which are concerned 
with forecasting outcomes of specific marketing 
decisions, plans and events; and also normative models 
which provide a basis for choosing a good, possibly 
even optimal, strategy from among alternative courses
of action.
24
While Naert and Leeflang (1978, p.42) foresaw that 
future models will be of the predictive and 
descriptive, rather than the normative variety,
Zoltners (1981, p.68) pointed out the advantages of 
normative models. These are:
significant opportunities may be overlooked when 
not looking for the "optimal" solution
- loss of credibility for the model builder if a 
better solution emerges without the use of the 
model
without optimisation it is meaningless to perform 
sensitivity analysis or "what if" questions
- optimisation allows the tracking down of input 
errors.
There are several drawbacks with the use of normative 
models:
- reality may be too complex to be incorporated in a 
model or the model might be an imperfect 
representation of the real world
they tend to preclude the incorporation of 
managerial judgement
the user might feel uneasy with the model produced 
solutions, especially if he does not trust the 
model.
There has to be a trade-off between the validity of the 
model and its acceptability. On the one hand the model 
will lead to better decisions if it represents all real 
world phenomena and on the other it should be used. 
Since managers like to be in control of their decisions 
they are less likely to accept a model that produces 
optimal solutions. Therefore, descriptive and 
predictive models might be more easily implemented in a 
managerial context.
Statistics are the third component. The relation of 
models to data shall be called statistics.
Manipulations such as aggregation, grouping and 
comparisons are handled in this section. Optimisation 
applies to all cases when a manager tries to improve 
the performance of the company. This can be done by 
formal management science methods such as linear 
programming. The fifth component is the interface 
between manager and system. Tools have to be provided 
to assure an effective and efficient communication.
This relates to input as well as to outputs such as 
reports (Little 1979a, p.10).
There are several problematic aspects of the marketing 
system which make it difficult to predict the market 
response to variations in the marketing effort (Lilien 
and Kotler 1983, p.6).
(a) Sales response to a single marketing 
instrument
The relationship between the market's response and 
the level of marketing input is typically unknown. 
It is a challenging task to summarise the 
behaviour of individual buyers at various stages 
of awareness, interest and intention into a 
measure of total sales response.
(b) Marketing-mix interaction 
Marketing effort such as pricing, personal 
selling, advertising, sales promotion or product 
development has to be combined in a sound mix. 
There is great uncertainty about the separation of 
joint effects. The result of a variation of any 
one of the elements is difficult to measure.
(c) Competitive Effects
The market's response is related to the 
competitors' efforts as well as to the company's 
own efforts. It is difficult to foresee the moves 
of competitors.
(d) Lagged Response
The response to marketing effort is, in most 
cases, not immediate, but occurs in a later time 
period than the initial expenditure. The carry­
over effects create a problem in the timing and
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distribution ot marketing expenditures over a 
planning horizon.
(e) Multiple Territories
Typically there is a different rate of response to 
marketing effort in each territory a company is 
operating in. It is difficult to assess the 
allocation of expenditure to territories due to 
the question of whether to spend in areas in which 
the firm is already doing well or in others which 
require development.
(f) Multiple Products
The allocation of limited funds to a range of 
products is another problem. The marketing 
strategy has to take into account the interaction 
among products. For example the raising of price 
for one product might lead to an adverse response 
for another.
(g) Functional Interactions
There is a need for joint decision-making in the 
areas of marketing, finance and production. If a 
demand created by promotional programmes cannot be 
satisfied due to restrictions in production this 
can lead to an adverse response of the market.
The same is true with the co-ordination between
finance and marketing, i.e. in the case of product
innovation failure.
In the light of the problems described above it is 
obvious that it is a very ambitious task to model all 
the relevant aspects in marketing decisions. This is 
documented in the fact that most models developed so 
far concentrate on specific aspects of marketing 
decision making. There are rarely any complete models 
available and, if so, their usefulness has to be 
questioned. Therefore, some authors argue that caution 
is necessary in the use of models (Troll 1983).
Others (e.g. Friesenwinkel 1984) point out that certain 
limitations should not prevent model building since a 
new insight into the inter-dependencies of decision 
variables is provided.
Weinberg and Montgomery (1973, p.26-28) discuss three 
uses of models in marketing. Firstly, as an aid in 
exploring the anticipated consequences of a broad range 
of decision alternatives. Secondly, some models 
provide a built-in ability to search for decision 
alternatives and finally the use of models allows the 
consideration of what might otherwise be politically
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unmentionable
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2.4 MDBS and the Microcomputer
The experience gained with the use of DSS has led to an 
increasing number of DSS-applications. Especially, 
with the evolutionary process of the microcomputer 
which has enhanced the use. Treacy (1985) gives an 
overview of the shift in hardware for DSS to the 
personal computer.
When, in the early 1970s, Montgomery et al (1971) 
reported the use of an interactive computer system on 
which they ran their DSS, this was supposed to be an 
exception. At that time most data processing systems 
were centrally located, and batch processing was the 
state of the art, making it very difficult for a 
manager to use it for decision support.
A DSS will only be used when the manager has easy 
access to it. With the evolution of distributed data 
processing it became easier to access a computer.
During recent years the microcomputer has become a 
common tool for managers (Lewis 1984).
This widespread and rapidly expanding diffusion has 
changed the way managers think about computers in 
general (Meador et al 1984, p.117). They are more pro­
active in their interest and less resistant to the idea 
that they themselves can be "hands on" users. They
hear about software tools like Visicalc or Lotus 1-2-3 
that make it easy for computer novices to begin 
building models and incorporating more quantitative 
analysis approaches into their planning and decision­
making.
In addition to the change in attitude the increase in 
power of microcomputers enhanced the use of DSS. 
Microcomputers can handle tasks that were thought of as 
only feasible by use of a mainframe. Healy (1983) 
draws a very optimistic picture of the opportunities 
for microcomputers. However, even if in disagreement 
with his view, the increasing capacity of micros has 
broadened their utility significantly. Today it is 
possible to run versions of mainframe DSS on a micro.
Additionally, there are opportunities to connect the 
micro to a mainframe (Ferris 1983). Thus, the 
advantages of a mainframe, namely data administration, 
overall intelligence about the distributed complex, 
high powered computation, and storage of the master 
data bases, are combined with the easy, distributed and 
independent access to the micro (Crandall 1983, p.19).
The linking of micros to networks offers new 
opportunities too. Nevertheless, there are still quite 
a few difficulties, concerning data formats, etc., to
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overcome, but the problems should be solved in the 
foreseeable future. (Little and Cassettari 1984, p.46)
In a survey Higgins and Opdebeeck (1984, p.251) found 
that the microcomputer is not to replace the mainframe, 
but is rather used for ad hoc modelling at all 
management levels, for independent modelling purposes 
which do not rely on a central data base, and for 
certain top management confidential data manipulation.
Vandermerwe and Carney (1987) found in a European 
survey that 74% of marketing executives were daily 
users of PCs. They concluded that this high usage rate 
demonstrates a good potential for future applications 
in the MDSS area provided that the users are better 
involved in the initial planning stages of an MDSS.
2.5. The MDSS Developatent Process.
Case studies provide evidence that the actual uses of 
DSS are almost invariably different from the intended 
ones (Keen 1980). Consequently, it has been pointed out 
that "adaptive” design and development is important to 
a successful implementation of a DSS (Meador et al 
1984, p.118). Keen (1980, p.15) stressed the following
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reasons:
- the designer or user cannot provide functional 
specifications
the user's concepts of the task or decision 
situation will be shaped by the DSS which in turn 
is shaped by the user
He concluded that an initial system must be built 
quickly to give the user something upon which to react.
A flexible DSS may not only allow personalisation as 
far as the user is concerned but may also provide a 
variety of options which are particularly desired by 
risk-averse users (Zinkham et al 1987).
A study (Alavi and Henderson 1981, p.1320) supported 
the hypothesis that an evolutionary implementation 
strategy is more effective than a traditional strategy.
How a successful implementation can be achieved shall 
be described by examining different steps of the model 
building process. The second section shall relate the 
theoretical view to the steps actually undertaken and 
shall specify the requirements that have to be 
fulfilled by an MDSS to be implemented.
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There is an overall agreement in the literature that 
the development process is crucial to the success of a 
DSS. In an empirical study Ginzberg (1979) showed that 
success in implementation efforts is positively related 
to the implementation process. The importance of user 
involvement is stressed in the literature (i.e. Meador 
et al 1984). In a survey Alter (1978) detected that 
only in less than one quarter of the cases in his 
sample the systems were initiated and implemented with 
the user's active participation. However, Mann and 
Watson (1984) argued that user involvement can vary 
according to DSS technology, the management activity 
and the nature of the task interdependence.
There are numerous approaches to the implementation 
process. A discussion can be found in Schultz and 
Henry (1981). One example of the development process 
shall be explained in more detail. The overall flow of 
the process formulated by Urban (1974) is described in 
figure 2.1. This process was used as a guideline for 
implementation of many DSS. It is important to 
understand the single steps as being iterative rather 
than treated in isolation.
a) Formation of priors
The model builder needs to have a tool kit of OR/MS and 
statistical techniques, as well as a number of
alternative model building approaches, so that he/she 
can effectively solve problems. It is important that 
the problem leads to decision models and not that the 
problem is forced to fit the technique. This approach 
is quite difficult to achieve since every model builder 
has his or her priors and is biased towards one 
approach without realising it. However, the model 
builder should consider a range of general models that 
could contribute to the real problem area in order to 
make an effective entry.
b) Entry
It is recommended that entry is made at the decision 
point to work with the decision level as soon as 
possible. The managers are required to understand 
modelling vocabulary and at best get some hands-on 
experience with models. The team has to be set up and 
commitment of time, personnel and resources is crucial 
to the success of the project. The importance of top 
management support has been pointed out by several 
authors (e.g. Sanders and Courtney 1985, p.87).
c) Problem Finding
In order to avoid having to solve a problem that does 
not exist, substantial effort is needed to define a
problem correctly. Among other aspects Urban (1974, 
p.5) suggests carrying out studies to determine:
- existing models or rules of thumb
the characteristics of the decision making process 
the existing flow and usage of information 
the stated and apparent goals of the organisation 
the information and formal organisation structure 
managers' definitions of their perceived problems
- the basic issues underlying current crises.
After the assessment of the situation a single project 
should be selected. It has to be simple, visible and 
significant in order to achieve a solution, gain 
recognition and provide a basis for future work.
d) Specification of model development criteria
First a decision has to be made whether the model is 
descriptive, predictive or normative. A specification 
of criteria relating to model's purpose and scope 
should be set. This has to be done in addition to the
criteria set by Little (1970) which have been explained 
in section 2.2.
e) Model Building
The actual model building is considered to be a kind of 
art. According to the problem and the criteria, the 
market characteristics are modelled. An iterative 
process is necessary until the characteristics are 
modelled correctly.
f) Estimation and Fitting
Data for model building can come from past data, 
subjective estimation or experimentation. Accordingly, 
empirical and subjective (Naert and Weverbergh 1981) or 
judgement-based (La Forge and Cravens 1985) models are 
distinguished.
In many cases past data are not available or neither 
the quality nor the quantity of past data is 
sufficient. Experimentation is in many cases too 
costly. Thus, subjective estimation is often the only 
way to produce data. This is especially true in 
marketing, where responses to marketing tools can often 
just be judged. See Saunders (1985) for a detailed 
description of the use of subjective estimation.
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g) Tracking.
Tracking is a method where past data are used to test 
whether the model meets actual results. The analysis 
of differences in the outcome provides an insight into 
the causes such as errors in the forecasting inputs, 
inappropriate parameter estimates, incorrect model 
structuring or random variation.
The analysis of differences, therefore, is important to 
the manager and leads quite often to the specification 
of new models or data needs. The aim is to establish 
the model's validity.
h) Continuing Use
With continuing use, tracking increases managers' 
confidence in the DSS and usually leads to elaboration 
and evolution. The model also needs to be updated in 
order to meet the changes in the environment. Training 
and maintaining commitment are necessary, especially 
when staff changes occur.
Taking this description of the model building process 
it is obvious that much time and effort has to be spent
on other issues than the actual formulation of the 
model.
2.6 Su— ary
As far as this thesis is concerned, it is the objective 
to test the hypothesis that
'A model can be used to support the optimum 
allocation of the marketing budget across 
products, segments and promotional tools'.
The budget allocation process is a semi-structured 
task, hence an area for which decision support systems 
might be suitable.
This chapter has looked at NDSS as a special form of a 
decision support system. DSS's objective is to assist 
rather than to replace managerial judgement. This is 
of particular importance in marketing due to complex 
and often inter-related decisions especially with 
budget allocation decisions. The applications of MDSS 
have increased in recent times due to the advent of the 
microcomputer. Suddenly decision makers themselves 
have access to, and are gaining the experience with, 
computers. Standard packages such as Lotus 1-2-3 allow 
the assessment of "what if?" questions and ease model 
building.
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Following the 'DSS school' of decision calculus the 
development of models is the focus of this thesis. 
However, the use of models does change the behaviour in 
decision making. Hence, resistance to change should 
not be underestimated. Therefore, particular care is 
required in developing marketing decision support 
systems.
For the future Little and Cassettari (1984 pp 45-47) 
predicted:
An increase in the amount of data used. MDSS will 
have to be able to support the decision making in 
a time in which the amount and quality of data are 
ever increasing (EPOS, panel information).
A dramatic increase in computer power which will 
enable more complex analysis. The development of 
new computer languages as well as expert systems 
will create a shift from analysing the market 
status to market response reporting.
The use of the microcomputer enabling the decision 
maker to become hands-on user.
The development of local area networks (LANs) 
linking micros with mainframes will increase the 
utility of MDSS.
Changes in management style will be possible, 
enabling managers to have a much deeper 
understanding of the responsiveness of their 
market. This will lead to a more creative 
approach to marketing since new ideas will be 
tested immediately.
Figure 2.1 DSS development process (Urban 19741
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Chapter 3. BACKGROUND TO THE CASE
3.1 Introduction
In the previous chapter the elements of an MDSS have 
been explained. In this chapter the objective is to 
highlight the importance of an MDSS in the UK 
pharmaceutical market and to provide the background to 
the case upon which the work reported here is based. 
Strong Governmental regulations have culminated in a 
unique market situation in the UK. Thus, to outline 
the environment in which the MDSS is to operate, the 
pharmaceutical market in the UK is described.
Particular emphasis is given to ethical pharmaceuticals 
prescribed by General Practitioners (GPs).
The first section comprises an analysis of factors 
influencing the supply and demand for drugs. Then, in 
the second section the prescribing process of 
individual GPs is related to research into buying 
behaviour. The tools available to pharmaceutical 
companies to influence the prescribing process are 
outlined in the third section. The fourth section is a 
brief discussion of findings about the effectiveness of 
the various promotional tools. The fifth section 
describes a case and the underlying problem. The sixth 
section is dedicated to explaining the kind of data 
used to conduct the research reported here. Finally, in
the last section, the main findings of this chapter are 
summarised and related to the aim of developing an MDSS 
for the pharmaceutical industry.
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3.2 The Pharmaceutical Industry
The pharmaceutical industry in the UK is one of the 
rapidly growing sectors of the British manufacturing 
industry. With an average growth rate of 4.9% between 
1970 and 1982, the growth in the industry was 
considerably higher than in the chemical industry and 
in the manufacturing industry as a whole (Jordan's 
Report 1984, p.2). Since the early 1980s the industry' 
production has grown by some fourty per cent (ABPI 
1988, p. 4). To explain the forces in this successful 
industry, supply and demand factors are explained and 
the lines of communication in the industry described.
3.2.1 Supply Factors
3.2.1.1 Market Size
With 3.5% of the world market for human pharmaceuticals 
the UK pharmaceutical market ranks sixth in the world. 
In the UK production was £4.283 billion in 1987, of 
which 39% was exported. Imports amounted to £856 
million (Business Monitor 1988).
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3.2.1.2 Market Segments
The pharmaceutical market can be divided into segments 
Cor veterinary products and Cor human medicine. The 
latter segment can be split into the ethical drug 
market - medicine that is available on prescription 
only - and into the over the counter market (OTC- 
products), products that are available without a 
prescription. 80% oC sales in the UK are accounted Cor 
by the National Health Service (NHS).
In 1948 the NHS came into existence. It extends to all 
residents, irrespective oC age, sex, and contribution 
to the scheme. Thus, economic barriers Cor reception 
oC health care are removed (Pradham 1983, p.199).
The NHS market Cor prescription drugs has three 
components. The segment oC general practitioners 
accounts Cor 75%, hospital sales Cor 21% and dispensing 
doctors Cor 4% oC the total (Jordan's Report 1987, 
p.ll).
The traditional prescription market is diCCerent to 
other markets in that the Cinal customer is not making 
the buying decision and is not paying Cor it either.
The decision to "buy" the drug is made by the doctor.
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while the NHS pays to r it. There is no direct 
relationship between the seller and the final customer.
Taylor (1983, p.15) identified four sets of factors 
which distinguish the prescription market from any 
ordinary market situation. Firstly, the utilisation of 
third party payment (i.e. state or insurance company). 
Secondly, the "agency" relationship. Required by law 
or due to a lack of knowledge, sick people need to 
appoint a doctor or a pharmacist as their agent and 
will follow his or her advice relatively uncritically. 
Thirdly, the emotional response of a sick person to 
those who provide care will be quite different from any 
other buying situation. Fourthly, intervening forces 
such as laws and professional and voluntary codes mean 
that the medical market is removed from any simple type 
of free market.
The complex relationships are summarized in figure 3.1. 
This diagram indicates the interaction of the health 
care consumer, the doctor and the medicine producer 
considering the involvement of Government, wholesalers, 
pharmacists and professional bodies. It is obvious 
that the doctor as the decider and the Government, 
responsible for the payment, are not involved in the 
flow of the product. Flow of information and the 
"agency" relationship are well illustrated in the 
diagram.
In order to cope with increasing costs in the health 
sector in 1983, and more dramatically in 1985 the 
government took drastic steps: it introduced 'the 
limited list', a listing of those products Cor which 
re-imbursement by the NHS is provided. Consequently, a 
new segment has evolved; the segment of products that 
are available on prescription only but have to be paid 
Cor by the consumer. This segment can be called the 
"private prescription market". OTC-products in turn 
are being paid Cor by the Cinal consumer, without the 
involvement oC doctors and the Government. Figure 3.2 
describes the pattern oC the three major segments.
Supported by a general trend toward selC medication and 
an increase in private health insurance, an increasing 
involvement oC the Cinal customer leading to a more 
cost conscious buying behaviour, can be expected. Thus, 
shiCts will include growth oC the OTC-market and the 
segment oC the private prescription market. (Jordan's 
Report 1987, p.5).
As is later described in section 3.5, the problems 
addressed in this thesis primarily relate to the 
ethical drug market. The emphasis shall be on the 
segment oC GPs as the biggest segment in the Ok's 
ethical drug market.
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3.2.1.3 Competition
Many companies in the pharmaceutical industry operate 
on a worldwide basis. Hence, economy of scale effects 
can be achieved in recovering large investments In R t 
D projects. Periods of ten to twelve years for the 
development of a drug are common and require an 
investment of between £50 and £100 million (ABPI 1985, 
p.17). In 1983 Hoechst AG as the largest drug company 
had a worldwide turnover of $2.55 billion while the 
fifteenth largest, Takedo, achieved $1.3billion (The 
Economist 1985, p.75). This relatively small 
difference indicates that there is no one single 
company which controls the world market.
These international companies compete with hundreds of 
smaller companies in each country. For example in the 
UK Chew et al (1985) counted two hundred and twelve 
companies. The smaller companies usually serve only 
certain niches in the market. It was observed that the 
concentration within the industry, measured as market 
share of leading companies, has decreased. This 
observation is also made in Germany, Switzerland and 
the UK (Sole 1980, p.83; Slatter 1977, p.47).
In 1983 the eighty-five major pharmaceutical 
manufacturers in the UK accounted for ninety-five 
percent of prescription sales. Sixteen of these
companies were British owned, thirty-six US owned and 
thirty-three European (Jordan's Report 1984, p.l).
The low concentration in the total market is not true 
for all segments of the market. For example, Beecham 
with approximately 5% total market share is assumed to 
hold a 90% plus share of the broad spectrum penicillin 
market (Jordan's Report 1984, p.ll). This example shows 
that effectively competition can be fairly limited in 
certain product markets.
On the other hand, shifts in the ranking of leading 
companies indicate that It is quite difficult to 
maintain a leading position over a long period of time. 
These shifts are taken as an indication of a strong 
competition within the industry (ABPI 1984, p.37-41). 
The Association of the British Pharmaceutical Industry 
has obviously an interest in demonstrating the fierce 
competition in the industry, which will enable a better 
position in negotiating prices and terms with the 
Government.
3.2.1.4 Barriers to Entry
Legislation, patents, cost of research and 
development, and product differentiation create 
barriers to entry in the industry.
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a) Legislation
As well as consistent quality control, licensing 
arrangements are subject to legislative influence 
(Hauptmann and Roberts 1985). The introduction of a 
new product is time consuming and costly due to the 
number and kinds of tests that are required (Martin 
1981, p.46-56). Smaller companies may find it 
difficult to compete under the strict regulations.
b) Patents
With the Patents Act from 1977 the patent life in the 
UK was extended from sixteen to twenty years. During 
this period the firm which invents a new product is 
protected against generic copying and can recover the R 
♦ D investments. After the expiration of a patent 
generics, products using the same substances as the 
original product, can be introduced by competitors. 
These companies do not have to recover high R ♦ D 
investments and are consequently able to offer the drug 
at a much lower price, imposing a major threat to the 
original manufacturer.
c) Research and Development
It is essential for many companies to develop new 
products themselves in order to obtain patent
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protection, allowing for higher margins. Only multi­
national companies are in the position to pay for basic 
research. Smaller companies are forced to channel 
their efforts into areas where a high probability for 
success is provided.
In recent years the sustained growth in research and 
development expenditures to £490 million in 1984 (ABPI 
1985a, p.16) and to £668 million in 1987 (ABPI 1988, 
p.15) has not been accompanied by the launch of new 
products (Wells 1983, p.8). Steward and Wibberley 
(1980) found that the number of the most innovative 
introductions, new chemical entities (NCEs), is halved 
to 20 per annum compared to the 1960s. This trend has 
also been observed in most other countries (Rigoni et 
al 1985, p .18).
d) Product Differentiation
Brand names provide a unique identification of a 
manufacturer's products. Therefore, the reputation of 
a manufacturer is linked to the perceived quality of 
the medicine, creating goodwill. From a marketing 
point of view the aim is to create a monopoly type 
situation in a segment in order to exploit the benefits 
of a differentiated product compared with generics.
Brand names play an Important role once the patent has 
expired. Then the reputation of the brand is the only 
shield against "branded generics", generics marketed 
under brand names, and "pure generics", which are 
marketed under the officially approved chemical name. 
Both types will usually be sold at a much lower price 
than the branded products.
3.2.2 Demand Factors
Not surprisingly, the aggregate demand for ethical 
pharmaceutical products is primarily dependent on the 
size and the composition of the population, the 
standard of living and the incidence of disease 
(Slatter 1977, p.21).
Additionally, demand is dependent on the economic and 
political environment. In particular, the kind of 
social security system influences the level of demand. 
Chew et al (1985, p.36) compared the systems in seven 
nations. In the US, for example, only 50% of the total 
population is covered by publicly funded health care 
schemes. The other half is either covered by private 
schemes or is required to pay directly. This situation 
obviously leads to a much more price conscious 
prescribing behaviour as opposed to a system as in the 
UK, where overall ninety-four percent of the cost of 
medicines is reimbursed. The demand for
pharmaceuticals in a country is consequently dependent 
on the degree of reimbursement allowed under the 
national security system.
Clearly, these factors are outside the control of 
pharmaceutical manufacturers, but a manufacturer can 
influence demand by developing new products in order to 
meet latent demand.
Por the market in the UK, important factors influencing 
demand are the role of the NHS and the prescribing 
doctors. These factors will be described in this 
section.
53
3.2.2.1 The influence of the NHS
In the UK forty-five percent of production is paid for 
by the NHS (Jordan's Report 1987, p.4). Since the 
expenses of the NHS have increased from £2,046 million 
in 1970 to £17,327 million with pharmaceutical services 
accounting for 9.8% in 1984 (ABPI 1985a, p.40), the NHS 
has tried to restrict the level of demand. Slatter 
(1977, p.23) called this policy "counter promotion".
Activities include the monitoring of doctors' 
prescribing habits, with the threat of imposing 
disciplinary arrangements if cost standards are not 
obeyed. Attempts have been made to inform doctors
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about opportunities of using cheaper generics instead 
of branded products. Since the doctor's independence 
is one of the basic principles built into the National 
Health Act of 1946, the efforts of the NHS in this 
respect have to be limited.
However, the NHS is in a strong position to negotiate 
prices. This is documented in the imposition of a 
price reduction by 2.5% and a price freeze until April 
1984 in June 1983 (ABPI 1984, p.10). On the other 
hand, the bargaining power of the NHS is limited, since 
the existence of a competitive industry earning 
"normal" profits is in the public interest. With a 
surplus of 680 million in 1984 (ABPI 1985b, p.ll) and 
of 835 million in 1988 (ABPI 1988, p.10), the 
pharmaceutical trade balance was a major contributor to 
the balance of trade.
The pricing policy is further controlled by the setting 
of a target for the rate of return in the industry of 
twenty-one percent. Additionally, under the terms of 
the Pharmaceutical Price Regulation Scheme (PPRS) the 
spending on promotion is limited to 9% of sales (APBI 
1985a, p.8). Any overspending has to be paid directly 
to the government, in addition to being added onto 
profits. This affects especially smaller companies 
which might find it difficult to employ a sufficient
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number of medical sales representatives to visit their 
target group of doctors (Chew et al 1985, p.42).
3.2.2.2 The Influence of the Doctor
In the marketing of ethical pharmaceuticals the doctor 
is in the centre of the supply (industry) and demand 
(patient) interrelationship. He or she is the decision 
maker. Therefore, it is important to examine the 
factors that determine this decision. At this stage 
only a broad overview will be provided, the next 
section examines doctors' prescribing behaviour in more 
detail.
It can be assumed that the physician's decision to 
prescribe a product is led by the search for the 
superior product. Sole (1980) distinguished subjective 
and exogenous factors which influence the decision; 
subjective factors such as age, experience, scientific 
interest, etc. Exogenous factors include the kind of 
illness and the features of the product. Depending on 
the diagnosis, the doctor will prescribe the 
appropriate drug at the appropriate doses.
Additionally, any inconveniences that have occurred 
during the previous therapy are taken into account.
Since the doctor's reputation is dependent on his/her 
success, it is important that the expectations toward a
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product are met. Usually, a medicine with which the 
doctor has experience will be chosen. In general, the 
prescription behaviour is best described as risk
Other factors influencing the decision are, for 
example, the status of the patient (NHS or private 
insurance), the prescribing habit of colleagues, 
information provided in journals and by the industry.
O'Brien (1984, p.12) found that the remuneration policy 
has an impact on the prescribing policy of a doctor.
He detected the highest average number of prescription 
items in countries where the doctor is paid on a "fee- 
for-service basis." Whereas in countries such as the 
Netherlands, Denmark or the UK the doctor is paid on a 
capitation principle and subsequently the lowest 
average prescription items are observed.
Although the emphasis in prescribing medicines is on 
performance, emotional appeals should not be ruled out 
completely. Smith (1975, p.66) described the 
relationships between the rational and emotional in 
physicians' motivation. Despite the rational self 
image of doctors, the image of a company plays an 
important role in their decisions. In this context 
Simon (1985, p.44) pointed out the role of goodwill as 
a barrier to entry for competitors.
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3.3 The Prescribing Process
The focus in this section is on the examination of 
buyer behaviour at the micro level, taking an 
individual GP as the object under study. Since Doctors 
prescribe as individuals rather than as groups, it is 
reasonable to explain the behaviour according to the 
models developed to describe consumer behaviour. Where 
necessary the model is extended to incorporate elements 
that are unique to the GP market.
Findings of research into diffusion processes as far as 
the adoption of new drugs is concerned are related to 
GP's prescribing process in the second part of this 
section.
3.3.1 Prescribing related to Buying Behaviour Theory
Consumer buyer behaviour is classified according to the 
extent of involvement required. Involvement shall be 
defined with Engel and Blackwell (1982, p.24) as "the 
activation of extended problem-solving behaviour when 
the act of purchase or consumption is seen by the 
decision maker as having high personal importance or 
relevance".
They made the distinction between low and high 
involvement processes for consumer markets. The high 
involvement purchase decisions occur on fewer 
occasions. For example, the decision to buy a car.
Low involvement decisions are for example, the decision 
to buy a certain dairy product. The process and the 
implication for a marketing strategy differ strongly 
between low- and high- involvement decisions. A high 
involvement process involves extensive problem solving 
and consequently, requires search for and use of 
information.
Howard and Sheth (1969, p.27), however, classified 
repetitive decision making into three stages: (1) 
extensive problem solving, (2) limited problem 
solving, and (3) routinised response behaviour. 
Extensive problem solving refers to situations in which 
the doctor has not yet developed well-defined and 
structured choice criteria. Limited problem solving is 
required when the choice criteria are structured but 
where a strong preference for a single brand is absent. 
Routinised behaviour occurs when the choice criteria 
are well defined and structured and the doctor has a 
high predisposition toward one or two brands.
Prescription serves psychological and social needs of 
GPs such as earning approval for giving good patient 
care (Haayer 1982, p.2022). Therefore, the decision to
prescribe a drug requires a high involvement on the 
part of the doctor. The risk involved and the 
dependency of a GP's reputation on making correct 
decisions explain this assumption.
However, there are cases, especially with a low degree 
of risk involved, in which limited problem solving or 
even routinised prescription behaviour can be assumed. 
In order to include the most complex decision situation 
the process of high-involvement with extensive problem 
solving is described.
In the absence of a definite empirical verification, 
buyer behaviour is best described using a model. As 
with all models, an attempt is being made to explain a 
process and to specify relationships.
Several models of buyer behaviour have been developed. 
These include the Howard and Sheth models (1969, 1974), 
the Howard model (1977), and the models introduced by 
Engel, Kollat and Blackwell (1968, 1973, 1978), and 
later by Engel and Blackwell (1982).
The Engel and Blackwell model has its emphasis on the 
process of decision making. Since the objective here is 
to describe the process of prescribing, with the view 
to understanding the likely impact of the elements of 
the communication mix discussed in section 3.4, the
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Engel and Blackwell model is chosen to illustrate the 
prescribing process.
Of interest here is the model for high-involvement 
processes (figure 3.3) considering the considerable 
risks involved in prescribing ethical drugs. This 
approach seems reasonable, although work by Stern 
(1987) might indicate a lower involvement of the doctor 
than anticipated or even be required.
The process of drug prescription will be explained 
using the model as a guideline.
a) Problem recognition
In contrast to consumer markets in the GP-market, 
problem recognition is not triggered by a stimulus 
related to the decision maker, but rather by an outside 
stimulus - the appearance of a patient with certain 
symptoms. Recognition of the problem takes place once 
the doctor examines the patient. The doctor's 
perception of a difference between an ideal state and 
the actual state of the patient's health triggers the 
recognition of a problem. It is obvious that a certain 
level of severeness in the perceived difference must 
have been passed before an actual treatment is 
indicated. This threshold effect will vary with the 
kind of illness.
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b) Search
Assuming a decision to prescribe has been made, the 
doctor now turns to the decision on the kind of drug to 
prescribe. Following a search within memory a decision 
might be made immediately. This is the case when a 
certain brand is preferred over others based on past 
experience. Then routinised behaviour can be observed.
In case the internal search does not lead to an 
immediate decision, the doctor will turn to an external 
search, making use of a variety of information sources.
The search process is primarily influenced by memory 
and beliefs. Memory is influenced by a string of 
events. Starting with some sort of ''stimulus", the 
process is triggered. Stimuli are partly in control of 
the marketing manager by means of advertising, 
conferences or sales calls for example. The process 
could also be triggered by a colleague's comment.
The first step is the exposure of the doctor to the 
stimulus. Preliminary information processing takes 
place. A certain degree of attention, allocation of 
information processing capacity to the incoming 
stimuli, is attracted. Comprehension refers to the 
short term memory where the meaning of the content is
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clarified. Due to the limited capacity of short term 
memory the information process is highly selective.
Once the stimulus is comprehended the meaning is 
compared with existing beliefs which are stored in 
long-term memory. If there is compatibility with 
existing beliefs these will be reinforced or changed 
and the message retained in long term memory.
c) Alternative Evaluation
Once the search has been completed, the choices need to 
be evaluated. A comparison with the evaluative 
criteria takes place. The outcome of this assessment 
is the formation of beliefs. This refers to a doctor's 
perception of the various choices compared with his 
standards. This in turn influences the attitude toward 
a product. An attitude is used here as the positive or 
negative evaluation of the prescription of a particular 
product. In case of a favourable attitude the next 
step involves the intention to prescribe the product in 
question.
The relationship between changes in attitude and 
changes in behaviour leaves room for debate. Fishbein 
(1967) concluded that there is little evidence 
supporting the hypothesis that knowledge of an 
individual's attitude towards some object will allow
one to predict his behaviour with respect to that 
object. Engel and Blackwell (1982), however, 
distinguished between low and high involvement decision 
processes. For low involvement processes they 
concluded that a behavioural act is undertaken followed 
by a change in beliefs. In high involvement processes, 
however, they observed an affection of the cognitive 
structure by new information due to the extended 
problem solving. Thus, changes in beliefs and 
attitudes occur, followed by a change in behaviour.
There are arguments for both viewpoints. The 
implication of this discussion is most important for 
promotional decisions. If there was no direct 
relationship between a change in attitude and 
behaviour, spending on promotions would be a needless 
waste.
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d) Choice
In the model choice is the outcome of intentions and 
unanticipated circumstances. Unanticipated 
circumstances do not play as major a role in the GP 
market as in other markets. Due to the pattern in the 
prescription market, common circumstances can not 
occur. Those include a momentary lack of funds, out- 
of-stock situations and the influences of exposure to
other brands at the moment of decision making. 
Therefore, intention is the crucial step in the 
decision process. Intention is not only influenced by 
beliefs and attitudes as explained above, but also by a 
GP's degree of compliance to norms and informational 
influence. Norms have a strong impact on the decision 
making process, since the GP has to make the decision 
in the light of the search for a superior medicine in 
order to cure the patient but needs also to take into 
account the expectations and codes of conduct of the 
National Health System. Other sources of influence are 
the opinions of colleagues in the community or in the 
special area of interest.
e) Outcomes
In terms of the model used, the choice of a product can 
result in either satisfaction or dissonance. Either 
outcome has a strong influence on future prescription 
behaviour.
Satisfaction, defined as an evaluation that the chosen 
alternative is consistent with prior beliefs with 
respect to that alternative (Engel and Blackwell 1982, 
p.501), will reinforce beliefs about a product and 
thus, will strengthen brand loyalty. In the case of 
dissatisfaction the opposite behaviour can be observed.
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Dissonance, however, occurs when cognition or beliefs 
do not fit together. Then the decision maker tries to 
resolve the post-choice doubts. Dissonance can be 
reduced by a re-evaluation of choices, leading to 
either an increased perception of the attractiveness of 
the selected choice and/or a downgrading of the option 
not chosen.
On the other hand, dissonance can lead to a post­
decision search of information, in order to confirm the 
wisdom of the choice.
3.3.2 Diffusion.
In the preceding section the prescription process has 
been examined at a constant point in time. Now, the 
emphasis is on changes in prescription behaviour over 
time, looking at dynamic effects. This approach leads 
to an overview of research into diffusion processes 
which examine product adoption issues.
Clearly, the decision process varies with the stage of 
the product life cycle and with the characteristics of 
the doctor, namely with his degree of innovativeness. 
These two aspects will be dealt with in this section.
The dynamic, perspective pursued in this section leads 
to the emphasis on the process of adoption of a drug
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that has recently become available In a market. This 
broad definition of an Innovation Includes newly 
developed products as well as existing drugs launched 
In a new market segment.
The traditional model of the adoption process consisted 
of five stages (Rogers and Shoemaker 1971, p.100):
1. Awareness; the Individual learns of the existence 
of the new Idea but lacks Information about It.
2. Interest In the Innovation Is developed and 
additional information is sought.
3. Evaluation; mental application of the new idea to 
his present and anticipated future situation and 
decision whether or not to try it.
4. Trial; application of the new idea on a small 
scale to determine its utility in the present 
situation.
5. Adoption; continuous use on a full scale.
This model has several weaknesses in that it implies 
that adoption is inevitable and it also does not allow 
for a rejection. Additionally, the order of the stages 
is too rigid to suit all cases and the model does not
allow for skipping of some stages or even an iterative 
nature of the diffusion process.
Consequently, Rogers (1983) introduced a new model 
taking the deficiency of the previous model into 
account. Again five stages were distinguished: (1) 
knowledge, (2) persuasion, (3) decision, (4) 
implementation, (5) confirmation.
This model will be described using figure 3.4 as an 
explanation of the inter-dependencies.
(1) Knowledge.
Knowledge refers to the individual's exposure to the 
innovation and the gain of some understanding of how it 
functions. An interesting aspect is the relationship 
between needs and knowledge. Do needs lead to 
knowledge or vice versa, does knowledge lead to a 
perception of a need? For a new medical drug Coleman 
et al (1966, p.59) found that initial knowledge about 
the product occurred due to a doctor's exposure to 
various communication channels, such as colleagues or 
industry sources. They concluded that only in the 
later stages of the innovation decision process did the 
doctors turn into active information seekers.
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The process may stop after the stage of knowledge 
depending on a doctor's attitude towards the 
innovation. If the information is perceived to be 
irrelevant to his or her situation no adoption will be 
achieved.
(2) Persuasion stage.
At this stage the individual becomes more 
psychologically involved with active information 
seeking as a consequence. Important influences for the 
decision process include the place where the 
information is sought, the kind of messages received, 
and the interpretation of the information.
(3) Decision Stage.
At this stage the individual decides to either reject 
or to adopt the innovation. An important means of 
coping with the uncertainty of the decision is a trial 
of the innovation on a small scale. Klonglan (1962 and 
1963) found evidence that a free trial speeded up the 
decision period by about a year when he examined the 
adoption process of a new weed spray among Iowa 
farmers. This finding underlines the importance of 
samples in the GP market.
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Rejection can occur when a prior decision to adopt is 
altered (discontinuance) or in a continued rejection.
(4) Implementation.
When the innovation is put into use, the implementation 
stage is reached. The implementation requires a change 
in behaviour. Still a certain degree of uncertainty 
exists. Therefore, the role of a change agent is 
important in providing assistance in the active 
information search by the individual.
Once the innovation becomes an institutionalized part 
of the individual's operations the implementation stage 
is completed.
(5) Confirmation Stage.
Reinforcement is sought after the adoption decision has 
been made. Conflicting messages may lead to a 
perception of dissonance, which in turn can lead to the 
reversal of the adoption decision. Re-evaluation 
and/or a further information search might be the 
consequence.
The rate of adoption varies among members of a 
population. This section describes the different 
categories into which innovativeness, the degree to
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which an individual is relatively early in adopting new 
ideas than other members of a system, can be 
classified.
Rogers (1983, p.243) showed that the adoption of an 
innovation generally follows a normal, bell-shaped 
curve when plotted over time on a frequency basis.
Using the mean and standard deviation the normal 
adapter distribution is divided into categories.
Rogers (1983, p.246) described as categories the first 
2.5 percent as innovators, the next 13.5 percent as 
early adopters, followed by 34 percent early majority. 
The 34 percent between the mean and one standard 
deviation are called late majority, while the laggards 
account for the last 16 percent.
These categories describe ideal types. The 
characteristics of the members of each category will be 
outlined very briefly.
The key characteristic of innovators is called 
'venturesomeness'. The individual desires the risky 
and hazardous and is eager to try new ideas. The 
social relationships are cosmopolitan, but innovators 
might not be respected by other members of the system 
mainly because their activity leads to change and 
instability.
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Early adopters have the highest degree of opinion 
leadership in most systems because they are an 
integrated part of the local social system. By 
carefully assessing the value of an innovation and the 
subsequent adoption they earn the respect of their 
colleagues by decreasing uncertainty for them.
The category early majority describes those who adopt 
just before the average member of the system. The 
latter deliberate for a long time and thus, seldom hold 
leadership positions, but have frequent contact with 
their peers.
The late majority's approach to innovation might be 
described as sceptical. Due to economic necessities or 
group pressures they are forced to adopt.
The last to adopt an innovation are the laggards. With 
their traditional values and limited resources they 
only adopt when it is very safe to do so. They tend to 
be resistant to change and isolated in social networks.
In summary, the innovators and early adopters have a 
very strong influence on the success or failure of an 
innovation (Gunston 1984, p.620). From the marketing 
point of view it is important to adjust the marketing 
strategy in order to take the findings just described 
into account. The implications for the marketing
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strategy are that initially the innovators need to be 
targeted, while after a few weeks the focus should turn 
to the early adopters. Once the early majority is 
covered, the return to normal coverage is advised, 
using word of mouth within the medical community to 
transmit the message (Flaum 1982).
This approach is sound, but its application requires 
the identification of members in each category. The 
problem in particular is to pinpoint the innovators and 
early adopters. For example, in a complex study 
Coleman et al (1966, p.157) established the description 
of innovators and early adopters in the GP market.
This group of GPs consisted of high prescribers of 
drugs for whom the image of a company plays an 
important role in their decisions.
The implication for the marketing of pharmaceuticals is 
the need to differentiate a product by using a 
brandname, unique package, or product offer.
3.4 Communication in the Industry
The pattern of the ethical pharmaceutical market 
requires the application of certain tools to 
communicate with the general practitioner. The role of 
the detailer (representatives), of advertising and of 
sales promotion is briefly discussed in this section.
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3.4.1 Detailer
In order to contact the GPs in the UK personally, 
approximately 50 sales representatives are required. 
Slatter (1977, p.30) has defined the task of a detailer 
a s :
To promote the use of and to sell 
ethical drugs and other pharmaceutical 
products to physicians, dentists, hospitals 
and wholesale drug establishments, utilising 
knowledge of medical practices, drugs and 
medicines. Inform customers of new drugs, 
explain characteristics and clinical studies 
conducted with drugs. Discuss dosage, use 
and effect of new drugs and medical 
preparations.
Consequently the following functions need to be 
performed (Slatter 1977, p.39) by:
Selling, by persuading doctors to write 
prescriptions for their firm's products.
- Providing information to doctors concerning new
products and new developments relating to existing 
products.
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Distributing samples and product literature to 
doctors.
Providing the company with information relating to 
side-effects discovered by prescribing doctors.
Arranging clinical trials and clinical research as 
appropriate.
Transferring the experiences of one doctor to 
others.
Sole (1980, p.202-203) additionally stressed the 
representative's role as a source of information. 
Knowledge gained about competition and doctor's 
reaction can lead to an adjustment of the marketing 
mix.
During a sales call the detailer has to take into 
account that the decision making unit quite often not 
only consists of the doctor himself, but also of nurses 
and receptionists. A favourable attitude of this group 
can enhance the acceptance of a company's products.
While Sole (1980, p.202) pointed out that the emphasis 
in Germany and Switzerland is on the detailer's calling 
on doctors, Slatter (1977, p.30) described the
importance of calling on pharmacists and wholesalers 
additionally, in order to ensure distribution.
Depending on a company's involvement in the market of 
OTC-products and their general strategy a second sales 
force is employed.
In 1983, 28,660 GPs and 16,190 dentists were registered 
(Social Trends 1985, p.115). For eight GPs there is 
one medical representative in the UK (Bennet 1984).
This ratio is similar to the situation in France, where 
a total of 8,000 detailers are expected to call on 
56,000 doctors (Bon, Nichon and Olivier 1985, p.52).
Taking into account a daily call rate of nine 
(Apfelbaum 1985, p.45). It is obvious that the 
detailers are kept busy by just calling on doctors, let 
alone calling on hospitals.
3.4.2 Advertising
The objective of advertising ethical pharmaceuticals is 
no different from advertising any other product - 
namely to produce awareness that will favourably 
motivate the subject to utilise (prescribe) the product 
(Ferm 1975, p.292).
The target audience for ¿tnical pharmaceuticals is 
doctors. It is uncommon, end in most countries 
restricted by law, to advertise drugs to the general
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public (Brownlee 1979, p.218). Some international 
companies advertise just in order to gain some public 
relation effects.
Journal advertising can reach numerous members of a 
target group at relatively low cost. The placement of 
advertisements in journals and magazines published 
especially for medical professions is particularly 
pursued by smaller companies. Thus, the reputation of 
a company can be enhanced and the increased awareness 
can support the detailer's sales call.
Direct mail offers the opportunity to channel the 
message to specific individuals rather than to a group. 
Promotional techniques are applicable that are not 
readily available in journal advertising. For example, 
product requests from the physician can be obtained in 
the form of self-addressed business reply cards 
included with direct mail promotional material. This 
technique establishes a measurable relationship between 
manufacturer and physician. (Ferm 1975, p.303).
The drawback with direct mail is that it has been used 
quite excessively in recent years, making it 
increasingly difficult to obtain the doctor's 
attention. To overcome the problem of over exposure to 
direct mail, Ferm (1975, p.303) suggests the 
development of a manufacturer sponsored journal or a
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'house organ'. The effectiveness can be questioned, 
since the doctor is confronted with enough journals 
anyway.
3.4.3 Sales Promotion
Sales promotion is defined as "all forms of clearly 
sponsored communication other than advertising and 
selling" (Ray 1982, p.14). Because of the structure in 
the market for ethical pharmaceuticals outlined above, 
these will hardly be forms of sales promotion that are 
common in other markets. For example, price-off 
packages, a common tool in consumer marketing, are of 
no value in this market.
Three aspects of sales promotion are demonstrated in 
this section: samples, visual aids and medical 
exhibits.
a) Sampling.
There is no better way of demonstrating the 
effectiveness of a drug than by the actual use.
Samples are an important tool in overcoming the initial 
resistance towards a new product. For well established 
products there is obviously no need for support by 
samples. However, the mis-use of this technique has
led to public pressure in order to restrict sampling 
(Smith 1975* p.329).
b) Visual Aids.
Sales assistance is also given by the use of aids 
especially designed for the sales presentation, such as 
folders containing product information. Various tools 
are to be left with the doctor as a reminder. These 
"give-aways” are widely accepted in the industry. The 
items may range from books of matches to useful medical 
equipment, depending on the creativity of the marketing 
department.
c) Medical exhibits.
Attendance at a medical exhibition offers the 
opportunity to discuss the features of a product in a 
more relaxed atmosphere than it is the case in the GP's 
practice. This has led to an increase in the number of 
industry sponsored conventions so that it is 
increasingly difficult to get the target audience 
interested in a certain event. The organizers have to 
differentiate in order to attract attention.
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3.4.4 New forms of communication
In a recent study it emerged that just seventeen 
percent of a detailer's time is spent on actually 
talking to the doctor, the rest was spent on various 
other activities, such as travelling (ApCelbaum 1985, 
p . 45). Therefore, new forms of communication have been 
sought (Bon, Nichon and Ollivier 1983, p.55).
Communication via telephone for example is becoming 
increasingly important, as well as product information 
on video cassettes. Future developments might include 
the use of systems like Prestel in the UK or BTX in 
Germany (Brasser 1985, p.60; Viehues et al 1985, p.65; 
Schultze 1985, p.68).
Meditel provides approximately 6,600 doctors within the 
NHS with news. The service is sponsored by advertising 
from the industry. Treatment viewdata is a 
commercially operated information service providing 
information about side effects, prices, etc. (Pfaff 
1985, p.1765).
The utilization of these new techniques is enhanced by 
the increasing use of micro-computers in practices.
The breakdown of pharmaceutical promotion expenditure 
shown in figure 3.5 (ABPI 1985a, p.32) indicates that
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sales representatives account for approximately forty- 
five percent of the total expenditure in the ethical 
pharmaceutical industry in the UK. This has not 
changed very significantly over the last fifteen years. 
The changes concerning the limited list might lead to a 
shift in the importance of the different elements.
When an increasingly more generic prescription is 
required, then there will be no need to promote a 
certain brand. Consequently, cuts in the size of the 
sales force seem to be inevitable.
3.4.5 Effectiveness of the Communication Mix
Numerous studies have been conducted aimed at the 
detection of influences in the prescription process.
An overview is provided by Reichwald-Dietzsch (1981a, 
1981b). The focus of each study differs widely from 
others. No attempt is made here to structure the 
findings, it is intended only to highlight a few 
important findings.
In a review of the literature Hemminki (1975) pointed 
out the importance of education, advertising and 
colleagues. She found that the studies reviewed 
suggested that doctors' education positively influences 
the quality of prescribing. This finding was confirmed 
by Klein et al (1981).
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Joyce (1970) found that GPs with higher education were 
associated with less prescribing of drugs of all kinds. 
On the other hand in England no significant difference 
in prescription patterns among doctors graduating from 
different medical schools could be established (Lee, 
Draper and Weatherall 1965). However, this study was 
conducted before the impact of the 'new' Universities 
could be tested.
Hemminki (1975) pointed out yet another problem area in 
that the life of a drug often only covers a time span 
of approximately five years. This indicates that the 
initial education for a doctor can only have a limited 
influence on the prescription pattern.
Williamson (1975, p.233) contended that doctors in 
group practices are more likely to rely on their 
colleagues' opinion while solo practitioners use 
literature and commercial sources. Peay and Peay 
(1984), however, could not establish a significant 
difference between the two.
Haayer (1982) found that rational prescription was 
related to physician rather than patient 
characteristics. The younger GPs tended to be more 
rational. However, Epstein et al (1984) concluded that 
doctors' attitudes to factors such as effectiveness, 
side effects, likelihood of compliance, cost and the
patient's perception of the doctor may influence the 
drug choice.
Hartsema and Christensen (1983) found that older GPs 
tend to have older patients. This implies that the 
GP's age does not explain higher prescription rates but 
functions as a proxy for older panels of patients who 
in turn have more chronic illnesses and hence need more 
drugs.
Demographic discriminators were also found to be of 
value to explain prescribing behaviour. Jones et al 
(1980) detected a higher prescribing rate in Wales 
compared with England.
Overall, Bush et al (1984) found family doctors in the 
US to be conservative prescribers, particularly in the 
case of hypnotics. Although Rosser (1983) detected a 
significant difference between actual and perceived 
rate of prescribing Diazepam, a tranquiliser.
In the category of tranquilisers Chambers et al (1983) 
concluded that more drugs in this class were prescribed 
by:
GPs rather than specialists 
GPs in solo practices
GPs who see a high number of patients
GPs who have been longer out of medical
school.
In the UK a favourable attitude towards industry 
supplied information was detected (Mil Research 1980). 
However, medical professionals expressed their concern 
about the total level of promotional activities which 
was considered as being excessive (Milpro 1985, p.5).
On the other hand, a doctor's attitude towards a source 
does not necessarily reflect its importance. Avorn et 
al (1972) found a discrepancy in doctors' perception of 
the influence of advertising and detailer and the 
actual effectiveness of these sources. As reasons they 
quoted either the doctors' unwillingness to admit 
reliance upon commercial sources or their lack of 
awareness of such influence.
In another study (ABPI 1975) it emerged that solo 
practitioners and older GPs tended to have a more 
favourable opinion of the detailer. It was found that 
representatives were regarded as the most important 
sources for information followed by medical journal 
articles. In this study it appeared that the least 
important communication media were mailings and 
advertisements. This attitude, however, mirrors only 
the perception. On the other hand, Segal and Hepler
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(1982) found that face to face consultation may be a 
more effective method of influencing prescribing than 
other methods of communication.
The importance of the source of information varies 
clearly with different stages in the diffusion process. 
Mapes (1977, p.620) suggested that "innovatory 
prescribing must proceed as something of an act of 
faith". Peay and Peay (1984) found that commercial 
sources play an important role at the first stage of 
the adoption process, while colleagues play a minor 
role. These findings are not in line with those by 
Coleman et al (1966), who concluded that colleagues 
serve a legitimising function in drug adoption.
The results of the various studies just outlined need 
to be related to how pharmaceutical companies can 
increase the effectiveness in communicating with 
doctors. This needs to be seen in the light of the 
aspects discussed in this section, namely buying 
behaviour and the diffusion process. Figure 3.6 
depicts how Sole (1980, p.191) summarised the value of 
the different communication tools in the various stages 
of the diffusion process. His findings stress the role 
of the detailer in creating awareness and interest, 
while the important influence of colleagues in the 
actual decision to adopt is stressed.
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3.5 The Company and its Problem
The previous sections in this chapter have described 
the environment in which pharmaceutical companies 
operate in the Uk, have looked at prescribing 
behaviour, and have analysed the effectiveness of the 
communication mix available to pharmaceutical 
companies. This information forms the background to 
the case example which is explained in this section.
The case example underlying this work is based on the 
situation of an American ethical drug manufacturer 
(hence called the Company) operating in the UK Market. 
The Company is operating in six therapeutical classes. 
Thus, based on turnover, it is among the top fifty drug 
companies in the UK. On a worldwide bases the company 
is among the largest fifteen companies.
As explained in the previous sections, the sales force 
is the dominant communication tool for this company. 
Just below fifty detailers are employed on a full-time 
basis, covering the entire UK area.
Changes in the PPRS had the effect that the company 
suddenly operated very much at the limit of the 
promotional expenditure allowance. However, it was 
just large enough not to suffer any immediate
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reductions, the company could still maintain the entire 
sales force.
The introduction of the limited list, however, had two 
major effects. Firstly, the most successful drug in the 
product portfolio, a tranquiliser was affected by the 
rule of generic prescribing in that therapeutic class. 
At the time of the introduction of the limited list, 
however, this drug was still under patent protection 
(to remain so for another two years). This change 
meant, that doctors had to prescribe by generic name 
and were not allowed to prescribe by brand name any 
more. Due to the patent protection the only drug 
available under the generic name was the company's 
brand Halcion. Thus, in their communication with 
doctors, the company only had to stress that the drug 
was still available under the NHS system but had to 
promote the generic name. Subsequently, sales suffered 
only marginally.
The second effect of the introduction of the limited 
list had much more impact. The second drug in question 
was taken off the list of re-imbursable medicine 
completely. The drug affected was a relatively new 
product which had been launched very successfully just 
before the introduction of the limited list. 
Strategically it had just turned into a 'Star' product 
with all the prospects of becoming the company's major
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cash generator in time to replace the other drug 
mentioned previously.
This development had an immediate impact on the role of 
the sales force. For the new product it would have 
been perfectly adequate to use the sales force to 
reinforce its 'Star' position. Starved of this 
product, the company was left with mainly mature 
products, of which most had reached their respective 
potential. Therefore the strategic question was, what 
to do with the sales force and how to employ it as 
effectively as possible. In the light of the PPRS 
changes this also included the question whether to 
maintain a sales force at all. In the light of expected 
new product developments in the medium term it was 
decided to keep the sales force but to examine its most 
effective use.
3.6 The Data
At this stage the company was introduced to market 
research data compiled by Medical Direct Mail 
Organisation (MDMO). The objective for MDMO is to 
supply pharmaceutical companies with detailed 
information on individual General Practitioners. This 
information is then directly translated into a call 
card system. An example of a call card is displayed in 
figure 3.7. Thus, the individual sales representative
in a company is provided with a fairly detailed profile 
of a doctor. Combined with the representative's 
personal knowledge the call card provides a good 
preparation for the sales call.
But it is not only of benefit at the sales call level. 
From a marketing point of view the call card system 
offers the chance for proper targeting. Searching for 
certain key information, i.e. number of patients, 
number of prescriptions in a therapeutic class, subsets 
of the whole GP population can be found. This subset 
can then be targeted for a special promotional activity 
carried out either by the sales force and/or by direct 
mail.
When the company adopted the call card system, data on 
19,000 GPs were available. The number has increased to 
more than 21,000 in the meantime. Tests for bias in 
this sample carried out by MDMO revealed the 
representativeness of the doctors included in the 
database. Without having access to the full database 
it is obviously difficult to substantiate this claim. 
Since no adverse comments were received from 
practitioners in the industry, one can assume that the 
effect of the bias is not that dominant. However, 
incomplete information on another 3,000 doctors is 
available, so that the whole database covers 
approximately 80% of the GP population.
The information is obtained based upon a questionnaire 
as shown in appendix 1 . The GPs participating are 
aware of the commercial application of the database.
As an incentive for participation a nominal sum is paid 
to charity for each completed questionnaire. For this 
study two samples of 1000 doctors from the MDMO 
database were selected. The first sample is used to 
carry out the analyses, the second sample functions as 
a hold-out sample to validate the findings.
The criterion for selection of the two samples was that 
the doctor responded to the questionnaire twice. The 
first time during the period January-April 1984 in the 
first mail shot and a second time during March-May 1985 
when the first update was conducted. Each sample was 
then constructed to be representative of the MDMO data 
set. This means that it was representative of the 
distribution of demographic information as well as of 
the information on brand preference.
Thus there is a bias in the samples towards more 
responsive doctors, reflected in the criterion of 
having responded to the questionnaire twice. Apart 
from that particular bias care has been taken to 
create samples as representative of the total MDMO 
sample as possible, thus as representative as possible 
of the entire GP population.
Using this procedure four sets of samples were 
available for analysis. Two sets of 1,000 doctors each 
covering 1984 and two sets of the same 1000 doctors 
each covering 1985. The reason for splitting the 2,000 
responses at each point in time into two sets is to use 
one set to develop the necessary analysis and use the 
second sets as a hold-out sample to validate the 
findings.
3.7 Summary
The market for ethical pharmaceuticals in Britain is 
dominated by the largest customer, the National Health 
Service. Consequently, the Government is not only 
restricting the market for safety reasons but also in 
its own interest, on financial grounds.
In respect of the latter the frequent updating of the 
re-imbursable list of drugs and price negotiations with 
the manufacturers are supposed to lead to a moderate 
increase in the total cost of the health system to the 
taxpayer. Unlike in other industries profits are 
restricted to a rate of currently twenty one percent of 
sales. This rate is fixed in the Pharmaceutical Price 
and Regulation Scheme in which marketing expenditure is 
limited to nine percent of sales for an individual
company.
Within this frame companies need to target their 
marketing efforts towards medical doctors, general 
practitioners in particular. They are at the centre of 
the complex relationship between NHS, industry and 
patients. In contrast to other markets the individual 
who makes the buying decision is not receiving the 
product and neither is he/she paying for it.
This specific market situation calls for the 
application of certain marketing tools. The most 
important element in the communication mix is the sales 
force. Journal advertising, direct mail and other 
forms of sales promotion play a relatively minor role.
The case example introduced in this chapter has 
highlighted the problem of a smaller pharmaceutical 
Company competing in the market following changes in 
the PPRS and the introduction of the limited list.
Torn between the need to maintain national coverage by 
the sales force, restricted by limited expenditure 
allowed, and the drop of a 'Star' product from the list 
of re-imbursable products, the Company was forced to 
target its sales force activities more effectively. 
Many, especially smaller, companies in the 
pharmaceutical industry faced a similar problem.
The advent of new market research information therefore 
fulfilled an apparent need of companies. The STARS 
database assists, via the call card system, the sales 
force at the level of the individual doctor. It also 
allows at the managerial level the fine-tuning of 
marketing activities by targeting specific doctors with 
promotional activities via the sales force or direct 
mail.
The successful implementation of the STARS database 
enhanced managers' belief in more scientific approaches 
to managerial problems. Thus, the ground was well 
prepared when the researchers presented the idea of 
taking the targeting effort and sales force allocation 
problems one step further by using the available 
information to segment the market and to tackle the 
resource, sales force in particular, allocation 
problems.
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Figure 3.1 The prescription market in the UK 
(Taylor, 1983)
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Figure 3.2 Pattern in the ethical drug market 
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chapter 4 MARKET SEGMENTATION
4.1 Introduction
The previous chapter outlined the important role of the 
sales force in pharmaceutical markets. Considering the 
constrained marketing budget it is obviously very 
important for pharmaceutical companies to allocate the 
scarce resource sales force and other promotional tools 
as effectively as possible.
One way of increasing the effectiveness of the sales 
force is obviously to focus on those doctors who 
respond best to the sales force effort. Therefore, 
this thesis sets out to test whether segmentation can 
be used to allocate sales effort and whether such a 
segmentation procedure can be implemented in practice.
In order to allow the test of these hypotheses this 
chapter provides a literature review on segmentation 
research.
Amendments in the regulations of the NHS have led to a 
change of the pattern in the GP-market as described in 
the previous chapter. In order to adjust to this new 
pattern and to obtain a competitive edge, the marketing 
strategy for the company will need to be redeveloped.
The different steps in the development of a marketing 
strategy are described in a model introduced by Doyle 
and Saunders (1985) as demonstrated in figure 1.1.
They point out the key role of market segmentation. 
Target markets should only be identified after the 
determination of market segments and an assessment of 
their attractiveness. Only then any decisions on 
resource allocation should be made. Consequently, this 
chapter is concerned with the review of the relevant 
literature on segmentation.
The GP market, as described in chapter three, is 
different to any other market. With the complex buying 
process involving users (patients), deciders (GPs), and 
influencers (NHS), it is very much an industrial 
market. With the key person being an individual 
doctor, however, similarities to consumer markets 
should not be overlooked. Hence, it is planned to 
identify approaches in consumer and industrial market 
segmentation research which are useful for a thorough 
approach to the segmentation of the GP-market.
To achieve this objective the following steps are 
undertaken. Firstly a brief description of the 
segmentation theory and its implementation will be 
provided, and secondly, bases for segmentation in 
consumer and industrial markets will be evaluated.
4.1.1 Market Segmentation defined
It has been acknowledged that the term "segmentation" 
was first introduced by Smith (1956). He defined it as 
a concept of "viewing a heterogeneous market as a 
number of smaller homogeneous markets in response to 
differing product preferences among important market 
segments" (Smith 1956, p.3).
According to another view (Choffray and Lilien 1980, 
p.78)
"market segmentation is concerned with 
grouping potential customers into sets that 
are homogeneous in response to some elements 
of the marketing mix."
Both definitions take into account that real markets 
are not homogeneous and that customers are different. 
Segmentation leads to the identification of customers' 
needs and thus enables a company to direct its efforts 
to satisfy those needs.
As early as in 1934 Frederick suggested dividing an 
industrial market into its component parts. He thought 
that five factors needed to be considered: industry, 
product use, company buying habits, channel of 
distribution, and geographic location.
During and after the Second World War, companies 
concentrated on the improvement of production 
facilities in order to meet the high demand. 
Consequently, mass production of undifferentiated 
products was the key to success. Once the initial high 
post-war demand was satisfied, companies no longer 
succeeded in providing undifferentiated products. 
Customers developed individual needs, the emphasis 
shifted from production orientation towards marketing 
orientation in order to satisfy the identified needs.
In this period the theory of market segmentation was 
developed.
The purpose of market segmentation is the 
identification of segments permitting the development 
of marketing strategies in order to satisfy specific 
needs and wants. It is clearly the objective to put 
the company in a more beneficial position, mainly to 
achieve increased profits. Thus, the incremental 
profits gained through segmentation need to offset the 
cost of segmentation (Bonoma and Shapiro 1984).
A crucial criterion for determining the desirability of 
segmenting a market is whether the segments have 
different elasticities with respect to price and 
promotional policies of a firm (Frank 1968).
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Depending on the product/market situation, segmentation 
can lead to any situation between the extremes of 
treating each single customer as a segment, as in some 
industrial markets, or having a homogeneous market and, 
thus, a single segment.
The term segmentation in this thesis will be viewed as 
a strategic issue of resource allocation, rather than 
for measuring and statistical analysis (Johnson and 
Flodhammer 1980). Therefore, the decision oriented 
approach to the problem is accepted as opposed to a 
behavioural research approach which is more concerned 
with the identification and documentation of 
differences among customer groups (Frank et al 1972).
4.1.2 The Segmentation Process
After having defined the term market segmentation and a 
description of its advantages, the focus in this 
section is now on the process of segmentation. Kotler 
(1984, p.264) pointed out the characteristics of 
segments:
Measurability, the degree to which the size 
and purchasing power of the segments can be
measured.
Accessibility, the degree to which the 
segments can be effectively reached and 
served.
Substantiality, the degree to which the 
segments are large and/or profitable enough. 
Actionability, the degree to which effective 
programmes can be formulated for attracting 
and serving markets.
Which are the considerations to be taken into account 
in order to derive segments which fulfill these 
characteristics? To answer this question a framework 
for key issues in market segmentation was developed by 
Wind (1978). Figure 4.1 outlines the five major phases 
of segmentation research, namely: problem definition, 
research design, data collection, data analysis, and 
data interpretation and strategy implementation.
In a changing market environment, as in the 
pharmaceutical markets, managers' needs are bound to 
change. Therefore, the argument is in favour of an on­
going segmentation. The segmentation model requires 
the selection of dependent and independent variables as 
bases or descriptors respectively (Wind 1978).
Four types of models are distinguished: a priori, 
clustering-based, flexible, and componential 
segmentation (COSEG) (Green 1977). Each model calls
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Cor a different research design beCore the data 
collection stage is reached. Analysis of the data 
requires the application of advanced mathematical 
techniques. In a joint effort the results should be 
interpreted, combining the researcher's statistical 
expertise and the manager's intimate knowledge of the 
market.
The framework demonstrates the importance of 
identifying bases for segmentation in order to pursue 
an a priori strategy. However, the identification of 
bases can also be very useful in applying the 
clustering approach by allowing a pre-grouping.
Johnson and Flodhammer (1980), as demonstrated in 
figure 4.2, proposed assessments of variables for 
industrial market segmentation. They used the 
categories (1) measurable, (2) available, (3) 
predictive, and (4) degree of usage to assess the 
usefulness and feasibility of conducting segmentation 
studies on certain bases.
Market segmentation has been defined, and major 
considerations in conducting segmentation research have 
been discussed. The remainder of this section is 
concerned with the identification of bases on which the 
GP market can be segmented.
The complex situation in pharmaceutical markets has 
been outlined in the previous chapter. In particular 
the GP-market with usually one decision maker but third 
party payment shows elements of both consumer and 
industrial markets. Therefore, the literature on 
segmentation approaches for both markets must be 
evaluated.
It is argued (Wind 1978) that most of the segmentation 
research approaches in consumer markets are equally 
applicable to industrial markets. However, especially 
the existence of a Decision Making Unit (DMU), as 
opposed to an individual, creates a much more complex 
situation in industrial markets. Consequently, in 
industrial markets additional considerations need to be 
taken into account. It is also arguable whether the 
same approaches can be used. For example, a 
segmentation based on life-style will hardly be 
applicable to industrial markets. Therefore, it can be 
concluded that a different approach to industrial 
market segmentation is necessary.
Green (1977) classified the different approaches using 
the categories a priori and post hoc. An a priori 
design requires the determination of a basis before the 
study is conducted while in a post hoc or clustering 
design (Wind 1978) the segments are determined on the 
basis of a clustering on a set of relevant variables.
Considering the objective of the literature review, 
this classification is not useful in our case. The 
approaches are classified according to each one's basis 
for segmentation.
4.2 Bases for Segmentation in Consiuaer Markets
A segmentation basis can be defined as a criterion 
according to which potential customers are grouped. In 
consumer markets, bases can be divided into the 
analysis of consumer characteristics and the analysis 
of behavioural differences (figure 4.3).
Early segmentation studies were mainly based on 
geographic grounds. Thus, a company selected its 
target markets in certain parts of the country and so 
avoided the service of the whole country. This is 
probably the easiest way to segment a market, but this 
approach is mainly cost driven and does not reflect a 
very strong marketing orientation.
The next popular category, the socio-economic and 
demographic basis, also offers the advantage of 
measurability and easy access to relevant data (Frank 
1968) .
Relevant in this category are bases like age, sex and 
education. It can be assumed that there is a
relationship between prescribing habit and age (year of 
graduation respectively). Sex as a basis is probably 
the weakest of the three mentioned but still might 
explain a different behaviour, especially for 
female/male complaints.
An important basis needs to be added to this general 
list; whether or not the doctor is a member of a group 
practice can have a significant influence on his/her 
prescribing habit.
Another dimension of consumer characteristics includes 
psychographic bases. The development of life-style 
segmentation intended to go beyond the information 
provided by demographic data. Thus, a "humanized 
portrait" (Wells 1974) of the customer group is drawn 
by focusing on specific attitudes (beliefs, values, 
interests, and intentions) and activities (Hustad and 
Pessemier 1974). This approach is sensible, since the 
probability that two people pursuing the same life­
style behave similarly is higher than that of two 
people of the same age.
However, there is the difficulty of measurement to 
overcome. In this particular case it is very difficult 
to use this as a basis for segmentation due to the lack 
of information. The questionnaire on which the data 
are based in the case described here does not include
relevant questions to allow a segmentation on li£e 
style.
Usually none of the various bases described is 
sufficient enough by itself (Frank, Massy and Wind 
1972). Consequently, complex segmentation models 
incorporate a number of bases as variables.
Various studies (Frank 1968) indicate that general 
consumer characteristics are not an exact basis for 
segmentation. The crucial step in applying the bases 
described is the conclusion drawn from membership of a 
certain group to an expected behaviour. This is the 
best argument in favour of using bases derived from the 
analysis of consumer response. Here the prediction of 
a certain behaviour is based upon the analysis of 
previous response.
Subjective measures of consumer response measure the 
consumer's perceptions, while objective measures are 
based upon post sales data.
A new dimension to segmentation research was introduced 
when first Yankelovitch (1964) questioned the use of 
demographic information and pointed out the importance 
of customers' values as a basis for segmentation and 
when later Haley (1968) introduced the concept of 
benefit segmentation.
Haley's approach identified market segments by causal 
factors rather than descriptive ones. The segments are 
identified on the basis of benefits being sought. This 
approach is based upon the ability to measure in detail 
customers' value systems combined with customers' 
attitude towards other brands in the same product 
category. This technique calls for the application of 
advanced multivariate statistical techniques. The 
application of which imposed a bigger problem at the 
time the concept was introduced compared with today's 
situation with increased computer power and techniques.
In the underlying problem, information on GP's 
preference for different products in product classes is 
provided. Based on the attitude or the preference, a 
market segmentation analysis could be conducted in 
applying a similar concept as benefit segmentation.
Objective measures of consumer response cover aspects 
of product usage. One basis for segmentation is the 
extent of usage. In the 1960s, quite a few studies 
were conducted which examined the results of 
segmentation along this dimension. For example, in the 
beer market companies identified the "heavy half"
(Twedt 1961). It was detected that a few percent of the 
total market population accounted for the majority of 
the consumption. Targeting this particular group of
customers required fewer resources and provided higher 
sales than targeting the other half.
The data provided for this study allows the 
identification of heavy users in the pharmaceutical 
market.
In addition the response to promotional activities such 
as direct mail could be used to identify those who are 
more likely to react positively to subsequent 
promotional activities. This basis can also be called 
"deal proneness".
Frank (1968) noted that brand loyalty is a real 
phenomenon but that the identification of a "brand 
loyal" customer is very difficult.
4.3. Bases for Segmentation in Industrial Markets
To some extent bases for segmentation in consumer 
markets can be applied to industrial markets as well. 
However, the emphasis in this section is on specific 
bases for industrial market segmentation. The second 
section briefly covers aspects of normative approaches 
to industrial market segmentation.
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4.3.1 Specific Bases
Specific bases for segmentation of industrial markets 
are illustrated in figure 4.4. The bases are grouped 
along five dimensions: organisation, DMU, individual, 
product, and behavioural differences.
Industrial markets have for long been a somewhat 
neglected area of market segmentation (Bonoma and 
Shapiro 1984). Early approaches (Frederick 1934,
Hummel 1954 and 1960) examined opportunities to segment 
on the level of the buying organisation. General 
characteristics such as industry type (SIC class) or 
demographic data were chosen. Applicable to the case 
reported here is the idea to distinguish between group 
and single practices, or to take geographical 
differences into account.
The next dimension for segmentation is concerned with 
the DMU. Here the position within the organisation, 
the composition (users, deciders, influencers, size) 
and the decision rules provide a basis. Since a 
similar situation will only be found in group 
practices, the DMU concept is clearly not applicable to 
a single doctor, this dimension is of limited value to 
the problem described here. Nevertheless, for group 
practices the composition of the DMU and decision rules 
could provide a basis for segmentation.
On an individual level, similar approaches as in 
consumer markets can be used. An interesting 
additional aspect is the basis "organisational role”. 
In a group practice, those individuals need to be 
identified whose task it is to communicate with the 
industry, and who might, subsequently, act as opinion 
leaders.
Using the dimension 'product', an interesting basis is 
provided by the end use of the product. The same 
product could be used for the treatment of different 
illnesses, hence enabling the identification of 
different segments.
In the questionnaire, on which the GP data are based, 
products are already allocated to product classes, 
leaving the respondent very little room for individual 
alteration. Consequently, this aspect of segmentation 
is not feasible.
Cost factors are of minor importance thus, the concept 
of "economic value to the customer" (Porbis and Mehta 
1981) is not applicable to the GP market.
Since information on the extent of product use is 
available, an important classification could be along 
the aspect of quantity, corresponding to the
identification of the "heavy half" discussed in 
consumer markets.
The most valuable approaches are listed under the 
heading "behavioural differences" which cover 
situational differences as well. Robinson et al (1967) 
developed the concept of distinguishing straight re­
buy, modified re-buy and new task, as different buying 
situations. Analysing the data available, segments 
could be identified consisting of users, occasional 
users and non-users.
The market could also be segmented using risk as a 
basis for segmentation. As stated in the previous 
chapter, GPs1 prescribing habits can best be described 
as being risk averse. However, the perceived risk in a 
prescription situation will vary according to a 
doctor's experience and with the patient's symptoms.
The degree to which a doctor is risk averse could form 
an interesting basis for segmentation.
4.3.2 Normative Approaches
So far different bases for segmentation in industrial 
markets have just been listed. It is obvious that 
there are interrelationships between the bases and that 
a single basis alone will not explain the pattern of
the market. The complex situation in industrial 
markets therefore calls for approaches which consider 
the complexity. Recent developments in research have 
led to the emergence of normative approaches. The 
first normative approaches consisted basically of two 
steps, while more recent developments looked at 
integrated solutions. Thus, in the next section the 
two stage approaches are discussed before the new 
developments are evaluated in order to identify 
valuable approaches to the problem discussed here.
4.3.2.1 Two Stage Segmentation
The first to develop a coherent framework to evaluate 
different segmentation approaches were Frank, Massy and 
Wind (1972). They first classified on the basis of 
organisational differences and derive macro-segments.
In the second step the market is further segmented 
within the macro-segments on the basis of differences 
within the DMU. A classification scheme values the 
characteristic of the situation (general or situation 
specific) versus the level of segmentation (divided in 
objective and inferred measures) and allocates the 
bases accordingly. They do not discuss the DMU 
characteristics in any detail.
Wind and Cardozo (1974) based their framework on the 
findings of Frank et al (1972). Following the
117
identification of macro-segments based on key 
organisational characteristics they define 
microsegments by composition of the DMU. Their 
contribution lay in the provision of a framework and 
the extension towards a more detailed consideration of 
the bases used by the DMU in purchase decisions.
Choffray and Lilien (1978) followed the Wind and 
Cardozo framework and introduced an approach consisting 
of five steps:
1. Development of macro-segments of organisations.
2. Determination of the structure of DMUs in each 
macro-segment. Use of a decision matrix in which 
columns correspond to phases of the decision 
process and rows to buying roles of individuals.
3. Index of inter-organisational similarity.
4. Cluster analysis to develop micro segments on the 
basis of similarity of DMU.
5. Identification of pattern in the purchasing 
process within each micro segment.
They extended their work further by describing the 
relationship of segment descriptors and segments in an 
example of the cooling industry (Choffray and Lilien 
1980).
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Other studies used the two stage approach by 
introducing conjoint analysis (Wind, et al 1978) or by 
diffusion pattern in each segment (Wind, et al 1982). 
The latter approach provides a contribution to solving 
the problem discussed here in concluding that there are 
different diffusion patterns in different market 
segments. This could apply to different segments in 
the pharmaceutical industry as well.
The two stage approach is of interest to the problem in 
that a guidance is provided to use demographic or 
general information to derive at macro-segments and to 
use more specific data for a focus on micro-segments.
Another useful approach is the proposal by Cheron and 
Kleinschmidt (1985) to look for the ideal overlap of 
macro-segments, micro-segments and other micro­
segmentation bases such as benefits sought, (figure 
4.5)
4.3.2.2 Recent Developments
Shapiro and Bonoma (1983) developed the Wind and 
Cardozo framework further by introducing the nested 
approach (figure 4.6). Their concept is based upon the 
assumption that three factors influence the purchase 
process: the company (demographics, operating variables
and purchasing approach), situational factors and 
personal characteristics of individuals.
The marketer moves from the outer nests, containing 
more general and easily obtainable segmentation bases, 
to the inner nests with the more specific ones.
They do not, however, provide a tool to decide when to 
stop and do not elaborate on the methodological 
difficulties in obtaining data.
Cheron and Kleinschmidt (198S) in a more recent 
contribution tried to bridge the gap between industrial 
markets and consumer markets by introducing an 
integrated framework. They concentrated on collective 
buying decisions only. Their framework is presented in 
figure 4.7. This approach is obviously only applicable 
to group practices in the GP market.
4.4 Su— ary
The role of market segmentation in the development of a 
marketing strategy has been stressed and important 
considerations in the process of segmentation have been 
explained.
A few bases for segmentation mentioned in the 
literature do provide useful starting points for a
1 2 0
segmentation of the GP market. Geographic and 
demographic information such as age, sex, single/group 
practice can provide helpful approaches. Psychographic 
aspects provide little support due to a lack of 
information.
Probably the most powerful approaches include the 
analysis of consumer response. Here the attitude and 
perception of a product versus its competitors' in the 
product class, provide the best bases. Thus, a similar 
approach to benefit segmentation could be pursued but 
the lack of information on GPs' value system creates 
difficulties. In addition, the usage rate could be an 
interesting basis as well as the identification of the 
"heavy half".
Bases from industrial market segmentation research 
include the organisation type, namely single or group 
practice. The organisational role in a group practice 
is of high interest but very difficult to assess. End 
use of the product is difficult to use due to the lack 
of information. The perceived risk could be an 
important factor to consider. Behavioural differences, 
such as response to promotional activities or attitudes 
towards products, are other interesting bases.
The research in normative approaches provides some 
guidance of how to use the different bases just listed.
Whether it is called a "nested approach" or "two stage 
segmentation", the basic idea is to pre-segment the 
market in macro-segments using general data such as 
demographic data. These macro segments can then be 
further segmented using more specific bases like 
attitudes, perceived risk, or promotional response.
I. Problem Definition
(a) Managerial requirements
(b) Baseline vs on-going segmentation
(c) Segmentation model
II. Research Design
(a) The unit analysis
( b) Operational definitions
(c) Sample design
<d) Data reliability
(e) Segment stability
(f> Segment homogeneity
(9 ) Segmentability of the market<h) Validation
(i) Cost considerations
III. Data Collection
(a) Primary vs secondary sources
( b) Conventional vs new data analysis procedures
IV. Data Analysis
(a) For determining the segments: 
Classification
(b) For determining the segments' profile: 
Discrimination
(c) For simultaneous classification and 
discrimination
V. Data Interpretation and Implementation of Results
(a) Determining the number of segments and 
selection of target segments
(b) Translating segmentation findings into 
strategy
Figure 4.1 Framework market segmentation 
(adopted from Wind, 1978)
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S e g m e n ta t io n
V a r i a b l e s
M e a s u r a b le A v a i l a b l e P r e d i c t i v e U s a g e
P r o d u c t / P r o c e s s 1 1 3 ( 2 ) 1
A p p l i c a t i o n 2 2 1 ( 7 ) 1
I n d u s t r y  T y p e 1 1 2 - 3 1
M a r k e t  S iz e 1 - 2 1 1 - 2 1
G e o g r a p h ic  L o c a t io n 1 1 7 1
B u y in g  P r o c e s s 2 - 3 2 - 3 7 1
B u y in g  C e n t r e 2 - 3 2 - 3 1 ( 7 ) 2 - 3
P r e v io u s  R e l a t i o n s 3 3 1 ( 7 ) 3
E n d - U s e r 2 2 1 ( 7 ) ' 1 - 2
1 •  h i g h ,  2 ■ m e d iu m , 3 *  lo w
A q u e s t io n  m a rk  i m p l ie s  a  n e e d  f o r  f u r t h e r  r e s e a r c h .
F i g u r e  4 . 2  A s s e s s m e n t  o f  v a r i a b l e s  f o r  i n d u s t r i a l  m a r k e t  s e g m e n t a t io n  
( J o h n s o n  a n d  F lo d h a m m e r ,  1 9 8 0 )
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Analysis of
Consumer
Characteristics
.--Age
I--Sex
I—  Religion 
1— Family Size
Socioeconomic
____ a n d
Demographic
Life Style
Social Class---- ,--Income
I__Education
I Occupation
P s y c h o g r a p h ic
Personality_____Innovative
I Compulsive 
I Ambitious
Life Style
G e o g r a p h ic
Analysis of 
Consumer 
Response 
(Behavioural 
Differences
Subjective Measures of
___ Consumer Response
(Perceptual Factors) Ë
Benefits 
Quality 
Brand Name 
Price 
Salesman
Objective Measures of 
Consumer Response 
(Usage Factors)
Product Usage 
Brand Loyalty 
Price
Sensitivity 
User Status
Figure 4.3 Bases for Consumer Market Segmentât
A. Organisation:
B. DMU:
C. Individual
D. Product
E. Behavioural 
Differences:
- Type
- Industry Type
- Demographics
- Geographic
- Composition
- Degree of 
Decentralization
- Decision Rules
- Demographics
- Organisational 
Role
- End Use
- Economic value to 
the customer
(EVC)
- Quantity
- Buying situation
- Source loyalty
- Risk perceived
- Benefits
Spekman
1981
Hummel
1954/1960
Wilson, Matthews 
and Sweeney 1971
Schiff, Fernandez 
and Winer 1977
Unger 1974 
Farbis and Mehta 
1981
Robinson, Faris 
and Wind 1967
Cardozo 1968 
Yankelovitch 1964 
Hlavacek and 
Reddy 1985
Figure 4.4 Bases for industrial market segmentation
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Figure 4.5 Requirements for implementation of 
segmentation framework 
(Cheron and Kleinschmidt, 1985)
Figure 4.6 Nested approach
(Shapiro and Bonoma, 1983)
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C onsum ption  U n i t I n d iv id u a l  g ro u p  fo rm in g  h o u s e h o ld , 
f a m i ly  g ro u p , o r g a n is a t io n a l  g ro u p
Se m e n ta t io n  
ty p e
M a c ro -ss 9 n s n ta t  io n M ic r o - s c ^ n e n ta t io n
S e gm en ta tion
v a r ia b le s
G e n e ra l d e s c r ip t iv e S i t u a t io n a l
s p e c i f i c
Ss9 n s n ta t io n
P ro ce d u re
A  p r i o r i D e s c r ip t iv e  v a r i ­
a b le s !  
e co no m ics , 
de m ograph ies
S p e c i f i c  v a r ia b le s !  
g m p  c o m p o s it io n , 
p u r c h a s in g  a c t i v i t i e s
A  p o s t e r io r i
,
D e s c r ip t iv e  v a r i ­
a b le s  c o n n e c t in g  
g ro u p  d i f f e r e n c e s
D i f f e r e n c e s  o f  
p a r t i c ip a t io n  and 
in v o lv e m e n t  o f
on  in v o lv e m e n t 
s t r u c t u r e s
mentoers i n  o b se rve d  
a c t i v i t i e s
Figure 4.7 Integrated framework! consumer/industrial market 
segmentation
(Cheron and Kleinschmidt, 1985)
Chapter 5 RESPONSE BASED SEGMENTATION OF THE GP MARKET
5.1 Introduction.
The first chapters in this thesis explained the need 
for market segmentation of the GP market in the UK, the 
previous chapter has outlined various approaches to 
market segmentation. This chapter reports on findings 
on a segmentation study conducted on the basis of data 
described in section 3.6 of this thesis.
Segmentation of the market in the case reported here is 
conducted with the objective of using these segments to 
allocate the marketing budget more effectively, ideally 
with the assistance of a model to be developed in 
subsequent chapters. Therefore the segments to be 
identified will form an input to the model to be 
developed.
Segmenting with the objective of more effectively 
allocate the marketing budget requires analysis of the 
market to examine whether groups of customers with a 
similar response to marketing effort can be identified. 
The importance of responsiveness is highlighted by 
Kotler (1984, p.123) when he stated that:
'Of central interest is the question, how do
consumers respond to various marketing
stimuli that the company might arrange? The 
company that really understands how consumers 
will respond to different product features, 
prices, advertising areas, and so on, will 
have enormous advantage over its 
competitors'.
Consequently, this chapter is thus testing the 
hypothesis
H3: It is possible to define market segments on the
basis of response to marketing stimuli.
The introduction into the methodology applied is 
followed by a discussion of the results and a summary 
of the findings.
5.2. Methodology.
If segmentation is conducted with the aim of allocating 
promotional expenditure, then the response to 
promotional effort is the best basis for segmentation. 
This is because it is a waste of resources to ignore 
differences in response to marketing effort and to 
spend effort equally on individuals who are less likely 
to respond to the chosen stimuli than others. Thus, 
response based segmentation is a meaningful way of
market segmentation with the view of allocating 
promotional resources.
The basic concept of response based segmentation as 
demonstrated in figure 5.1 is as follows:
Purchase behaviour is measured at two distinct points 
in time. Relating the change in purchase behaviour to 
expenditure on promotional stimuli, i.e. sales force, 
direct mail or advertising, then individuals' 
responsiveness can be measured. This is exactly the 
aim of the exercise, to identify doctors who are 
similar in their response to promotional effort.
Figure 5.2 summarises the steps taken to conduct this 
analysis. As explained in section 3.6, data sets 
covering two snapshots are available. Brand preference 
is chosen to represent purchase behaviour in the 
absence of access to 'real' prescription data. When 
filling in the questionnaire the doctor clearly stated 
his or her attitude. In the light of the discussion of 
buyer behaviour in section 3.3.1 it is controversial to 
assume that a change in attitude will be followed by a 
change in behaviour. That is it is not necessarily 
guaranteed that more prescriptions are written once a 
more positive attitude towards a drug is achieved.
Fishbein (1967) concluded that there is no consistent 
evidence supporting the hypothesis that knowledge of an 
individual's attitude will allow the prediction of the 
way he will behave. Engel and Blackwell (1982, p 442), 
however, concluded that for a high involvement 
decision, as which the prescription of drugs is treated 
in this thesis (chapter three), the link between 
attitude and behaviour is closer than in low 
involvement decisions. They claim that a change in 
attitude is a valid marketing goal. Consequently, it 
is not unreasonable to treat brand preference as a 
proxy for purchase behaviour in the absence of access 
to 'real' prescription data.
Due to the Government's amendments to the limited list 
discussed in chapter three, various drugs could not 
prescribed further through the NHS. Consequently, 
changes to the questionnaire had to be made to 
accommodate the new situation when it was sent out for 
the second time. This does to some extent hamper the 
ability to analyse change in preference, because 
obviously the comparison has to be for like with like. 
Here for some therapeutic classes it was impossible due 
to the different products listed in the questionnaire.
These changes ruled out hypnotics as a class to analyse 
due to the introduction of generic prescribing. 
Therefore, the analysis is conducted for two
therapeutic classes of interest to the company, 
contraceptives and anti-rheumatics. These were the 
only classes of interest that stayed stable over the 
period in question. The analysis for each class is 
carried out independently from the other. The data 
available for the two classes are biased to some extent 
since the sequence of products as listed in the 
questionnaire was apparently not changed. Thus, a bias 
towards those products which are listed first in the 
questionnaire might be expected. However, there is no 
evidence that this possible bias actually materialised.
The objective of the analysis here is to identify those 
doctors who are significantly responsive to promotional 
effort. The sequence of the analysis is displayed in 
figure 5.2.
For a particular product in a given therapeutic class, 
the doctor will have had a certain preference. Again a 
certain preference will have been stated in the second 
questionnaire. A weighting as displayed in table 5.1 
for the permutation of possible changes in preferences 
is given and is being allocated to doctors in the 
second step of the analysis. In this second step each 
doctor is being allocated a value for each product in 
the class to be examined to express the doctor's change 
in preference.
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As indicated in step 3 (figure 5.2), the matrix showing 
the doctors on the vertical axis and the change in 
preference for products on the horizontal axis has to 
be turned around. This turning of the matrix was 
unfortunately not possible on the version of SPSSX on 
which all the other analyses discussed in this thesis 
were conducted. The data at this stage had to be 
transferred to a system called SAS which offered the 
required facilities.
In step 4 promotional expenditure is added for 
individual products broken down into sales force and 
direct mail/advertising.
For each individual doctor a separate regression 
analysis according to step 5 is conducted. Then the 
final step allows the identification of individuals who 
are statistically significant in their response.
5.3 Response Based Segments
Table 5.2 summarises the results of the individual 
regression analysis.
For anti-rheumatics the results are very discouraging. 
The one-tail and two-tail tests indicate that only very 
few doctors are statistically significant in their 
response to promotional effort. There is only a
marginal difference between the actual and expected 
number of responsive doctors.
Similar results are obtained for contraceptives. The 
individual effects of journal advertising/direct mail 
and sales force are not conclusive. However, the 
combined effect of all promotional activities is 
significant. Many more doctors shifted their 
preference towards drugs on which was spent a high 
proportion of promotional activities.
Only for contraceptives the combined effect of 
promotional effort indicates a higher than expected 
number of responsive doctors. But even this is only 
slightly more than 10% of the population of doctors.
The questions that arise from this analysis are:
Are only 10% of all doctors responsive to 
promotional effort? i.e. does promotional effort 
not work, is it a waste?
Who are the responsive doctors?
Are doctors who are responsive in one therapeutic 
class, responsive in others as well?
Should promotional effort not be geared to those 
who are responsive?
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A more detailed analysis of the profile of the 
responsive doctors reveals that they tend to be high 
prescribers in the respective product class. There is 
a bias toward higher number of prescriptions overall.
These findings are obviously encouraging because they 
point toward a link between doctors' potential and 
their responsiveness to promotional effort.
From the analysis presented here, it seems as if 
promotional activities do have far less impact than 
might be assumed. At least from these data it does not 
seem that there is a significant shift in preference 
towards those drugs on which there were heavy spends. 
But it has to be borne in mind that this analysis is 
based on only two therapeutic classes. Hence the 
conclusion stated above has to be treated with 
appropriate care. There is no significant correlation 
between doctors who are responsive in either class. 
Further work is necessary to establish links. The 
problem, however, is which therapeutic classes to 
include to achieve an accurate picture. As outlined 
above, the structure of the data available does not 
allow the conduction of this analysis across all 
therapeutic classes. Thus, the analysis as presented 
here has to be limited to a snapshot of two therapeutic
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Do these discouraging results not postulate the 
reduction of promotional spending or even its complete 
deletion? Yes, there is evidence that promotional 
expenditure does not work as might be expected in 
winning new customers. However, this, winning of new 
customers, can only be one aspect of the success of 
promotional expenditure. The other obviously is to 
attract the current customers. The regression analysis 
explained above will not have detected those 
individuals who maintained their preference for a 
highly promoted product. Thus, the regression analysis 
is geared towards detecting aggressive gains, and is 
obviously neglecting defensive moves.
This discussion needs to be seen in the light of 
objectives for promotional activities. As far as the 
brand attitude is concerned, Rossiter and Percy (1987, 
p.152) distinguished four objectives:
- to create brand attitude when the target market 
is unaware
- to increase brand attitude when attitude has 
only been moderately favourable.
- to maintain brand attitude when maximal 
favourable attitude existed already
- to modify brand attitude for re-positioning 
purposes
- to change brand attitude when a negative
attitude existed
Since the data available did not allow the detection of 
a negative attitude and measured preference only in 
relation to a given therapeutic class, changing and 
modifying attitudes could not be addressed in this 
thesis. Only the objectives of increasing and 
maintaining attitude as a result of promotional 
expenditure could be addressed here.
This defensive element in promotional efforts can best 
be illustrated using table 5.3. There, for the leading 
contraceptives their 'current' market share (as of the 
second snapshot) is related to how this translates into 
preference as far as the database is concerned. I.e. 
the 18.4% market share of Logynon is equivalent to 10% 
of doctors having this product as first choice, 3% as 
second choice etc. The next column displays the sales 
increase over the period of the two snapshots, i.e. 16% 
increase for Logynon. The last column indicates the 
proportion of promotional effort for a product relative 
to total promotion for contraceptives, i.e. Logynon 
accounted for 16.5% of total promotion. Underneath, 
figures are given tor how the preference has changed. 
The expenditure lias had little impact on 21% of GPs who 
are still not prescribing the drug. Another 21% have 
gone down in their preference, while 32% of GPs 
indicated an increase in preference for Logynon.
The example shows two interesting pairs of products. 
Logynon and Microgynon, as well as Trinordinol and
Ovranette. Both pairs have similar market shares 
(18.41/17.3% and 9.3%/8.9% respectively). Within both 
pairs there are differences in success. While 
Logynon's sales went up 16%, Microgynon's only 
increased by 8%, Trinordinol's sales increased by 9%, 
Ovranette's only by 4%. Can these differences be 
explained by the completely different promotion 
strategies?
The successful products account for 16.5% and 13.4% of 
total promotional expenditure in this class, while on 
the two less successful ones next to nothing was 
spent. However, a more detailed look at how 
promotional expenditure has worked stems from the 
figures in the third column in table 5.2. For the 
first pair there is hardly any difference in the number 
of people who increased their preference. 32% went up 
in their preference for Logynon, 29% increased theirs 
for Microgynon. A similar pattern can be observed for 
Trinordinol, and for Ovranette, up 27% and 26% 
respectively. Clearly, the difference in promotional 
effort had no visible effect on the number of doctors 
increasing their preference.
On the other hand, staggering differences can be 
observed when looking at the other side, losing 
preference. For Microgynon, 27% went down in their 
preference; almost as many as increased the preference.
Logynon, however 'lost' only 21% oC doctors, which is 
considerably less compared with those who were won. A 
similar pattern was seen for the other pair: Ovranette 
•lost' 25% while Trinordinol only lost 19%.
These differences indicate very clearly the importance 
of promotional effort in reassuring and maintaining 
current customers. It seems as if the increases in 
sales for the two highly promoted product were mainly 
achieved by losing fewer of their existing customers.
5.4 Summary.
This chapter analysed the dynamic behaviour of GPs. It 
tried to segment the market on the basis of response to 
promotional effort. The results in two therapeutic 
classes indicate that only a few more doctors, compared 
with expections from random data, are significantly 
shifting their preference towards products which are 
heavily promoted. The results indicate that 
segmentation purely on the basis of response, although 
very desirable under the objective of allocation of 
promotional effort, is not feasible with the data 
available.
It is, however, argued that winning new customers (i.e. 
increasing preference for a product) is only one aspect 
of how promotional efforts work. The other is the
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value in maintaining loyalty of current users. In an 
example of the contraceptive market it is demonstrated 
how, with completely different promotion strategies, 
products won a similar number of new customers, but 
that those products on which little was spent lost a 
significant higher number of current customers. In 
that example promotions worked clearly to the effect of 
keeping preference at a high level rather than 
increasing it. There are strong indications that these 
phenomena caused a significantly higher increase in 
sales for the promoted product. These findings led to 
the conclusion that segmentation based purely on 
dynamic aspects would not lead to very meaningful 
results.
The conclusion drawn from the work reported in this 
chapter is that hypothesis H3 has to be rejected. The 
analysis of the available data could not establish that 
it is possible to define market segments on the basis 
of response to marketing stimuli. Consequently, the 
following chapter describes a different approach to 
market segmentation to overcome the problems 
encountered with dynamic approach to segmentation. A 
static approach, analysing the market at one particular 
point in time, avoids the problem of non-compatibility 
of data experienced in the approach described in this 
chapter.
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1. Compare change of preference in product class:
Old Data
first
second
third
other
no
2. Allocate a value for 
doctor's change.
3. Turn around the matri
Before 
PI ... P23 
D1
New Data
first
second
third
other
no
product to express each
After
D1 ... D1000 
PI
D1000 P23
4. Add promotional expenditure
D1 ... D1000 SF JM
PI
P23
5. Regression Analysis for each individual doctor to 
express the relationship of change in preference and 
promotional expenditure.
S = aSF + bJM ♦ c(SF x JM) ♦ U
S Change in preference
SF Sales force expenditure
JM Journal advertising/direct mail expenditure
Figure 5.2 Sequence in conducting response based segmentation 
in a therapeutic class
Change in preference
1 first choice
2 second choice
3 third choice
5 other choice
9 no choice
From\TO 1 2 3 5  9
1 0
2 4
3 5
5 8
-4 -5
0 -1
1 0
4 3
-8 -10
-4 -6
-3 -5
0 - 2
9 10 6 5 2 0
Table 5.1 Weightings for change in preference
Doctors who are responsive to:
Anti rheumatics
Two-Tail Test One-Tail Test
Journal/direct mail 
Sales force 
Combined
2.7%
3.9%
2.2%
6.5%
7.3%
4.9%
Contraceptives
Journal/direct mail 
Sales force 
Combined
3.8%
3.1%
7.8%
6.7%
4.7%
11.7%
Calculations are based on the 5% level significance.
Table 5.2 Results of response based segmentation
C O N T R A C E P T I V E S *  ANALYSIS O F  C H A N S  - L E A D I N G  BRANDS 1 45
Current 
Market Share
Seles
Increese
Proport ion 
Of Promotion
LOGYNON 08 18.41 ♦ 161 16.51
101 First 2 11 steo le no
31 Second
21 Third 211 down
1 11 Other 321 up
MICROGYNON 10 17.31 ♦81 .21
121 First 141 steole no
61 Second
21 Third 271 down
101 Other 291 up
TRINORDIOL 21 9.31 ♦ 91 13.41
31 First
21 Second
11 Third 191 down
141 Other 271 up
OVRANETTE 19 8.91 ♦41 .61
51 First 251 steble no
31 Second
21 Third 251 down
141 Otl»«r 261 up
EUGYNON 04 7.61 '33* 1.81
11 First
21 Second
11 Third 181 down
141 Other 281 up
MARVELON 09 4.91 441 1 11
11 First SOI stsole no
11 Second
11 Three 111 down
91 Other 191 up
MINOVLAK 14 1.71 >101) .31
41 Other 701 steole no
111 down
81 up
Table 5 . 3 Promotional expenditure and change in preference
continued
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Current 
Merket Shere
Seles
Increese
P r o o o r t  to n 
o f  P r o m o t i o n
FEMULEN 06 2.St
it Third 
9t Other
It .41
6 9 1  s t e o l e  n o
101 d o w n  
1 it up
10ESTRIN 07 3.7t
It First 
it Second 
lot Otnor
♦7t 131
S61 s t e o l e  no
181 down 
131 up
BREVI NOR 01 3.St
2t First 
it Second 
13t Other
( 2 2 1 )
191 down 
161 up ,
3 I MOVUM 02 3.ft
it First 
1t Second 
1 it Ot her
.31
591 steble no
131 down 
141 up
0EP0PR0VERA 24 0 . 2 1 ♦ 4 7 1
931 steole no 
71 up
Table 5.3 contd.
Chapter 6 STATIC SEGMENTATION OF THE GP MARKET
6 .1 Introduction
In chapters one and two it was explained that it is 
intended to develop a model assisting in the resource 
allocation to products, market segments and promotional 
tools. The area of analysis has focused on the GP 
market in the UK. Chapter three concluded that the 
scarce resources of the marketing budget should be 
focused on those doctors who are likely to give the 
highest return to the promotional expenditure. This 
obviously calls for segmentation of the GP market. 
Consequently, aspects of market segmentation have been 
reviewed in chapter four. It is apparent that 
creativity and open-mindedness are keys to a successful 
segmentation study.
This chapter builds on the conclusions drawn and 
summarises static approaches to market segmentation. 
Static segmentation refers to the segmentation study 
being undertaken at a particular moment in time. Such 
a 'snapshot', in this case, is provided by segmenting 
the market based on the 1985 data only.
Segmentation is only meaningful when the segments 
identified reflect a difference in response to 
marketing stimuli. This aspect was addressed in the
previous chapter, when an approach to dynamic 
segmentation, (segmentation based on change in response 
over time), was discussed. However, the conclusion 
taken from the previous chapter is that the data 
available in this case are not sufficient to establish 
viable segments based on response to marketing stimuli.
In the absence of sufficient data to identify dynamic 
segments, it is attempted in this chapter to test 
hypothesis H4 which states, that it is possible to 
define static segments which reflect dynamic behaviour. 
The test of this hypothesis will then be linked to 
testing hypothesis HI which states that segmentation 
can be used to allocate sales effort.
The results of the static segmentation approach are 
summarised in four steps. First, the methodology in 
approaching the segmentation study is outlined. Then 
the results of the macro-analysis, that is segmentation 
based prescriptions across a number of therapeutic 
classes, are presented. This is followed by the third 
section which outlines the procedures taken to validate 
the findings. The following section then presents the 
conclusions drawn from the findings and a discussion of 
an example of the micro-analysis, which is a 
segmentation study based on preference within a 
therapeutic class. The final section in this chapter 
summarises the findings.
6 .2 Methodology
The objective is to segment the GP market so as to 
allow the most effective allocation of the marketing 
budget, sales effort in particular. Therefore, the aim 
has to be to single out segments in the markets which 
have high potential for prescribing and which are 
responsive to promotional effort.
This chapter discusses two approaches to static market 
segmentation based on the macro-analysis and on the 
micro-analysis.
The analysis at the macro level aims to identify groups 
of doctors within the GP population in general, not 
specifically related to a particular therapeutic class. 
This analysis is helpful in understanding the structure 
of the GP population, in order to make decisions 
relative to the product portfolio.
The analysis at the micro level aims to identify groups 
of doctors relative to a specific therapeutic class.
The understanding of the market structure in a 
particular therapeutic class enables segmentation and 
targeting for a particular product.
The focus in this chapter is on the macro-analysis, an 
example of the micro-analysis is discussed in section 
6.5.
The Company in the example used here is only operating 
in a limited number of therapeutic classes. Therefore, 
the market could be segmented just on bases important 
to those classes. For the macro-analysis, however, it 
is important to identify groups of GPs independently 
from the current product portfolio. This will give an 
understanding of the market structure as a whole. This 
less biased approach overcomes the problem of using an 
a priori variable to discriminate between groups, 
whereby the choice of the a priori variable dictates 
the outcome.
Theoretically, the problem of choosing the bases for 
segmentation can be solved using Automatic Interaction 
Detection (AID) (Assael, 1970) by sorting through large 
numbers of alternative bases to produce a hierarchy.
As demonstrated by Doyle and Fenwick (1975) its 
application has been found to be unreliable and 
misleading, mainly due to the successive splitting of 
the market producing very small cell sizes unless very 
large samples are available.
Whereas AID achieves the hierarchy of bases by 
sequentially taking an a priori basis, cluster based
segmentation (Green 1977) uses cluster analysis to 
group on a number o£ criteria simultaneously. This 
less biased approach offers the advantage of seeking 
out meaningful segments from a large data base 
(Saunders 1980, p. 442).
Purchase behaviour or descriptive information can both 
be used for a priori or cluster based segmentation.
From the practitioner's standpoint purchase behaviour 
is the primary classification criterion because it 
focuses upon the very action the marketer is trying to 
change. Descriptive information, however, can provide 
a deeper understanding of the segment under 
examination, but by itself is a less useful guide to 
strategy (Brown 1983). This is mainly true because 
descriptive information can only act as a proxy for 
purchase behaviour.
Beside a priori and cluster based approaches. Wind 
(1978) distinguishes two other segmentation approaches 
- flexible and componential designs. Both designs rely 
on compound analysis and were discarded as being 
inappropriate in this study due to the number of 
products in the GP market and type of data available.
The approach taken in this case is in analogy to Bonoma 
and Shapiro's (1983) nested approach, as outlined in 
figure 4.6 in chapter four, whereby the segmentation
process is conducted from the outer nests, containing 
the more easily obtainable segmentation bases, to the 
inner nests containing the more specific ones. As 
discussed in previous chapters, a priori segmentation 
had been applied to focus on the GP market within the 
NHS market as opposed to the hospital market or the 
private prescription market.
Consultations with market research companies and with 
the Company's sales representatives, sales managers, 
marketing managers and market research personnel 
revealed that beyond this a priori segmentation there 
was no clear evidence for how the market could be 
further divided. The existence of various segments was 
hypothesised but no clear basis for segmentation 
emerged.
In order to achieve an unbiased approach (Saunders,
1980 p.442) to segmentation it was then decided to 
apply cluster analysis since no other a priori bases 
could be established. Following the a priori 
segmentation which identified the GP segment, the aim 
is to group doctors according to more specific 
variables, thereby taking into account the variables in 
the inner nests following the nested approach to 
segmentation.
Cveritt (1974, p.7) classified cluster analysis 
techniques into four main types:
(i) Hierarchical techniques - in which cases or 
entities are classified to demonstrate 
hierarchical connections (Zupan 1982 p.13).
(ii) Optimisation - partitioning techniques - in which
clusters are formed on the basis of optimising a 
clustering criterion. f
(iii) Density or mode-seeking techniques - in which 
clusters are formed by searching for regions 
containing dense concentrations of cases or 
entities.
(iv) Clumping techniques - which allow an overlap of 
classes or clumps.
Blashfield and Aldendefer (1978) in an analysis of 
published articles based on the use of cluster analysis 
found that agglomerative hierarchical methods were by 
far the most dominant methods as far as frequency of 
application is concerned. Subsequently, the focus of 
this review will be on those agglomerative hierarchical 
clustering methods.
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Hierarchical clustering techniques may be subdivided 
into agglomerative methods and divisive methods. While 
the divisive methods partition the set of N entities 
into finer partitions, agglomerative methods proceed 
with a series of successful fusions of the N entities 
into groups (Everitt 1974, p.8 ).
Aldendefer and Blashfield (1985, p.35 pp) distinguished 
the following agglomerative methods:
(i) Single Linkage (Sneath 1957)
Cases are joined to existing clusters if at 
least one member of the cluster is at the 
same level of similarity as the one under 
consideration.
(ii) Complete Linkage (Sokol and Michener 1958)
Cases will be joined to existing clusters on 
the basis of similarity to all members.
(iii) Average Linkage (Sokol and Michener 1958)
Cases are joined to existing clusters on the 
basis of similarity to the average member.
(iv) Ward's Method (Ward 1963)
Cases are joined to existing clusters as to 
maximise the variance within clusters.
The objective function measures the error sum 
of squares (ESS) according to 
n
ESS » E (Xi2 - 1/n (EXi)2) 
l«l
with X± being the score of the ith case of n 
cases.
Consecutively joining cases on the basis of 
minimising the error sum of squares leads to 
a hierarchy of clusters starting from the 
stage at which all cases are in their own 
cluster to the final stage when there is only 
one cluster. It is obvious that there is a 
strong increase in 'stress' (ESS) at the 
final stages of the clustering process, when 
the most differing cases are combined.
Blashfield (1980) found that Ward's method is widely 
used in the social sciences. In the case reported here 
it was found to produce the most robust solutions, 
which is in line with results of previous studies 
(Blashfield 1976, Wishart 1978).
Having outlined the various clustering techniques and 
having decided to use Ward's method, it is then 
important to decide on the variables to include in the 
cluster analysis.
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Since it was the aim to identify groups of doctors who 
behave similarly, it was decided to use the behavioural 
data to segment the market, leaving the demographic 
information to describe the groups.
Ideally, the analysis could have been conducted at the 
brand level, measuring brand preference. Since the 
data contain information on several hundred brands, the 
statistical validity is not secured with 'only' 1 0 0 0  
cases, besides the enormous computational demand which 
makes this approach infeasible anyway.
In order to overcome the problem of the large number of 
brands a solution could have been to sample brands to 
include in the cluster analysis. This approach was 
rejected in favour of a more comprehensive approach. 
Rather than arbitrarily sampling the variables, the 
analysis was conducted at a higher level, based on a 
census.
The data available (C.F. questionnaire in appendix 1) 
not only identified the doctors' brand preference in a 
therapeutic class but also the number of prescriptions 
written in the therapeutic class in question. At the 
level of therapeutic class the number of prescriptions 
written in a class is treated as a variable. As 
variables are included in the analysis the number of
prescriptions written in all 43 therapeutic classes 
covered in the questionnaire to guarantee an unbiased 
approach.
It is common to normalise and factor analyse data prior 
to clustering. In this case normalisation was not 
conducted because it would have caused overall high and 
low prescribing GPs to be treated the same as if they 
prescribed therapeutic classes in similar proportions. 
This would have been less useful than identifying GPs 
who were overall high prescribers. For the same reason 
factor analysis was not conducted (it automatically 
normalises data) and, besides, enough processing power 
was available to conduct clustering without data 
reduction.
To illustrate the approach further and to justify why 
all classes have been considered instead of clustering 
on the basis of factors is the more important since the 
magnitude of values between variables differ. As can 
be seen in the questionnaire displayed in appendix 1 , 
the highest level classifying prescribing in the 
therapeutic class of betablockers, for example, is more 
than seven prescriptions per week. For contraceptives, 
for example, the scaling is different to the extent 
that seven to nine prescriptions per week only qualify 
for the second highest level on the scale, while the 
highest level is in excess of ten prescriptions per
week. The differences in scaling take into account the 
relative level of prescribing in the various 
therapeutic classes.
However, the aim is to identify doctors who are similar 
relative to other doctors. Therefore, the absolute 
number of prescriptions in a therapeutic class with, 
for example, relatively few prescriptions compared to 
others, is of little value. What is important, 
however, is to determine that even in a class with a 
few prescriptions, the doctor is a relatively high or 
low prescriber. Secondly, if the objective is to have 
an unbiased approach then there is little value in 
grouping therapeutic classes which bear no relationship 
with each other. There seems to be no logical reason 
why one should group, say, betablockers and 
cont racept ives.
Consequently, all therapeutic classes are considered 
with equal weight. Thus, a compromise has been found 
between the desire for an unbiased approach and the 
need for a meaningful number of logical variables to be 
included in the cluster analysis.
6.3 Macro-Analysis
Using the methodology outlined in section 6.2 in the 
Macro-analysis seven groups of doctors are identified 
as segments in the GP market. Using demographic 
information to describe doctors in the groups, the 
following profile can be drawn. The results of the 
Macro-analysis are displayed in table 6.1. This section 
provides an overview of the segments identified.
•Dr Average'
Approximately one fifth of the population could be 
described as being average. Across the therapeutic 
classes these doctors prescribed an average number of 
prescriptions. All the other information available 
underlines that picture. Although they tended to work 
in slightly larger than average sized practices they 
reported to prescribe overall slightly less than 
expected.
'Early Majority'
This group consisted of high prescribers across the 
therapeutic classes. This large group, a quarter of 
the population, consisted of active doctors, who 
prescribed new drugs earlier than the rest of the 
population, hence the label. The high number of 
prescriptions written by members of this group is 
reflected in their self-reported classification. The
high number of prescriptions is related to the above 
average size of the practice and the number of patients 
each is responsible for. This highly attractive group 
only saw an average number of pharmaceutical 
representatives.
'High Energy'
Only 10% of the population could be labelled as 'High 
Energy*. These were very high prescribers across the 
therapeutic classes and were male dominated. Being 
older, and more experienced, they tended to be involved 
in the early stages of new drug introductions. Doctors 
in this group scored the highest points across 
demographic criteria. Their high number of patients 
and prescriptions was paired with a high number of 
pharmaceutical representatives seen.
'Young Conservative'
A large group in the GP population was prescribing 
little across therapeutic classes. These doctors were 
younger and conservative as far as the adoption of new 
drugs was concerned. Their conservative prescribing 
behaviour may have been due to their more recent 
education, which emphasised on writing fewer 
prescriptions. To some extent the few prescriptions 
can be explained by the below average number of 
patients seen by doctors in this segment.
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•Thrifty Housewife'
Twice as many women are in this group compared with 
women* share of the total population. Their very low 
number of prescriptions can be explained by the fact 
that quite a large number of female doctors worked on a 
part-time basis. Consequently, they could only see few 
patients, hence their low prescribing compared with 
other groups. The male part of this group consisted of 
older, and probably semi-retired doctors.
•Odd Balls'
This very small group (3%) is described by its very 
erratic prescribing behaviour across therapeutic 
classes. Doctors in this group basically had in 
common that they did not fit in with any other group. 
Since it is only a small group there is no practical 
significance in pursuing a further analysis.
•Quasi Homeopath'
Approximately four percent of doctors can be described 
as 'Quasi Homeopaths', since apparently they did not 
prescribe at all, or just very little. There was no 
clear pattern of this rather small group as far as 
demographic information is concerned. Thus it should 
be treated in a similar way as the 'Odd Balls': with
little attention.
6.4 Validation
The existence of the segments identified and described 
in the previous section must be validated. The most 
comprehensive framework for validating cluster based 
segmentation was developed by Choffray and Lilien 
(I960,
Appendix 4.2). They suggested a three step process:
1. Tests on the sensitivity of cluster analysis.
2. Tests on the non-randomness of the structure 
observed in a dissimilarity matrix, and the 
determination of the number of clusters retained.
3. Determination of the non-uniqueness of the 
clustering solution retained.
6.4.1 Elimination of outliers
In order to obtain intra-segment homogeneity, thereby 
decreasing the sensitivity of the cluster analysis, the 
data need to be searched for extreme outliers. Their 
inclusion in the analysis would distort the picture and 
would artificially create less robust groupings.
According to Blashfield's (1976) suggestion, single 
linkage cluster analysis was applied. This clustering 
method combines clusters on the basis that every member 
of the cluster is more similar to at least one member 
of the same cluster than to any member of any other 
cluster. This process tends to generate long, loosely 
connected clusters.
Outliers in this process, those individuals who are 
fitted into groups under increasingly higher stress in 
the final stages of the clustering process, are easily 
detected and subsequently 24 doctors were excluded from 
further analysis. This procedure enabled the 
achievement of more robust clusters without the 
distorting influences of these extreme outliers.
6.4.2 Non-randomness of the data structure
The choice of the number of clusters in the final 
solution is a problem with all clustering techniques. 
Some authors (e.g. Friedman and Rubens 1967) suggested 
that the number of clusters should be set when the 
further combining of clusters results in a 
disproportionate increase in stress. This is a rather 
crude method but inspection of the dendrogramme (figure 
6 .1 ) indicates a leap in stress at the seven cluster
solution which is more than double the increase in 
stress compared with the eight and nine cluster levels.
In order to test Cor non-randomness in a more 
sophisticated way ChoCCray and Lilien (1980 p.200) 
recommended the generation of five to ten random data 
sets on which to apply the same method of cluster 
analysis. This process is undertaken to ensure that 
the results obtained from the cluster analysis of the 
data in the sample are significantly different from the 
results achieved with random data.
Subsequently, ten random data sets covering the 
relevant number of cases were generated. As in the 
case of the original data set. Ward's method was 
applied. Figure 6.2 demonstrates the results of the 
cluster analysis of the random data compared with the 
actual results. The increase in stress is plotted 
against the level of clustering. This analysis remains 
inconclusive as to which level of clustering is the 
appropriate one. Doyle and Saunders (1985, p.30) 
succeeded in supporting their choice of clustering 
level conclusively using this method.
Although this first test for non-randomness remained 
inconclusive, a further test could be applied. Using 
the clustering methods complete linkage, average 
linkage and the centroid method, cluster memberships
were compared with the solution obtained by Ward's 
method. As expected, the solutions were not identical, 
but 67.7, 54.6 and 68.1 per cent of of the cases 
respectively were allocated to the same clusters. The 
null hypotheses that these allocations were random 
could be rejected with 99.9 per cent confidence.
Managerially, none of the statistical tests for the 
number of clusters is satisfactory (Saunders 1980). For 
management the real criterion is the utility of the 
solutions. This depends on such factors as the value of 
the segment, its accessibility, competitive activities, 
and management's capacity to implement different 
segmentation strategies. The approach taken was to 
present to management as clearly as possible several 
levels within the clustering hierarchy, so that they 
could choose which one to adopt.
Initially, the seven cluster solution was presented 
along with the eight and nine cluster solutions, which 
brought a split in the groups of 'Early Majority' and 
'High Energy' (Maier 1986). The profiles of these new 
segments are outlined in table 6 .2 .
The segment of 'High Energy' which itself is a 
relatively small segment accounting for ten percent of 
the population broke down almost equally into two 
smaller segments. The smaller of the two contained the
less active members oC an already very active group of 
doctors, which showed a high involvement in clinical 
trials, hence the label 'Initiator'. The second group 
is less innovative but very active. The label 
'Enthusiast' seems to describe members of this group 
adequately.
The segment consisting of the 'Early Majority* which 
overall showed a strong interest for Paediatrics 
(child-related illnesses) broke down into two smaller 
segments with a strong discriminating display of 
interests. While the larger group still expressed a 
strong interest for paediatrics, the smaller group is 
described by the complete lack of interest for this 
part of medicine. 'Child Lover' and 'Kinderschreck' 
are the labels chosen for these two groups.
Management liked the idea of being even more precise, 
but finally the seven cluster solution was adopted on 
the grounds of utility. It was found that the seven 
cluster solution adequately reflected management's 
perception of the market, moreover, with larger groups 
identified as unique segments there is obviously less 
danger for the solution not being robust.
6.4.3 True cluster solution
To further test for the non-uniqueness of the cluster 
solution found, the second data set was used as a 
validation sample. The validation process consisted of 
five steps:
1. Cluster analysis (Ward's method) of the original 
data set.
2. Discriminant analysis (Plank 1985) was used to 
obtain functions describing the characteristics of 
the cluster solutions.
3. Discriminant functions were applied to the 
validation sample. Thus members of the hold-out 
sample were then allocated to the clusters 
previously identified.
4. Cluster Analysis (Ward's method) of the validation 
sample.
5. Comparison of cluster memberships.
The overlap in membership as obtained by the 
discriminant functions was compared with the membership 
obtained by the cluster analysis. 71 per cent of 
doctors were allocated to the same clusters. This
overlap in the cluster membership is significant at the 
99.9 per cent level.
6.4.4 The Experiment
The segments described in this chapter are all based on 
the analysis of static information, a 'snapshot'.
It is, however, very important to identify groups in 
the market place which respond differently to elements 
of the marketing mix. Only then is it really 
meaningful to segment the market. As demonstrated in 
chapter four, many segmentation researchers choose as 
bases for segmentation static market measures 
(demographics or psychographics) upon the assumption 
that these bases will explain dynamic behaviour; i.e. a 
response to the marketing mix.
To test for this assumption, that the static segments 
identified can be used to explain dynamic behaviour, a 
natural experiment (Lilien and Ruzdic 1982) was used.
As part of the company's promotional activities, the 
database was used for a direct mail campaign promoting 
a mature product. The GPs included in the samples used 
for the analyses reported here were included in this 
mail shot. Upon response GPs were offered a free
product sample plus a world map as an Incentive to 
respond.
As shown in table 6.3 two segments showed a significant 
higher response than expected whilst one segment showed 
a significant lower rate of response.
The low response rate from segment 'Young Conservative' 
seems to confirm the view that this group does present 
a considerable problem for pharmaceutical companies.
Not only are they below average prescribers, they also 
seem to be less responsive to marketing stimuli.
The very high response rate from the 'Quasi Homeopaths' 
is probably surprising but might be explained by a 
certain degree of 'deal proneness■.
Good news for pharmaceutical companies is the high 
response rate from the very attractive group labelled 
'Early Majority'. This large group consisting of high, 
fairly innovative prescribers is a very attractive 
target.
The 'High Energy' doctors probably were too busy to 
respond, while the group 'Dr Average' did not show any 
significant difference in response compared to the
average.
The results of the natural experiment confirm two 
important points. Firstly, the results are in line 
with the descriptions of the segments using the 
demographic information. Secondly, the results confirm 
hypothesis H4 which states that static segments can be 
used to explain dynamic behaviour.
6 .5 Conclusions and Discussion
Taking into account the heavily restricted promotional 
budget, it is very important for pharmaceutical 
companies to focus their efforts on those segments of 
doctors which have the highest potential. The database 
upon which the analysis is conducted offers the unique 
opportunity for not only determining segments but it 
offers additionally the possibility of targeting the 
individual doctor in a particular target market 
segment.
In consumer markets segments might be identified, thus, 
it might be known that certain segments exist. The 
problem, however, is then the second step: targeting. 
Where are the members of the target market segment? How 
can they be approached?
Since the database has been set up for targeting 
purposes, this second step is not a problem in the
underlying case. What has been lacking, however, is a 
first step, a proper segmentation procedure. The 
results of the macro-analysis provide exactly that.
The problem then is somewhat reduced, to the selection 
of target segments.
However, while the macro-analysis does provide an 
important overview of different groups of GPs in the 
total population, it is additionally possible to 
examine specific therapeutic classes in isolation.
This approach is called micro-analysis♦
Here the objective is to determine groups of doctors 
with similar brand preference patterns in a therapeutic 
class. Thus, a profile of doctors with a certain 
preference pattern can be drawn. This enables the 
marketing manager to position the brand, and allows the 
sales manager to decide which doctors should be 
reassured in their preference and who should be 
targeted to be won from the competition.
The benefit of this approach is that it does overcome 
one of the problems of dealing with databases. The 
organisation of the MDMO database enables the location 
of individuals fulfilling the requirements of a 
specific characteristic, i.e. first choice Mogadon. 
However, the more specific the profile of the group in 
question is (i.e. the number of criteria increases).
the smaller the population is which fulfills all the 
criteria. Thus, it is very often the case that 
management's desire for specific profiles in a 
population leads to only a few individuals in the 
desired group. But as outlined in chapter four, 
segments need to have a certain size to make it 
worthwhile to pursue a separate marketing programme.
This is exactly where the value of the micro-analysis 
can be appreciated. The methodology applied is again 
cluster analysis. The clustering variables measure the 
preference for a particular drug in the therapeutic 
class. Values for each product's variables indicate 
first, second, or third choice, as well as whether the 
product is an also-run, or other choice. The last 
value can occur on a doctor's response for a number of 
products whilst the former are mutually exclusive. 
Obviously, the same degree of caution is required as 
for the situation described in chapter six as far as 
possible bias towards products listed at the top of 
lists in the questionnaire are concerned. Apparently, 
the sequence of products listed was not changed. Hence 
there is a possibility of bias in the data, although no 
evidence was detected.
Again Ward's method is chosen to identify groups of 
doctors with a similar preference pattern. The
analysis will be explained using the therapeutic class 
of hypnotics as an example.
Hypnotics can be divided into barbiturates and 
benzodiasepins. Whilst the former are indicated when a 
patient suffers from uncontrolled pain, the latter are 
indicated when respiratory depression is diagnosed 
(MIMS, 1986 p.61). The reason for choosing hypnotics 
is that the class contains the Company's most 
successful product. In addition, this class is a prime 
example for the confusion observed following changes in 
the limited list in April 1985.
These changes meant that within the NHS section of the 
hypnotics market doctors had to prescribe by the 
generic name. Thus, although there were only thirteen 
separate names listed on the questionnaire, many more 
products (brands) were actually available. For 
example, temasepam was produced under 10 brand names 
(MIMS 1986). The interesting twist was that while the 
doctor prescribed the generic product, the Chemist 
finally made the decision as to which of the temasepams 
to distribute. As a consequence, there was no need for 
pharmaceutical companies to promote their brand to 
doctors any more, in particular when the final decision 
was being made by the Chemist. This decision was made 
on the basis of safety and, more importantly, on 
margins available to the Chemist.
As if this situation was not difficult enough, the 
company's flagship Halcion, known in generic terms as 
Triazolam, was still under patent protection. This 
implied that the only product available under the 
generic name Triazolam was the brand Halcion.
Therefore the company had available a semi-branded 
product, a differential advantage to be exploited by 
the use of the promotional mix. It was therefore still 
worth promoting.
In the context of the size of promotional spending on 
competitive products, it was then the question of how 
to spend on the promotional mix and, more importantly, 
what proportion to spend on current prescribers as 
opposed to new customers. The other interesting 
question was which competitive product to attack and 
which group of doctors to convey the message to. Thus, 
segmentation on the basis of preference within the 
therapeutic class of hypnotics was a valuable step 
towards tackling these problems.
The following segments (table 6.4) were determined for 
the hypnotics market, in which Temasepam, Triazolam and 
Nitrasepam are the leading generic products.
Cluster 1, 'Temasepam and Nitrasepam'
This group, 18% of the population, preferred Temasepam 
and Mitrasepam, both of which were almost used by 
everybody in this group. This group was distinct from 
others by its particular dislike of Triazolam. Doctors 
tended to be older but were not very attractive targets 
since they prescribed a below average number of 
prescriptions in hypnotics.
Cluster 2, 'Do Not'
This group consisted of doctors who either did not 
prescribe hypnotics (41%) or, if they did, had no 
explicit brand preferences. This is, they did not 
usually have a first, second, or third choice, but only 
used a product among others. Consequently, the three 
leading products are shown as other choices.
These doctors generally saw a fewer than average number 
of patients and were low prescribers. Not 
surprisingly, when cross tabulated with the membership 
of the macro-analysis, this group consisted of 'Thrifty 
Housewives', 'Odd Balls', and 'Quasi Homeopaths'.
More than a third of the population belonged to this 
segment. Preference was given to Temasepam but all 
used Temasepam and Nitrasepam. Significant was the 
distinct position of Triazolam as being either second 
or third choice by three quarters of the population. 
This had important implications, especially since this 
group tended to be younger (potential for the future!) 
and saw more than an average number of patients. Above 
all, this group had a high potential since there was a 
tendency to high prescribing in that therapeutic class.
This group showed good potential for Triazolam, 
currently being an also-run. Since the majority of 
doctors in this group were users already, the usage 
rate and the preference had to be increased.
Cluster 4, 'Use many brands'
One fifth of the population was distinct in that they 
favoured a broad variety of products. As reasons for 
this showing it can be stated that these doctors 
actually prescribed very carefully different products 
for different symptoms or, alternatively, that they had 
to work with patients who were on specific drugs 
already before they saw the doctor. The latter could 
quite frequently be observed for Nitrasepam. This
Cluster 3, 'Temasepam, Nitrasepam, Triazolam'
relatively old product had been prescribed Cor years. 
Older patients were used to (or even addicted to) this 
product, their doctors were reluctant to switch thus 
avoiding distressing the patient.
Doctors in this group tended to be older and they 
tended to write a high number oC prescriptions. 
Therefore it was no surprise to Cind a number of 'High 
Energy' doctors in this group.
Cluster 5, 'Temasepam, Triazolam'
With 5% this is the smallest group in the current 
analysis. These doctors favoured the two new products 
and disliked the old Nitrasepam. Almost everybody used 
Triazolam. These doctors were younger but wrote fewer 
than average prescriptions. This applied also to 
hypnotics. Therefore, it was no surprise to see 'Dr 
Average' and the 'Young Conservative' having a 
stronghold here.
Cluster 6, 'Nitrasepam, Triazolam'
This small group (6%) is different by its dislike of 
Temasepam. The majority here favoured Nitrasepam, with 
Triazolam coming second. As suspected, older doctors 
who had not quite changed their preference over the 
years, showed in this group. They tended not to
prescribe a lot of hypnotics (the lack of opportunity 
might explain this preference), although overall they 
were 'Dr Average' 'Early Majority' or even 'High 
Energy*.
The segments identified with the micro-analysis can be 
very effectively used for brand positioning. Analysing 
the profile of segments with a certain brand preference 
enables the determination of which competitive brands 
need to be attacked. The marketing mix can then be 
adjusted accordingly.
It is important to utilise the two approaches for 
static segmentation suggested in this chapter together 
and not in isolation. The macro-analysis provides the 
basic frame for a segmentation study of the GP market, 
while the micro-analysis can then be used to fine-tune 
the marketing strategy within a specific therapeutic 
class. The value of this process can best be 
appreciated when the macro-analysis is combined with a 
micro-analysis for each therapeutic class in which a 
company is operating.
At the first stage, the macro-analysis' identification 
of seven segments, some implications for the 
development of a marketing strategy can be shown. By, 
simplistically, dividing the segments into two groups.
the attractive and unattractive segments, a harvest 
strategy for the latter and a build strategy for the 
former groups could be recommended.
The 'Young Conservatives', 'Thrifty Housewives' and 
'Quasi Homeopaths' constitute 44 per cent of GPs but 
only account for 20 per cent of reported number of 
prescriptions. These segments could be harvested. In 
terms of promotional activities their exposure would be 
reduced. Obviously this cannot be achieved for 
advertising due to its inflexibility. They would also 
still be included in, selected, and usually cheaper 
direct mail campaigns. The sales force effort, 
however, would be heavily reduced.
This strategy would liberate funds within the heavily 
constrained marketing budget. These funds could then 
be used to build the other market segments. The call 
rate among existing clients within the group of 'Dr 
Average', 'Early Majority' and 'High Energy' would be 
increased.
The existence of the segment of the 'Young 
Conservatives' does impose a threat to the long term 
success of pharmaceutical companies. This large group 
seems to be very careful or conservative as far as 
prescribing is concerned. Whether this phenomenon is 
due to a fashionable anti-drug trend or could be
attributed to a tendency to 'play it safe' whilst they 
are 'finding their feet' is difficult to distinguish 
from this data. However, if this trend persisted, 
amplified by older doctors retiring, the overall number 
of prescriptions is likely to decline. This possible 
threat cannot be left untackled. It is recommended to 
launch market research activities to obtain a better 
understanding of this group of doctors. Although these 
doctors might not currently be an attractive target, 
their sheer number does require a different approach.
It is therefore recommended that campaigns and 
activities catering for the specific needs of this 
group must be developed.
An important element of any marketing strategy is the 
introduction of new products. For new products the 
segments of the 'High Energy' and 'Early Majority' 
doctors would be targeted first. They would be treated 
as the innovators and early adopters (Rogers 1983) with 
particular emphasis on detailing and direct mail 
activity. Later in the launch the focus would shift to 
'Dr Average'.
Considering the importance of personal selling in 
pharmaceutical markets, the segmentation procedures 
outlined in this chapter demonstrated the importance of 
the allocation of sales effort to segments, thus
proving hypothesis HI, which states that segmentation 
can be used to allocate sales effort.
6.6 Su— ary
In the previous chapters the pharmaceutical industry 
was introduced, doctors' prescribing behaviour analysed 
and the importance of segmentation highlighted. The 
previous chapter failed to identify significant 
segments on the basis of response to marketing stimuli. 
This chapter presents the findings of two approaches to 
market segmentation on a static basis. The first, the 
macro-analysis, takes into account the prescribing 
behaviour across therapeutic classes, the second, the 
micro-analysis, is based upon preference patterns 
within therapeutic classes.
The macro-analysis, based on cluster analysis, revealed 
the existence of seven distinct groups within the GP 
population. A profile of the seven groups was 
presented, namely of 'Dr. Average', 'Early Majority', 
'High Energy', 'Young Conservative', 'Thrifty 
Housewife', 'Odd Ball', and 'Quasi Homeopath'.
A set of validation procedures was carried out to prove 
the existence of these segments. Apart from conducting 
statistical tests managerial utility is the key aspect
in the validation of the findings. In presentations to 
marketing management, sales management, sales 
representatives and market research experts in the 
industry, the seven cluster solution was found to be a 
valid representation of the reality as experienced by 
the practitioners.
In addition, the results of a natural experiment 
supported the view that these segmentation studies 
produced meaningful segments by detecting significant 
differences in responses to marketing stimuli. It was 
found, for example, that the group of 'Young 
Conservatives' as defined by the static segmentation 
approach consisted of doctors who were less likely to 
respond, i.e. they were showing a difference in 
behaviour, which could have been predicted from the 
static analysis. This finding proves hypothesis H3 
which states that it is possible to define static 
segments which reflect dynamic behaviour.
Obviously, the macro-analysis can only give a rough 
guideline as to which doctors to target. For any 
particular product the situation will be different.
Thus, the analysis of a specific therapeutic class is 
then necessary. This exactly has been done in the 
micro-analysis.
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Demonstrated on the example of hypnotics, groups with 
similar brand preference pattern are detected, using 
cluster analysis. This analysis at the brand level 
enables the tackling of positioning problems.
There is, additionally, scope to match the two 
analyses. A segment detected by using the micro­
analysis can be described in the terms of the macro­
analysis. I.e. a segment with preference for product 
might consist mainly of 'Young Conservatives', which 
obviously would have to be treated differently if it 
consisted of 'High Energy' doctors.
Therefore, the two analyses have to be seen as being 
complementary rather than seen in isolation.
This chapter has tested two hypotheses
His Segmentation can be used to allocate sales effort
H3: It is possible to define static segments which
reflect dynamic behaviour.
Both hypotheses have been tested successfully. It was 
demonstrated that segmentation can be used to allocate 
sales effort using the example of the pharmaceutical 
industry. In the same industry it could be shown that 
static segments did reflect differences in dynamic


TEST F O R  N O N R A N D O M N E S S
NUMBER OF CLUSTERS
■ ACTUAL DATA ♦  RANDOM DATA
Figure 6.2 Test for non-randomness
'(
ar
ly
 M
aj
ar
il
y'
 
la
ar
yy
188
C l u s t e r  2 C l u s t e r 3
C l u s t e r  2 A C l u s t e r  2B C l u s t e r  3A C l u s t e r  3 8
' C h i l d  L o v e r ' ' K i n d e r -  
s c h r e c k '
' I n i t i a t o r s ' ' E n t h u s i a s t '
L A B E L ' A v e r a g e  
t o  H i g h  
P r e s e r v e r s '
' H i g h
P r e s e r v e r s '
' H i g h  t o  
v e r y  h i g h  
P r e s e r v e r  s '
' V e r y  h i g h  
P r e s c r  V e r s '
S I Z E 1 7 1 7 1 4 1 6 1
S E X M a l e  a b o v e  
a v e r a g e
M a l e  a b o v e  
a v e r a g e
M a l e ! M a l e !
AGE 1 9 3 6 - 4 6 ,  n o  
y o u n g e r
O l d e r ,  n o  
y o u n g e r
1 9 3 6 - 4 6 ,
o l d e r
1 9 2 6 - 3 6  . 
o l d e r
I N T E R E S T S C a r d i o l o g y ,  
G e n e r a  1 
P a e d i a t r i c s ,  
O b s .  G y n a e .  
N e o n a t o l o g y
C a r d i o l o g y , 
G e n e r a l !  No 
P a e d i a t r i c s
C a r d i o l o g y , 
O b s .  A G y n a e .  
N e o n a t o l o g y
G e n e r a l  ,
P a e d i a t r i c s ,
D e r m a t o l o g y
I N N O V A T I V E ­
N E S S
A v e r a g e I n n o v a t l v e 2 5 1  C l i n i c a l  
T r i a l s !
I n n o v a t i v e
NUMBER  OF 
P R E S C R I P T I O N S
H i g h  t o  
a v e r a g e
A v e r a g e  t o  
h i g h
A v e r a g e  t o  
h i g h
H i g h !
P A T I E N T S
S E E N
H i g h A v e r a g e  t o  
h i g h
H i g h ! H i g h !
R E P S  S EEN A v e r a g e  t o  
l o t*
A v e r a g e  t o  
h i g h
A v e r a g e  t o  
h l  g h
H i g h
P R A C T I C E
S I Z E
H i g h  t o  
e x c e p t i o n a l l y  
h l g h
M i x e d A v e r a g e  t o  
v e r y  h i g h
A v e r a g e  t o  
e x c e p t  v n a  11 y  
h i g h
P A T I E N T S
R E S P O N S I B L E
A v e r a g e  t o
h i g h
A v e r a g e  t o  
h i g h
T o w a r d s  v e r y  
h i g h
H i  gh
T E R R I T O R I E S 1 . 6 . 1  7 , 2 5 . 3 0 , 5
Table f. 2 Description of cluster 2 and cluster 3
189
Til« Ex o. rl Mn t
Or Average 17.SS
Early Majority 25.21**
High Energy 18.51
Young Conj.rv.tlYt 13.11**
Thrifty Housewife 19.71
Odd Balls 10.51
Quasi Homeopath 36.01**
Kesponj« rttt ov.r.ll 191.
** indicate differences significant at the 5% level
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HYPNOTICS (NMS)
190
CLUSTER 1 CLVSTCR 2 CLUSTER 3 CLUSTER 4 CLUSTER S CLUSTER S
L A IC I T aaazepaa ,
R it r a z e p a a
■DO « O f Teaazepaa ,
N i t r a z e -
P4M.
T r ia z o la a
“ Use «any Teaazepaa .
T r ia z o la a
N i t r a z e -
p e a ,
T r ia z o la a
S U I U S 17S 3SS its S I SS
ASC O ld e r 11 4 1 -S I 
Y ounger
O ld e r m i  m
Younger
1 9 2 4 -3 4  
O ld e r
S C I N a ie ! 2SS f a n a le 2SS f e a a le
in t e r e s t s le e d t e -
t n c s
le e d ia -
t r i e s
OP*. 1 
S yn a e .N e o . 
Sonerà  1
INNOVA-
TIVCNCSS
Coaaon
U sa.
C e l le a g u e s
Coaaon
Use!
M I S C H I
TIONS
Low-
A ve ra g e
Loa A v e ra g e -
Lea
M l g l Loa -
A ve rage
Lo a -
A v e ra g e
PATICNTS
S U N
A v e ra g e ! A v e ra g e -
Loa
N ig i -
A v e re g e
M ig N -
A v e ra g e
A v e ra g e ! A v e ra g e - 
Mi gn
REPS SKCN Loa ! A v e ra g e  ♦
PRACTICE Loa A v e ra g e -
E ie e p t -
to n a l
Loa
PATIENTS
I C S I .
A ve ra g e A v e ra g e  ♦ A ve ra g e ! A v e ra g e -
Loa
M C S C I1 I -  
TIONS 
IN  CLASS
L e a -
A v e ra g e
41S Oo 
R ot
A v e ra g e -  
V e ry  N i g l
Lea-
A ve rage
Loa
NACIO 
« M ICIO
1 .2 A .4  
A ve ra g e
S .S .7
Loa
« .2 A . 2 I .
31
H t g le r
3 A .3 I  
V e ry  H i go
1 .4
A v e ra g e -
1 .2 1 .3 1  
A ve ra g e  ♦
r e m -
TO IIK S
7 .1 4 .2 0 .
2 4 .S 2 .S I
I .  4 . S . 7 . I .
I I .  1 9 .2 1 . 
3 0 .4 0 .4 1 .  
« 4 .S S .71
1 0 1 1 .1 4 .  
3 1 .3 7 .3 1 .  
4 1 .4 S .4 I .  
S 7 .S I .S 2 .  
S S .7 0 .7 1
4 .S . S . 9 ,
1 7 .2 1 .2 4 .
3 S .3 S .S 2 .
S 1 .7 1 .7 S
11 1 l . 2 t . 3 7
Tabi« &.4 Micro-Analysis - Hypnotic«
HYPNOTICS (NNS) C o n td .
CLUSTES 1 CLUSTES 2 CLUSTES 3 CLUSTES 4 CLUSTER 1 CLUSTER
LABEL *Oo n o t* Teaazepaa .
N i t r a z e -
p s « .
T r ia z o ls a
*Us« «a n y  
b ra n d s "
Taaazepaa,
T n a z o la a
N i t r a z e
p a e .
T r ia z o l-
SIZE lit 171 3S1 191 11 S I
AMYTAL O th e r
O th e r O th e r
NEMSUTAL O th e r
NITRAZEPAM 361 F i r s t  
9S1 US«
O th e r ! 2 11  F i r s t  
A l l  US«
321 F i r s t  
901 use
Do n o t 4S1 F ir s  
931 use
S 00IU M -
ANYTAL
O th e r
SONERVL O th e r
TEMAZEPAM S S I F i r s t  
SSI Us«
SOI O th e r i l l  F i r s t  
A l l  Us«
4 11  F i r s t  
9S1 Use
711 F i r s t  
1001 1 . * 2 .
N o t !
ISAACORAL P o p u la r
MELLOORN 231 3 . O th e r O th e r
CMLOROIA- 
ZEPOSIOE
P o p u la r
OXAZEPAM P o p u la r
SOMIMCI
O th e r 711 2 . 0 . P o p u la r 1S1 F i r s t 271 F i r s t
941 US« SSI US«
Table 6.4 contd.
192
Chapter 7 Model Foundation
7.1 Introduction
The previous chapters have outlined the general area of 
decision support in marketing problems and discussed 
the specific example of a company in the pharmaceutical 
industry. The need for market segmentation was noted, 
and approaches to market segmentation were discussed 
(chapter four). As outlined in chapter five, response 
based segments could not be identified considering the 
data available. However, the segments determined by a 
static basis in chapter six demonstrated evidence for 
differences in response to marketing stimuli.
Therefore it was concluded that the segments derived on 
the basis of a static analysis represented a meaningful 
way of describing market phenomena.
This chapter aims to take the analysis further by 
examining the consequences of market segmentation: the 
subsequent allocation of resources to the segments 
identified. The objective of this thesis is to test 
hypothesis H5, which states that:
It is possible to develop a model assisting 
in the optimum allocation of the marketing 
budget to products, segments and promotional 
tools.
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This chapter provides the background for testing this 
hypothesis. The results are discussed in chapter eight. 
Background will be discussed by relating the problem to 
be solved to approaches documented in the literature. 
While chapter two gave an overview of how the work 
reported here fits in with research into decision 
support systems, the emphasis here follows on more 
specifically by focussing on models and their 
parameterisat ion.
Following Piercy's (1987) distinction between the 
prescriptive approach to budgeting problems and the 
process orientated approach, this work's focus is 
clearly on the former. The prescriptive approach based 
on management science techniques is also reflected in 
the way the term decision support systems was used in 
chapter two, namely closely related to model building.
Clearly, Piercy is drawing attention to an important 
area which has received relatively little attention in 
the literature, the implementation of budgeting 
decisions. The two approaches, however, should not be 
seen as mutually exclusive. Although it is crucial to 
understand the process of implementing budgeting 
decisions, there is still room to build better models 
which, when successfully implemented, will hopefully 
lead to better decisions.
As discussed in chapter three, marketing expenditure in 
the pharmaceutical industry is restricted by the 
government via the PPRS to not exceed nine percent of 
sales. Hence, the marketing budget is usually more 
restricted than in many other industries. Within these 
restrictions, it is of paramount importance to employ 
the limited resources to best effect. As outlined in 
chapter three, sales force, direct mail and advertising 
are the three dominant areas of the promotional mix in 
the pharmaceutical industry. The sales force, 
accounting for 44% of promotional expenditure (ABPI,
1986), is the dominant tool. A model assisting in the 
allocation of the marketing budget, however, needs to 
include all these three elements of the promotional 
mix.
The second section in this chapter reviews the 
literature on models available to assist in decisions 
in the relevent areas for this thesis, namely 
advertising, marketing mix, and the sales force. The 
third section looks at approaches to parameterisation, 
with particular emphasis on the application of 
subjective estimation. The final section is dedicated 
to a summary which will be the basis for the 
application to be discussed in the following chapter.
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7.2 Review of specific MDSS
Naert and Leeflang (1978, p.119) distinguished three 
purposes or intended uses for models:
1. Descriptive models.
2. Predictive models.
3. Normative models.
Descriptive models are used to describe decision 
processes with the aim of making these decision 
processes more explicit or to explore ways of 
improvement. Clearly, this application is not at the 
centre of the problem discussed here. Predictive 
models, however, aim to forecast future events. This 
is of interest here but these models do not prescribe 
what to do. Normative or prescriptive models achieve 
exactly that. Their purpose is the determination of an 
optimal policy in the light of a given objective such 
as sales or profit maximisation. Therefore, the 
emphasis of these models is very much geared toward 
action and decisions. This class of model serves to 
allocate resources optimally.
According to the requirements of modelling the 
allocation of the marketing budget to segments, 
products and media, the literature on marketing models 
has been reviewed. Models describing buyer behaviour
or environmental developments can be left out of the 
review since these follow the descriptive rather than 
the prescriptive approach. It is more appropriate to 
review what Lilien and Kotler (1983) call 'Micro- 
marketing Decision Models', which study individual 
elements of the marketing mix.
They list as areas for micro-marketing decision models:
product decisions
advertising
distribution
price
promotion
sales force issues.
Of this list only the models related to advertising, 
sales force issues and promotion are applicable.
Further analysis of models in the area of promotions 
reveals (Lilien and Kotler 1983, p. 534) that they are 
used to determine size of incentive, conditions for 
participation, distributor vehicle, duration, timing 
and the overall budget. Apart from the question of 
budgeting, no other area is of interest in this case.
Since rates for advertising budgeting can easily be 
applied to direct mail (the only vehicle for sales 
promotion of interest in this case), sales promotion 
models are left out of the review.
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Thus the focus of the review is on advertising models, 
sales force models and on marketing mix models which 
deal with the inter-action of the elements of the 
marketing mix. Before a review of specific models is 
undertaken, the next section highlights some of the 
issues tackled in models for advertising, sales force 
and marketing mix decisions.
Advertising DSS
Three different decision areas for advertising can be 
distinguished (Lilien and Kotler 1983, p. 485). 
Objective setting and budgeting are addressing problems 
such as how much to spend. Secondly, in copy decisions 
the message itself has to be evaluated. Thirdly, 
decisions on the type of media to be used have to be 
made. All these decisions are highly inter-related.
The effects of advertising have for long been debated, 
primarily because advertising accounts for the majority 
of promotional expenditure in consumer markets, hence 
it has high 'visibility'. Little (1979b, p.631-632) 
identified three major areas for controversy in 
advertising modelling: shape, dynamics and inter-
actions
a) Shape. By shape is meant the shape of a curve 
showing sales response to advertising. Here the 
debate is whether the relationship 
sales/advertising is linear, S- shaped or a 
different pattern. What are the sales with zero 
advertising?
b) Dynamics. Here the question is how fast sales 
respond to an increase in advertising. Also the 
rate of decay for a decrease in advertising, the 
question of whether a hysteresis effect (same 
level of sales following a withdrawal of 
advertising) can be expected and the problem of a 
change in effectiveness over the time period.
c) Inter-actions. The controversy is whether to 
advertise when sales are low or vice versa. Also 
the debate about the kind of inter-action with 
effects of other marketing variables (additive, 
multiplicative, or more complicated) is mentioned.
Marketing-Mix Models
Marketing-mix models are concerned with product, place, 
promotion and price. The problems of an inter-action 
of these variables have been discussed in section 2.2. 
Nevertheless, there have been trials to include all the 
decision variables in one model. Lilian and Kotler,
(1983 p.663) define the following features for a 
marketing-mix models
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1. Allow for inter-actions among marketing-mix 
elements in general.
2. Permit advertising to increase or decrease price 
sensitivity.
3. Permit price to increase or decrease price 
sensitivity.
4. Permit positive or negative interactions among 
promotional vehicles.
5. Permit varying effectiveness over time and across 
market segments.
6. Incorporate advertising/selling interactions that 
are positive and that include order effects.
7. Incorporate advertising and promotional 
effectiveness explicitly.
8. A good marketing-mix model should incorporate 
competitive effects.
These requirements are difficult to meet and just a few 
models incorporate most of them. As one example 
Brandaid (Little 1975) is included in the list of 
models examined here.
Sales Force Decision Models.
Sales force decision models typically consist of two 
major structural components; a representation of market 
behaviour and an allocation technique (Laforge and 
Cravens 1980, p.245).
Cravens (1979 p.310) identified three key sales force 
resource decision areas:
(a) Determining the size of the sales force.
(b) Allocation of sales people to appropriate work 
units (e.g. territories, products, customers, 
etc.).
(c) Deployment of a salesperson's effort within the 
assigned work unit (e.g. among customers).
The response of the market to alternative levels of 
selling effort can be measured and expressed in various 
terms including (1 ) sales volume; (2) the change in 
sales volume; (3) the change in buyer awareness and
attitudes; (4) the probability of favourable buyer 
reaction such as continued patronage or conversion from 
prospect to customer status; and (5) profits (Lambert 
and Kniffin 1970, p.3).
Comer (1979 p.344) noted that the result of attempts to 
model sales force problems is a series of models which 
have decomposed a sales management problem without a 
basis for linking them together again.
(a) Models for sales force size.
In trying to optimise the industrial sales force,
Meidan (1982, p.65) identified three major 
difficulties:
Working with historical data for future decisions.
The problem of identifying the right factor to be 
maximised; i.e. profits, sales or return on 
investment.
Many sales-oriented firms fail to realise that the 
individual salesperson is just one important 
factor in the marketing-mix.
He then identified five methods available to a firm 
optimising the sales force size.
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1. Method developed by Fogg and Rokus (1973):
This is a quantitative method for deciding between 
various selling methods, choosing the number of 
sales agents and management structure required. 
This is applicable if profitable sales are the 
required objective of the company.
2. The "vaguely right" approach (Lodish 1974) is 
applicable when a large company is dealing with 
numerous accounts. Then subjective data often 
need to be used.
3. Simulation enables a number of variables in 
different combinations to be taken into account.
4. The dynamic approach intends to model the 
changeable interaction of the selling effort.
5. Return on time invested (ROTI) could be used for 
control purpose applied in a large company with 
autonomous units.
As can be seen from the review discussed in the next
section, decisions on the sales force size were among
the first decisions to be modelled. Many trials were 
undertaken to use management science techniques such as
linear programming or more sophisticated techniques to 
solve the problems.
(b) Allocation of sales people to work units
Models Cor the allocation across customers, 
territories, and products have been distinguished.
(bl) Models for allocation across customers
The models help in assessing the time that has to be 
spent with a customer or with prospects. These models 
usually assume the situation of a f i x e d  sales force 
size and fixed territories. Since in many markets 
sales forces are organised by products, models usually 
cover one product.
Depending on the type of market, some models provide 
very detailed assistance, i.e. in the allocation of 
salesmen to accounts on the basis of individual 
competence. Some models take the perspective of a 
single salesman, while other models assist on an 
aggregated level.
(b2) Models of territory response
Sales in a salesperson's territory can be 
conceptualised as being a function of eight classes of
variables (Ryans and Weinberg 1979, p.454): (1)
environmental factors; (2) competition; (3) company 
marketing strategy and tactics; (4) sales force 
organisation, policies and procedures; (5) field sales 
manager's characteristics; (6) sales-person ' s 
characteristics; (7) territory characteristics; (8) 
individual customer factors.
One component of the sales territory alignment problem 
is the problem of how to aggregate in the best way 
small geographic building blocks, called standard 
geographic units (SGUs), into reasonable sales 
territories. A firm aligning sales territories 
according to sales potential, actual sales, workload, 
numbei of accounts or key accounts, etc. will need the 
appropriate actual or forecast data for each SGU 
(Zoltners 1979, p.361).
(b3) Models of sales effort allocation across products
Often a sales force handles a range of products, as it 
is the case in the pharmaceutical industry. The 
objective is to allocate the sales effort across 
products to optimise the benefits to the company.
These benefits are difficult to assess. The support of 
new products, for example, might assure long-term 
profitability but could neglect short-term profits.
In the pharmaceutical industry generally two approaches 
are taken to deal with the problem. An indirect way is 
to introduce a compensation plan according to 
requirements; the direct way is to allocate the effort 
via a 'sales programme' in which the sales manager 
determines which products have to be promoted. The 
'sales programmes' can be changed much more easily than 
the compensation structure.
(c) Deployment of salesperson's effort within a work 
unit
Models developed for this purpose cover aspects like 
routing problems. Also the allocation to prospects or 
customers is an area of interest under this heading.
Review of different MDSS
The "heart" of a DSS is the model describing the 
underlying process in the real world. The relevant 
literature has been screened for models and DSS 
developed for the purposes outlined before, namely for 
advertising, marketing mix and sales force allocation. 
Particular emphasis is put on sales force models due to 
the sales force's important role in pharmaceutical 
markets. The result is summarised in the form of a
matrix in Table 7.1
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The criteria for the review are the following:
(a) Reference refers to the source of information and 
additionally, if available, to the "brand" name of 
the model.
(b) Resource describes the element of the marketing- 
mix which is modelled.
(c) Entity describes the specific aspect of the 
resource which is modelled.
(d) Sales response examines the way in which the 
response to the use of a single resource is 
modelled. Here is described the kind of function 
representing the reality and additionally, to what 
extent subjective judgement is included.
(e) Search procedure classifies the processes used in 
order to gain an output. 'Optimal* solutions 
achieved due to the use of linear or dynamic 
programming and also 'good' results due to the use 
of heuristics are identified.
(f) Inter-relation refers to the incorporation of more 
than one element of the marketing-mix or the 
inclusion of other dimensions.
(g) Carry-over effects address the question as to 
whether efforts in previous periods have an effect 
in the actual period.
(h) Application looks at industries or markets for 
which an implementation is reported in the 
literature. This aspect was included to gain an 
idea of the environment that might be suitable for 
a specific system.
(i) Comment covers aspects that are worth noting in 
addition to the other aspects.
Lessons to be Learnt
The review of the literature reveals that there is no 
single model reported that would cover all the aspects 
required, namely the allocation of marketing budgets to 
segments, products and promotional tools. Closest are 
marketing mix models which intrinsically are very 
difficult to calibrate due to the complexities 
involved. However, the application of 'BRANDAID' 
developed by Little (1975) is close to the requirements 
here. The lesson to be learnt from that model is the 
application of subjective estimation as a way to 
parameterise the model. The review of advertising 
models does contribute much to the calibration or
208
parameterisation of models. Here the discussion of the 
shape of the response function is valuable. Again, 
decision calculus applications (Little 1970) offer 
interesting starting points for this case.
Sales Force models are probably the richest source for 
inspiration, since many were actually developed for 
pharmaceutical markets.
Early models such as 'CALLPLAN' (Lodish 1971) and 
'DETAILER' (Montgomery et al 1971) explicitly employ 
subjective judgement to parameterise the model.
'DETAILER' is applied to pharmaceutical markets in 
respect to sales force allocation to products. Hobday 
and Raeh (1977) report a slight modification of 
'DETAILER' and its application in the British 
pharmaceutical industry.
Lodish (1980) built on his earlier work to allocate the 
available call time not only to products but also to 
segments, an important step forward with regards to the 
problem to be tackled here: the allocation to products, 
segments and promotional tools.
The review of the literature did not reveal the 
existence of a model catering for the requirements 
discussed in this case. However, those models which 
were related to these problems rooted firmly on the
application of subjective estimation as a means of 
model parameterisation.
7.3 Parameterisation
In the model building process as outlined in chapter 
two, the specification stage is followed by 
parameterisation. This process is dependent upon the 
availability of data on which a model's parameters can 
be determined. In the case described here objective 
data, by definition, can not be available 
comprehensively. This is because the Company's 
decision makers have never worked under the assumption 
of allocating the resources to segments. The concept 
of segmentation was introduced to the company as the 
result of the work reported in the previous chapters.
However, managers have always been allocating resources 
to products and media; data and experience therefore 
existed for decision making with respect to allocating 
promotional expenditure to products and promotional 
tools, but not in respect to expenditure on segments.
Under the circumstances that objective data simply do 
not exist, Naert and Leeflang (1978, p.206) recommended 
the use of subjective estimation as the only way to 
parameterise a model. The purpose of subjective
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estimation is to elicit judgements from decision makers 
and to quantify them (Lilien and Kotler 1983, p.128). 
They claimed that this is not necessarily an inferior 
way of obtaining data compared to the collection of 
objective or 'hard' data. This is because decision 
makers will have made decisions based on their 
judgement implicitly throughout their working lives. 
Subjective estimation just calls for an explicit 
expression of decision makers' beliefs/intuition.
Saunders (1985 ) pointed out the danger in any 
subjective estimation is that intuition is dressed into 
an analytical technique. If the estimates are poor, so 
will be the results. However, the application of this 
technique still allows the building of models even when 
insufficient objective data are available. Moreover, 
subjective estimation forces the model builders and the 
decision makers to interact. This process can only 
enhance mutual understanding and can only be beneficial 
to successful implementation.
Lilien and Kotler (1983, p.129) added an additional 
advantage which is important to the case reported here: 
the quantification of beliefs helps pinpoint the extent 
and importance of differences among decision makers 
with respect to the decision problem. The decision 
makers are forced to quantify their beliefs and to 
defend their judgement. By questioning the assumptions
underlying the judgements, new insights might be 
gained.
Having decided to apply subjective estimation to 
parameterise the model, the method of how best to 
obtain the estimation has to be determined. This has 
to be done with the objective in mind that eventually 
the estimates have to be transformed into a 
mathematical representation. Clearly, it is 
inappropriate to ask for a mathematical representation 
of the decision makers' beliefs, since this is 
definitely alien to their way of thinking.
The most favoured approach is one developed by Little 
(1970) who put forward five questions, the answers to 
which are subsequently converted into a response 
equation. These five questions are:
1. What is your market share percentage now? SI
2. What level of advertising is necessary to maintain
market share? A1
3. What would the market share be next period if
advertising were reduced to zero (Ao)? So
4. What would market share be next period if 
advertising were increased to saturation (Am)? Sm
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5. What would the market share be next period if 
advertising were increased to 50% above 
maintenance rate (Am)? S3
Figure 7.1 shows graphically how these answers are used 
to sketch the shape of the response function.
Managers often find it more difficult to estimate 
effects as results of extreme actions. Therefore to 
estimate the ultimate market share achievable at 
saturation expenditure is probably less reliable 
compared with estimating the effects of more gradual 
increases around the familiar expenditure level.
Consequently, Saunders (1985) suggested an alternative 
to Little's approach by asking incremental questions 
about expenditure levels close to those experienced by 
the decision makers:
What is current market share? SI
What level of advertising is necessary to maintain 
market share? A1
What would market share be if advertising were
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changed by the following percentages:
Increased by 20% (A1.20)? SI.20
Increased by 40% (A1.40)? SI.40
Decreased by 20% (AO.80)? SO.80
Decreased by 40% (AO.60)? SO. 60
The model builder can then convert the answers into a 
response curve using curve fitting techniques. This 
allows the application of general equations.
This issue then raises the more fundamental question of 
'realistic' shapes of response curves. Saunders (1987) 
reviewed nine propositions with respect to the shape of 
the response function. His findings (C.F. figure 7.3 
displaying likely shapes of response functions) for the 
various propositions were:
1. Effect zero when effort zero
This is intrinsically not true, although there is no 
theory for or against the case.
2. There is a linear relationship between cause and 
effect.
Although there is no evidence for or against this 
proposition, it is reasonable to assume that this 
proposition is not true at the extremes. For example.
intuitively it would make sense to assume that with 
increasing market share an increasing disproportional 
effort is required to gain the final percentage points 
to gain one hundred percent share.
3. There are decreasing returns to scale with effort 
As explained in the previous proposition, this 
phenomenon does make sense intuitively. Empirical 
evidence supports this proposition.
4. Saturation.
Apart from the logical constraints of market share 
models with the obvious upper limit of one hundred 
percent, it is difficult to find evidence for the 
existence of saturation levels.
5. There are increasing returns to scale with effort 
This is only true within limits. Ultimately this 
proposition has to be rejected.
6. There are first increasing, and then decreasing 
returns to scale ('S-shape')
Intuitively, the increasing returns to scale followed 
by a decrease at a certain level of expenditure make 
sense, primarily in advertising. Evidence, however, 
for its existence is fairly limited.
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7. Threshold effects.
The suggestion that marketing effort must reach a 
critical level (threshold) before it will have any 
effect at all is not supported by evidence and may be a 
monstrous myth.
8. Supersaturation
The existence of supersaturation, when sales decline as 
a consequence of excessive marketing effort is not 
supported by evidence.
The next issue to be solved is the decision to choose 
the mathematical expression to fit the data. Naert and 
Leeflang (1978, chapter 5.3.1) gave an overview of 
popular mathematical representations. Saunders (1987) 
provided a summary of expressions used in the 
literature which is detailed in table 7.1. As to the 
question which of the mathematical representations to 
select, Saunders concluded (1987, p 31) that no 
expression is ideal. This conclusion is founded upon 
analysis of testing the various expressions with 
respect to goodness of fit and shape. In selecting the 
mathematical expression he suggested the following five 
steps (Saunders 1987, p 31):
- (1) Determine the propositions that are critical 
to the operations of the model.
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- (2) Select the most simple expression that makes
the model robust in operation.
- (3) Estimate and validate the model.
- (4) IC the fit is poor go back to step 2
- (5) If the fit is good, do not assume that the
expression is the actual response function and 
be sceptical about the conclusions. In 
particular, question if the results are a 
function of the expression rather than the 
data.
In the case discussed in this thesis, the response to 
marketing stimuli must be modelled. If this response 
is to be measured in terms of market share, then the 
requirements for the mathematical expression of the 
response curve are that it should allow for saturation 
and for diminishing returns to scale or S- shaped 
response. Consequently the following models need to be 
taken into consideration for the application to be 
discussed in the next chapter:
Modified exponential model 
- Gompertz model 
Logistic model 
Decision calculus model
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7.4 Summary
This chapter has outlined the foundation for the model 
to be developed, which in turn is discussed in the next 
chapter.
Following on from the literature review on decision 
support systems presented in chapter two, the emphasis 
in this chapter is on models assisting in decision 
making in the areas identified in chapters three to 
five, namely, sales force, advertising and marketing 
mix decisions.
The section reviewing marketing models describes the 
elements of decision making in the three mentioned 
areas, before models presented in the literature are 
reviewed. From this review it is concluded that there 
is a gap in the literature; no model could be detected 
which would cover the elements desired in the case 
described here. However, some important contributions 
were noticed which enable further development in order 
to accommodate the problems to be solved here.
In particular experiences with BRANDAID (Little 1975) 
and DETAILER (Montgomery et al 1971) and its 
applications in the UK pharmaceutical industry (Hobday 
and Raeh 1977) provide excellent starting positions for
further development. None of these models, however. 
Includes the allocation of resources to segments.
The common denominator of those models is that they all 
require the application of subjective estimation for 
parameterisation. Subsequently, some issues related to 
subjective estimation in parameterising models are 
discussed. The discussion focuses on two aspects, the 
process of subjective estimation - how best to obtain 
estimates from decision makers and how to translate 
these estimates into a response curve. Some techniques 
with respect to eliciting estimates from managers are 
presented. In particular, contributions by Saunders 
(1987) offer usable advice in applying subjective 
estimation. He suggested judgements for a response by 
phrasing questions in increments around a familiar 
spending level rather than expecting managers to 
estimate response to marketing stimuli at extreme 
levels of expenditure as suggested by Little (1971).
When translating the estimates into a response 
function, the shape of the response function is 
important. Propositions made in the literature with 
respect to realistic shapes of response curves are 
discussed. It is concluded that decreasing returns to 
scale and saturation, particularly important in market 
share models are features of realistic response curves.
These features are fulfilled by four types of models 
which are s
- Modified Exponential Model
- Gompertz Model
- Logistic Model
- Decision Calculus Model
These models have to be considered for the application 
to be described in the following chapter.
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Chapter 8 RESOURCE ALLOCATION - THE APPLICATION
8.1 Introduction
Based on the literature reviews presented in chapter 
seven, this chapter now outlines an application of a 
resource allocation model. Specifically, hypothesis H5 
is tested which states that:
It is possible to develop a model assisting 
in the optimum allocation of the marketing 
budget to products, segments and promotional 
tools.
The products to be included in the model cover the 
portfolio of the company described in chapter three and 
include five products at different stages of their 
respective product life cycles.
As discussed in chapter three, marketing expenditure in 
the pharmaceutical industry is restricted by the 
Government via the PPRS to not exceed nine percent of 
sales. Hence, the marketing budget is usually more 
restricted than in many other industries. Within these 
restrictions, it is of paramount importance to employ 
the limited resources to best effect. As outlined in 
Chapter three, sales force, direct mail and advertising 
are the three dominant areas of the promotional mix in
the pharmaceutical industry. The sales force, 
accounting for 44% of promotional expenditure (ABPI, 
1986), is the dominant tool. A model assisting in the 
allocation of the marketing budget, however, needs to 
include all three elements of the promotional mix.
Segments in this context are those identified in the 
macro-analysis presented in chapter six. These seven 
segments comprise 'Dr Average', 'Early Majority', 'High 
Energy', 'Young Conservative', 'Thrifty Housewife',
'Odd Ball', and 'Quasi Homeopath'.
The second section in this chapter specifies the model 
to be used. The third section covers estimation and 
fitting of the model. The fourth section describes the 
optimisation procedure. The fifth section discusses 
the results achieved via the optimisation. The sixth 
section summarises validation procedures. The final 
section is dedicated to a summary.
8.2 Model Specification
In terms of the model building process outlined in 
chapter two, the previous chapters have discussed in 
detail the stage of problem finding, namely the 
allocation of the marketing budget to products, 
segments, and promotional tools. This section is now 
concerned with the determination of the model
development criteria as well as the actual model 
building.
Having decided upon the class of model, the variables 
to be included have to be selected. The dependent 
variable chosen is gross profit, since profit is often 
the ultimate objective in business. In the case 
reported here the real profit figures might not even be 
known to the marketing decision makers. This is due to 
some technicalities specific to multinationals which 
include issues such as transfer pricing. Gross profit, 
however, is the objective according to which the 
marketing manager's performance is judged - hence the 
choice as the dependent variable.
The next section outlines the process of developing a 
model measuring the gross profit across products, 
across the segments identified in chapter six as a 
function of promotional expenditure on tools such as 
sales force, direct mail and advertising.
Gross profit can be expressed as
E 8.1 GP - GM x SALES
with GP Gross Profit
GM Gross Margin
SALES Total Sales
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Total Sales however can be expressed as 
E 8.2 SALES = SHARE (X) x SIZE
with
SHARE (X) Market Share as a function of
promotional expenditure X 
SIZE Market Size
Thus, equation E 8.1 can be rewritten as
E 8.3 GP = GM x SIZE x SHARE (X)
With the introduction of a number of products p (p * 
1...P), the gross profit equals the sum of gross 
profits for individual products. Thus, equation E 8.3 
can be written as:
PE 8.4 GP « p51(GMp x SIZEp X SHAREp (Xp ))
When the model is further developed to cater for 
different segments s (s = 1...S), sizes and shares will 
vary in the market segments. The gross margin, 
however, is assumed to be fixed for a product across 
segments. Thus, equation E 8.4 is further developed
to:
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E 8.5
In this equation the market share is expressed as a 
function of promotional expenditure X. This 
expenditure X comprises the sum of the expenditure on 
sales force, direct mail and advertising. To allow for 
the interaction of the elements of the promotional mix 
m (m = 1...M) in their effect on market share in a 
market segment, market share can be expressed as:
( MSMAXp, s f - SNOWp (|)))
with
SMAX Maximum Market Share in a Segment 
Current Market Share in a SegmentSNOW
MSMAX Maximum Market Share available in a 
Segment due to the effect of a 
single Medium.
F Response Function measuring Market 
Share as a function of
expenditure on a particular 
Medium.
Thus, equation E 8.6 states that the market share 
for a product in a particular market segment 
cannot exceed SMAX, the maximum market share. The 
effects of the interaction of the promotional 
tools is catered for by the multiplicative term in 
the equation. This term is in turn dependent on 
the response functions which measure the 
achievable market share as a function of a single 
promotional tool. When equation E 8.6 is 
substituted into equation E 8.5, the final version 
of the model is developed.
P SGP = p-1GMp Xs£1(SIZEp>s X SMAXp>s
((SMAXp ts - SNOWp>s) X
M
m« i((MSMAXp,8(m
‘
Fp ,s ,m < xp,s,m )) /
(MSMAXp>Sj, m - SNOWp t S > ) > )
where
GP Gross Profit
GM Gross Margin
SIZE Market Size
SMAX Maximum Market Share in a Segment
SNOW Current Market Share in a Segment
MSMAX Maximum Market Share available in a
Segment due to the effect of a 
single Medium.
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F Response Function measuring Market
Share as a function of 
expenditure on a particular 
Medium.
The ceilings SMAX and MSMAX in equations E8.6 and E8.7 
prevent the model predicting market shares which exceed 
1 (i.e. 100%). However, rather than using 1 as the 
ultimate ceiling for market shares available it is more 
realistic to assume an upper ceiling which is based on 
the current market shares. This is especially important 
in the case of products with a low current market share 
for which a dominant market share in subsequent periods 
is often unrealistic.
In the model the difference between the current market 
share and the ceiling forms the basis for measuring the 
impact of promotional effort. The multiplicative term 
in the equation determines the effect of promotional 
effort. If, for example the response functions Fp>Sim 
all equalled the value of the current market shares 
SNOWp'S, then the multiplicative term would amount to 
one, hence the predicted market share would not change 
compared to the current market share.
The use of multiplicative representations is widely 
used in marketing (Lilien and Kotler 1983, p.73). In
particular interaction effects can be well captured as 
Naert and Leeflang (1978, p.74) observed.
Here, the interaction of the promotional tools is 
realised in the multiplicative term, which for each of 
the tools calculates a factor around 1. By multiplying 
values around 1 the result of the multiplicative term 
In turn is around 1. A value for the multiplicative 
term greater than 1 indicates that the predicted market 
share will be smaller than the current market share. 
Obviously, the opposite is true for values smaller than 
1, which would indicate a rise in market share.
The model as described in equation E8.7 is robust in 
that it does not allow for market shares to exceed 1.
It is also logically consistent in that it accounts for 
interaction between the tools of the promotional mix.
8.3 Parameterisation
In the model building process as outlined in chapter 
two, the specification stage is followed by 
parameterisation. This process is dependent upon the 
availability of data on which a model's parameters can 
be determined. In the case described here objective 
data, by definition, can not be available 
comprehensively. This is because the Company's 
decision makers have never worked under the assumption
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of allocating the resources to segments. The concept 
of segmentation was basically introduced to the Company 
as the result of the work reported in the previous 
chapters.
However, management has always allocated resources to 
products and media; data and experience therefore 
existed for decision making with respect to allocating 
promotional expenditure to products and promotional 
tools, but not in respect of expenditure to segments.
As explained in the previous chapter, in the absence of 
hard data it is appropriate to apply subjective 
estimation. Therefore a framework was established which 
enables to obtain the best possible quality of 
estimates. This had to be done with the intention to 
eventually transform the estimates into a mathematical 
representation. As discussed in the previous chapter 
it is clearly inappropriate to ask for a mathematical 
representation of the decision makers' beiiefs, since 
this is definitely alien to their way of thinking.
The Saunders (1987) and Little (1970) approaches were 
combined in this case. Of the five products for which 
the model was to be developed, three were established, 
while one was a newly launched product. The fifth 
product was an old one but with no recent history of 
promotional activity. The company, in the absence of
its new star product which became a victim of the 
limited list (chapter three), decided to promote this 
well established product again.
It was found, however, that the methods described for 
estimating response to marketing stimuli as discussed 
in the previous chapter did not fit the requirements of 
all the cases which had to be tackled. For example, 
for an established product there is usually no problem 
in establishing current market share. In addition it 
should not be too difficult to estimate the required 
level of expenditure to maintain that market share.
However, in the case of a new product the current 
market share will be close to zero. The corresponding 
maintenance expenditure is obviously close to zero as 
well. Thus, any estimate of market share as a function 
of multiples or even fractions of the maintenance level 
inevitably neglects the projected growth in market 
share. The use of the maintenance level as a reference 
is clearly inappropriate.
In this case a much better reference seems to be the 
budgeted level of expenditure and the forecast market 
share. Managers will have made the original budgeting 
decision with a certain objective in mind, which is 
usually closely related to market share. Use of this 
figure as a reference point will enable the most
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accurate estimation of expected market shares as 
functions of fractions or multiples of this reference 
expenditure.
Consequently, the questions are amended to fit the case 
of an established, mature product with no recent 
history of promotional expenditure as well as that of a 
new product. These questions are outlined in table 
8.1. For the established products, the Saunders 
approach was taken with the questions listed in table
The estimation of response to promotional expenditure 
was carried out in a workshop with relevant marketing 
managers of the company and two model builders acting 
as catalysts. Present were the marketing director, who 
in twenty years with the company had been brand manager 
for most of the products in question. The current brand 
manager for three of the five products was also 
present. He also had experience as a brand manager of 
the other products. The third participant was the 
market research manager, usually in charge of 
monitoring promotional expenditure in the market place 
and its effect on market shares. The brand manager in 
charge of the remaining products, who had only recently 
been appointed, was unable to attend the workshop due 
to other commitments.
The first part of the workshop was held outside the 
company's premises. A full day was spent on the 
estimation of the first three products. The same time 
was spent with the same group of people to estimate the 
other two products, on the company's premises. All 
parties involved agreed that a workshop held off the 
company's premises is much more productive due to fewer 
interruptions.
It was decided to focus attention on the five most 
attractive segments with respect to size and 
significance, namely 'Dr Average', 'Early Majority', 
'High Energy', 'Young Conservative', and 'Thrifty 
Housewife'. The 'Odd Ball' and 'Quasi Homeopath' were 
excluded from the analysis.
But even then the estimation exercise had to cover in 
total five products, five segments, and three 
promotional tools. Since advertising cannot be 
targeted down to a segment level as obviously direct 
mail and sales force effort can, the response to 
advertising expenditure for the five products was only 
estimated at the unsegmented level, by treating the 
market as one big market. This meant that five 
advertising response curves and twenty-five response 
curves for direct mail and sales force expenditure 
respectively had to be estimated.
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By having to estimate in total fifty-five response 
curves mainly on a segment basis, an interesting side- 
effect could be observed. The profiles of the segments 
were re-inforced. For the first time the decision 
makers were forced to view actively the market not as 
one big single market but as a sum of a number of 
segments. Particularly helpful were the labels 
allocated to the segments such as 'Dr Average' or 
'Young Conservative'. These labels helped enormously to 
bring the segments to life and they enhanced 
considerably the ability to imagine the segments' 
characteristics.
At the time of the estimation the budget was not 
allocated to segments; it was allocated to products and 
the promotional tools only. When estimating the 
response to expenditure on a segment basis, the amount 
allocated to a segment was calculated as the budgeted 
level of expenditure in proportion to the size of the 
segment in question. For example, if total budgeted 
expenditure for sales force for a particular product 
totalled £100 K, then the allocation to 'Young 
Conservatives' (who account for 28% of the market) was 
calculated as £2 8 ,0 0 0 .
With the help of a Lotus 1-2-3 spreadsheet the answers 
to the questions were easily converted into a graphical 
form. This graphical representation was then assessed
by the decision makers in terms of whether this 
response curve represented a realistic relationship. 
This often initiated an interactive process which led 
to adjustments to the answers to the questions.
As far as the shape of the response function is 
concerned, in this case decision makers' experience 
indicated the existence of saturation as a plausible 
form of response in the short run. Depending on the 
product/market situation the existence of diminishing 
returns or S-shaped response was acknowledged.
Data were subsequently obtained in the workshop by 
going through an iterative process of estimating the 
response, plotting the results, adjusting the 
estimations, etc.
The next issue to be solved was the decision which 
curve to choose to fit the data. The characteristics 
of the curves as plotted required the mathematical 
expressions to allow for saturation and, preferably, 
the market share of greater than zero at zero 
expenditure. With these characteristics clearly the 
exponential model, linear model (no saturation), or 
quadratic models (supersaturation) do not fit the 
requirements. Consequently, four models were taken 
into consideration (figure 8.1):
Modified exponential model 
Gompertz model 
Logistic model 
- Decision calculus model
The modified exponential model is intrinsically a non­
linear model. However, once the saturation level alpha 
O is known it can be estimated using regression 
analysis. Although the R 2 values are reasonable, the 
drawbacks in using this model are twofold: first it 
assumes no market share at no expenditure, and secondly 
it has not the ability to display S-shaped behaviour.
The logistic model again can be estimated once alpha O 
is known. This model does allow for s-shaped behaviour 
and a positive market share at no expenditure.
However, the R2 values are not as good as in other 
models (Saunders, 1987). Moreover, using the equation 
in an optimisation procedure, the application or at 
least the first-order derivatives are required. The 
rather complicated form of the equation seems to make 
life unnecessarily difficult.
The same argument applies to the decision calculus 
models, which obviously make an optimisation procedure 
unnecessarily more complicated. In particular it is 
very difficult to parameterise the model with the 
approach taken in this case. The three other models
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can be parameterised using regression analysis once a 
few simple logarithmic transformations are made. The 
complicated mathematical structure of this model 
prohibits taking this approach. Thus, the decision 
calculus model was rejected in this case.
The Gompertz model by comparison is easily 
transformable into a format which allows it to be 
parameterised using regression analysis. The Gompertz 
model can be used to express market share S as a 
function of promotional expenditure X.
E 8.8 S * ao * ai ** (- 0 2 ** X)
After a few transformations equation E 8.7 can be 
rewritten as:
E 8.9 In ( - In ( S / ag ) ) » A ♦ B * X
with A » In In a^
B * In a2 .
This model was easily parameterised using regression 
analysis and it displayed high values for goodness of 
fit (R^) yet showed the desired features without being 
too complicated. A selection of cases was fitted to 
all three curves, leaving the decision calculus model 
out, as is demonstrated in examples displayed in
figures 8.2 to 8.4 representing the estimates of sales 
force expenditure in segment 'Early Majority' for 
product Dalacin.
Because the Gompertz model showed not only superior R2 
values, but also displayed the requirements best, i.e. 
S-shape and shares greater than zero at zero 
expenditure, it was chosen to represent the managers' 
estimates. In addition the shape followed most closely 
the data as estimated by the managers. Therefore a 
compromise was found between the desire to be as 
accurate as possible and the ability to parameterise a 
model best.
Subsequently, all fifty-five response curves were 
fitted to the Gompertz model. Table 8.3 provides an 
overview of the raw data created inclusive of R2 
values.
8.4 Optimisation
The worked example of the optimisation procedure 
addresses a problem of the optimum allocation of the 
marketing budget across five products, across five 
relevant segments ('Dr. Average', 'Early Majority', 
'High Energy', 'Young Conservatives' and 'Thrifty
Housewives') and across three media (sales force 
advertising, and direct mail).
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The optimisation problem is then to maximise gross 
profit according to
E 8.10 Max GP = E GMD x E,(SIZEd <s 
p « l  V  s « i
with
E 8.11 SHAREp,s (Xp >8) «
SMAXp,s - ( ( SMAXp> s - SNOWp / S ) X
3
m * i (  ( M S M A X p f s > m  -  F p , s , m ,  ( X p , s , m )  ) /  
(MSMAXp ,8#m - SNOWp , s ) ) )
Subject to
E 8.12 E Xp( 8 = B
B the available marketing budget 
all Xp9g tm > 0
Since advertising can not be channelled to Individual 
segments, expenditure on advertising is treated as 
total advertising expenditure across segments. Hence 
the model contains fifty-five variables.
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This optimisation problem can be described as 
constrained and non-linear (Beightler et al 1979). The 
complex structure of the problem in this case means 
that analytical derivatives are not available, making 
the choice of the appropriate optimisation routine more 
difficult.
However, a transformation (c.f. FORTRAN programme in 
appendix 2) allows to view this problem as an 
unconstrained problem. This approach offers the 
advantage of the application of an easy to use quasi- 
Newton algorithm as introduced by Gill and Murray 
(1972). This algorithm is implemented in the NAG 
routine E04 CGF.
The optimisation procedure is conducted using the NAG 
routine and utilising the computer language FORTRAN.
An example of the full programme developed is displayed 
in appendix 2.
The following is read in:
- Gross Margin, data on the respective gioss margin 
by product.
Market Size, data on the monetary value of each 
market segment for each product.
Current Expenditure, data on current expenditure 
for each product by segment and medium. This
information allows the initial start of the
optimisation procedure.
Current Market Share, data on the current market 
shares for products in each of the five segments. 
Coefficients of Response Curves, data on the 
coefficients of the individually estimated 
response curves.
Maximum Market Shares, data on the highest 
realistically achievable market share for each 
product in each segment.
Achievable Market Shares, data on the highest 
realistically achievable market share for each 
product in each segment with the sole use of one 
particular medium.
8.5 Results and Discussion
The results of the optimisation procedures are 
displayed in table 8.4. The model calculates a gross 
profit of £4.021 million with a current allocation of 
the fixed marketing budget. This compares with a gross 
profit figure of £6.507 million if the allocation is 
completely unconstrained. An increase of more than 50% 
in gross profit is indicated by re-allocating the 
marketing budget.
The optimum allocation shows a strong shift away from 
the utilisation of the sales force in favour of 
increasing use of advertising and direct mail. A cut 
in the expenditure on sales force from £ 1 million, 
representing 66% of total promotional expenditure is 
probably expected since this level is well above the 
industry's standard of 44%. However, a suggested level 
of spending at £100,000 amounts to a tenfold decrease. 
This is such a strong cut that it is basically 
questioning the conventional wisdom in the industry 
which states that the sales force is the most powerful 
promotional tool.
This result might therefore reflect the under­
estimation of the effect of the sales force and an 
over-estimation of the effectiveness of direct mail and 
advertising by the marketing managers when estimating 
the response to marketing expenditure. In particular 
the findings reported in chapter five which suggest an 
less effective role of promotion in gaining new 
customers should be taken into account. These findings 
call for further investigation, for example with the 
use of time series data and econometric models. The 
results of this investigation should then be used to 
verify the estimates used here.
The low level of expenditure for the sales force 
postulated by the results reported here might be o very
strong strategic indicator in the long run, but in the 
short-term expenditure on the sales force is fairly 
fixed.
Obviously expenditure on direct mail or advertising can 
be adjusted as and when required. When deciding on 
sales force expenditure the company has to take a 
number of considerations into account which are not 
easily quantifiable. Apart from the question whether 
it is possible to adjust the number of representatives 
in an ad-hoc manner, it is the more general problem of 
dealing with people to whom the company might feel a 
degree of loyalty which would actually prevent any 
drastic short-term measures.
If one accepts that as far as the sales force is 
concerned the company's flexibility is somewhat 
limited, the model needs to take this into account.
This results in the extension of the optimisation 
procedure to provide for additional constraints. In 
this case the optimisation procedure can be run at 
various levels of constraints expressed as fractions of 
current expenditure levels. At the extreme the 
optimisation can be run under the constraint that no 
reduction in sales force expenditure is possible. The 
result of this is displayed in table 8.5.
The result indicates a slight drop in profits 
achievable compared to the unconstrained solution.
Probably, the most realistic version is the result 
displayed in table 8.6. This is achieved using a limit 
of 80% of sales force expenditure. A gross profit in 
excess of £6.2 million is not too different from the 
results of the unconstrained solutions.
Overall, it is obvious that considerable improvements 
in gross profits are achievable by re-allocating the 
marketing expenditure. Although the unconstrained 
solution suggests a significant cut in sales force 
expenditure, results at certain fixed levels of sales 
force expenditure are still significantly higher than 
is currently achievable, and the results are still 
within five to ten percent around the optimum solution.
8.6 Validation
The results discussed in the previous section must be 
validated. One area to be checked is the proneness to 
depend too closely on the starting position. As 
explained in section 8.4 the initial starting data used 
comprised the current expenditure on products and 
media, whereby the expenditure by segment was 
calculated on the basis of being proportionate to the 
size of the segment. By re-allocating the budget a
gross profit increase of more than fifty percent was 
achieved.
Is this increase the result of the choice of the 
starting data? By starting relatively closely to what 
the end-result is going to be, there is clearly a 
danger of 'overlooking' an even better 'optimum' 
solution.
Two approaches were taken to test for the presence of 
that problem. First the real data were reshuffled -the 
real expenditure was allocated to different products, 
as shown in table 8.7. The results indicated that the 
gross profit was slightly reduced to £6.504 million, a 
reduction of £3000. This deviation was less than one 
percent. More importantly, the expenditure was 
allocated to the same sets of products, segments and 
media. The individual value of the allocated 
expenditure fluctuates by no more than ten percent.
To test for an extreme case, the initial data set was 
altered to cater for almost total allocation of the 
budget to product 5, the sales force, and the segment 
'Early Majority'. A nominal sum was allocated to 
direct mail in segment 'Early Majority' and product 1. 
Again the gross profit figure achieved deviated by 
£2000 (table 8.8) from the original result. Although a 
significantly higher number of iterations was
necessary, the same set of products, segments and media 
were selected for the allocation of the budget. Again 
the deviation of the absolute expenditures from the 
first result was less than ten percent.
The results of these two extreme sets of starting data 
have validated the contention that the choice of the 
starting data has a negligible impact on the optimum 
allocation of the budget. The results are robust.
8.7 Su— ary
Following the market segmentation procedures explained 
in the previous chapters this chapter has focused upon 
the allocation of the marketing budget to those 
segments identified, the product portfolio and the 
promotional tools available.
In fact, this chapter has tested hypothesis H5 which 
stated that:
A model can be used to support the optimum 
allocation of the marketing budget across 
products, segments and promotional tools.
Based on a review of marketing decision support systems 
which concluded that there is a gap in the literature 
to cater for the problems specified (Chapter seven), a
model has been developed to bridge the existing gap. 
Based on the experience reported in the literature the 
parameterisation of the model was achieved with the 
assistance of subjective estimation. The optimisation 
procedure developed has been explained before the 
results of an example using five products, five 
segments and three promotional tools have been 
displayed and discussed.
The results suggested that a considerable increase in 
gross profits can be achieved by re-allocating a fixed 
budget. The initial solution suggested that this can 
be achieved by significantly cutting expenditure on 
sales force. However, these savings can often not be 
realised in the short term. To test for the 
implications of treating large parts of the sales force 
expenditure as fixed, the model was constrained to 
allow for various levels of constant current 
expenditure. Although a drop in profit was noticeable, 
the changes were far smaller than expected. The gross 
profit figures achieved were still well above fifty 
percent higher compared to the current profit levels. 
This suggests that the majority of the extra profit was 
achieved by allocating the effort more accurately to 
the right products and target segments.
The conclusion of this chapter is that hypothesis H5 is 
accepted; it is possible to use a model to support the
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1. What is the forecast market share?
2. What is the ultimate market share if expenditure is 
increased to saturation?
3. What is the lowest level market share will reach if 
expenditure is reduced to zero?
4. Budget expenditure?
5. Market share next period if:
Budget expenditure increased by 200%
Budget expenditure increased by 100%
Budget expenditure increased by 50%
Budget expenditure increased by 25%
Budget expenditure decreased by 25%
Budget expenditure decreased by 50%
Budget expenditure decreased by 75%
Budget expenditure decreased by 100%
Table 8.1 Questions for a new product
2 6 0
1. What is the current market share?
2. What is the ultimate market share if expenditure is 
increased to saturation?
3. What is the lowest level market share will reach if 
expenditure is reduced to zero?
4. Maintenance expenditure?
5. Market share next period if:
Maintenance expenditure increased by 200%
Maintenance expenditure increased by 100%
Maintenance expenditure increased by 50%
Maintenance expenditure increased by 25%
Maintenance expenditure decreased by 25%
Maintenance expenditure decreased by 50%
Maintenance expenditure decreased by 75%
Maintenance expenditure decreased by 100%
Table 8.2 Questions for an established product
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Chapter 9 IMPLEMENTATION
9.1 Introduction
The previous chapters explained the need Cor focusing 
promotional effort in the pharmaceutical industry and 
the need to segment the GP market (chapter three)« 
introduced segmentation concepts (chapter four)« 
presented a dynamic (chapter five) and a static 
(chapter six) appioach to market segmentation« reviewed 
relevant marketing models (chapter seven), before 
finally a solution for the resource allocation was 
suggested (chapter eight). The aim of this chapter is 
to highlight some issues that are related to the 
implementation of the various analyses.
Work on this study started in January 1985; since then 
the various findings of the work have been reported to 
the Company's management. This allowed the observation 
of responses to the findings. These are discussed in 
three steps. Firstly, the issue of market segmentation 
as a marketing management problem. Secondly, the 
implementation of the segmentation study for sales 
force direction. Finally issues related to the budget 
allocation procedure.
Clearly, all these issues are interrelated but can be 
structured along these lines.
9.2 Market Segmentation
Market segmentation is certainly one of the most 
important aspects of strategic market planning as Abell 
and Hammond (1979, p.49) observed. Although the 
company distinguished between high and low prescribers, 
no formal segmentation of the GP market was applied. 
This can be explained by the fact that it is difficult 
to apply a pure marketing philosophy to pharmaceutical 
markets.
In the pharmaceutical industry it is not as straight 
forward a process to give customers products they want 
as it is in other industries. Mainly due to the long 
product development process, including the time 
consuming approval process, marketing management is 
often reduced to selling existing products in the most 
effective way. In an international company the 
individual subsidiaries are even more restricted as far 
as product developments are concerned. With a US based 
parent company the Company in question is definitely no 
exception.
As outlined in chapter three the sales force is the 
most important factor in the promotional mix. 
Consequently, the influential position of the sales
department adds to the sales orientation of the 
Company.
This process is further enhanced by the spread of the 
Company's product portfolio. The products are applied 
in different therapeutic classes, hence appeal to a 
variety of doctors. Consequently, sales management 
felt that, at the end of the day, they had to 
communicate to each and every doctor in the country. 
This attitude is probably best summarised in a sales 
philosophy as: 'The more doctors we see, the higher our 
sales are going to be.'
Market segmentation, as a marketing management tool, 
clearly will lead to a less wasteful allocation of 
resources.
The project's official start, the first few months were 
spent with familiarisation with the industry and a 
review of marketing decision support systems, coincided 
with the Company's adoption of a new sales force 
targeting system. As explained in chapter three, the 
STARS database is the basis for providing the sales 
force with detailed information on individual doctors. 
The adoption of this system, including the call card 
system, clearly reflects the Company's desire to 
improve call effectiveness.
Very appealing to sales management in this context was 
the ability to identify individual GPs who fulfil 
certain criteria. As explained in chapter 3.6, 
however, users become quickly disillusioned with this 
facility once they discover that with only a few 
criteria the data set is sometimes very small indeed.
This disillusion was enhanced further by the 
remoteness. All data manipulations have to be run on a 
mainframe computer. Consequently, the basic benefit of 
adopting the use of the STARS database has been the 
enhanced information base for the sales force. 
Apparently the implementation went smoothly and was 
well received by the sales force.
In the early stages of the adoption of the STARS 
database the proposal was made to use this system not 
only for targeting but rather for segmentation and 
targeting. Consequently, the data described in chapter
3.6 were obtained. This was done with marketing 
management's and the managing director's backing but 
against the reservation of sales management, who 
thought that they had enough to do with the 
implementation of the targeting system.
A lengthy process followed to incorporate the data into 
a manageable form. Quite frequently the limits of the 
computing facilities were tested and various technical
problems had to be solved. In the context of sales 
management's scepticism about sample size, and validity 
of conclusions drawn from samples, it became clear that 
further enlargements of the sample size were clearly 
out of question.
Interviews with marketing managers, sales managers and 
market researchers were conducted to gain an 
understanding of what kind of segments to expect to 
find. This process not only enhanced the author's 
understanding but also focused the minds of personnel 
involved on the project's issues and basically enhanced 
a mutual understanding. When the first segmentation 
results were presented, the seven cluster solution was 
shown along with a nine cluster solution. This nine 
cluster solution was very appealing since it showed a 
breakdown of the two most interesting segments the 
'Early Majority' and the 'High Energy' group.
Management found both solutions appealing, but the more 
precise classification in the nine cluster solution was 
favoured. But the desire for detail must be balanced 
with managerial aspects. The segments need to have a 
certain size in order to make it worthwhile to pursue 
different strategies. Further validation procedures as 
discussed in chapter six led to the adoption of the 
seven cluster solution. Throughout the discussions it 
has always been very helpful to managers to label the
groups with catchphrases such as 'Thrifty Housewives', 
etc., to make the segments come to life and make the 
exercise less of a statistical analysis.
Although the results of the segmentation analysis were 
obtained on the basis of a sample, it is possible to 
use the description to allocate the remainder of the 
data base into the seven segments. Using discriminant 
analysis to arrive at a description of the segments 
other doctors can be allocated with up to 80% 
confidence. This result was achieved by allocating the 
members of the hold-out sample to the clusters 
identified following the procedure outlined in the 
validation section in chapter six.
9.3 Sales Force Direction
Apart from the implications for marketing management 
outlined in the previous section, particular attention 
was given to implementing the segmentation results to 
direct sales force efforts.
Each salesperson has to cover approximately 700 doctors 
in the allocated sales area. Since he/she can only see 
up to five doctors in a day, the afternoon is spent 
with chemists and doctors in hospitals, it 
theoretically takes 140 working days to see all the
273
doctors in the area. If it was possible to focus the 
attention on those doctors who are worth visiting, i.e. 
high potential prescribers who are responsive to 
promotional effort, then those could be seen much more 
frequently than just once or twice a year. It is 
therefore interesting to examine how the salesperson 
actually selects the doctors to be seen.
Apparently, each representative enjoys a high degree of 
freedom in selecting doctors. He/she is given guidance 
as to which products to promote but to whom, is 
basically up to the representative. There is, of 
course, a control mechanism in that each 
representative's performance is measured against the 
actual sales in the allocated area. However, there is 
usually a lag of up to six weeks until he/she has seen 
the feedback. On the other hand, there is a commission 
element in the pay, enabling sales management to link 
special promotional programmes with incentives.
Therefore, each representative is inclined to see the 
most promising doctors anyway, but through his/her own 
effort. Clearly, under these circumstances there is a 
danger of approaching doctors who are either easy to 
see or are present 'customers' already. Consequently, 
high potential doctors might be overlooked due to their 
being difficult to approach and/or their preference for 
a competitive product.
With the representatives heavily relying on the STARS 
data, the new targeting system based on the 
questionnaire used in this analysis, there is, 
additionally, the danger that they overlook doctors on 
whom no data are available in the STARS database.
The analyses reported here touch on two issues related 
to the direction of the sales force. One is the 
additional information on the call card as to which 
segment a doctor belongs. The other issue is the 
allocation of doctors to segments on which no 
information is available.
The former issue is related to the actual 
practicalities of using the segments in the field. The 
latter is important because one third of the population 
is not covered by the STARS database. Is it therefore 
feasible for the representative, with the help of 
his/her sales manager to allocate the 'missing' doctors 
into the classification?
These two issues were tackled in field work. The 
author was given the opportunity to spend a week 
visiting GPs with a sales representative of the 
Company. This field work was used to 'validate' the 
statistical analysis in trying to actually meet a real 
•Dr. Average' or 'Young Conservative'. Although of
little statistical relevance, it was a very rewarding 
exercise to test the plausibility of the 
recommendations.
Sales management accepted the idea that there are 
differences in the prescribing patterns of doctors. 
However, from an implementation point of view they 
thought that a seven segment solution was by far too 
complicated. They opted for a two cluster solution, 
combining 'Young Conservatives', 'Thrifty Housewives', 
'Odd Balls', and 'Quasi Homeopaths' into the group that 
they should not see and the other into a second group 
with potential.
Although at this level the findings were obviously 
watered down, it is at least a first step to formally 
differentiating between doctors who deserve a lot of 
attention and others who do not.
Marketing management, however, had to face the 
challenge of the considerable threat to the long term 
success of their business in the existence of the large 
group of 'Young Conservatives'. A special marketing 
programme for this important group for the future had 
to be developed.
The work on this thesis has supported hypotheses H2 and 
H3. The implementation has demonstrated that
segmentation can be used to allocate sales effort and 
it has been shown that such segmentation procedures can 
be implemented in practice.
9 .« laBi ementation of the Allocation Model
Marketing management had been the department with the 
most involvement during the project's duration. The 
members were, therefore, already familiar with the 
segments, when in the last phase of the project the 
focus turned towards the allocation model.
As described in the previous chapter, the model was 
supposed to allocate resources to products, segments 
and media. Although management obviously had 
experience in allocating resources to products and 
media, the aspect of segments was completely new. 
However, two interesting aspects emerged during the 
estimation process of the model: managers were forced 
to discuss and to justify their expectations of the 
outcomes of certain levels of spending, and thus were 
forced to formally outweigh the pros and cons of 
promotional expenditure in general. Secondly, it 
reinforced the results of the segmentation study, in 
that the managers started to think of the market as a 
sum of segments. By deciding that one group would be 
more responsive than others, suddenly the value of the
segmentation study became apparent but also the value 
of proper allocation emerged as an important issue.
During the process of subjective estimation these 
insights occurred. Two full days were spent 
subjectively estimating the response curves for 
products, segments, and media. Three decision makers 
from the Company were involved: the marketing manager, 
the market research manager, and a senior brand 
manager. The estimation process was conducted with the 
assistance of a program written on Lotus 1-2-3, which 
enabled the display of an individual response curve as 
the data were estimated. Thus, it was possible to 
instantly see and judge whether a proposed data 
selection made sense and represented a logical 
approximation of the managers' beliefs.
It is obvious, that after initial difficulties, the 
segments were a completely new dimension, the managers 
became more familiar with the concept. Although, a 
very time consuming and tiresome exercise, all parties 
involved felt that they gained a better understanding 
of the market and moreover, of their own decision 
making process. As a result these managers seemed to 
be more committed than ever to implementing some of the 
findings.
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The results of the optimisation procedure were not 
easily obtained. The rather complex relationship of 
the elements of the promotional mix required a lengthy 
inter-active process until the model specified in 
section 8.2 was determined.
The implementation of the optimisation procedure was by 
far more difficult than expected. This was due to 
hardware as well as software problems. The NAG 
routines used were by no means user friendly. In a 
complex situation which requires the simultaneous 
optimisation of fifty-five variables it is often very 
difficult to distinguish whether unsuccessful runs are 
due to flaws in the model specification, due to 
mistakes in the software configuration, or plainly 
results of insufficient hardware. In the process of 
developing the model, all these problems occurred, 
often not in isolation.
The consequence of these difficulties has been that the 
optimisation procedure required substantially mere time 
than anticipated. This meant that when the results 
were obtained, a number of changes had taken place.
Firstly, the results were obviously out of date. This 
problem can be overcome by convincing management of the 
benefits of repeating the estimation exercise and the 
subsequent recalculation of the optimisation procedure. 
Secondly, changes on the management structure led to
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the appointment of a new marketing manager. This 
process obviously does not allow for the continuity 
desired for a smooth implementation.
9.5 Summary
This chapter has highlighted some of the observations 
made with respect to the implementation of this study's 
findings.
The conclusion is that the concept of market 
segmentation is fairly new to this pharmaceutical 
company due to its sales orientation. Restrictions on 
promotional expenditure and the advent of powerful 
databases, however, enhanced the desire and the ability 
to be more accurate in the marketing effort. Product 
managers and marketing managets in the case reported 
here are satisfied that the segments identified are a 
meaningful representation of the market place.
Involving them in discussing the various levels of 
segments has enhanced their commitment in subscribing 
to the ideas presented.
It is more difficult to implement segmentation for 
sales force direction. It is possible to add 
information to the call card used in the sales force 
with regards to which segment a doctor belongs.
However, this will only benefit the sales force 
direction when the appropriate training is provided.
As an intermediary step the Company decided to use the 
segmentation study to allocate the doctors into two 
groups, those who are worth seeing and those who are 
not. This is at least a step towards implementation 
and it is hoped that, with more experience with the 
call card system and the segmentation study, the 
findings will be implemented to direct sales force 
effort more effectively.
Work on the budget allocation part of the project 
reinforced the implementation of the segmentation 
study. The estimation of response curves for segments 
forced the managers involved to have a better 
understanding of the segments' profiles.
Subjective estimation was found to be a valuable tool 
in gaining understanding and commitment from the 
managers involved. This process was very much enhanced 
by using Lotus 1-2-3 implemented tools which allowed 
the assessment of 'What if?' scenarios. Using the 
graphic facilities the estimation could visually be 
checked.
The results of the optimisation procedure were out of 
date when presented to the Company, therefore little
can be said about implementation of this aspect of the 
project. The process, however, developed in this 
thesis starting with the subjective estimation will 
have to be followed through again in order to develop a 
budget allocation model which can be implemented in the 
current financial year.
The work on this thesis has supported hypotheses H2 and 
H3. The implementation has demonstrated that 
segmentation can be used to allocate sales effort and 
it has been shown that such segmentation procedures can 
be implemented in practice. As far as implementation 
of the budget allocation procedure is concerned it is 
too early to conclude from observation.
CHAPTER 10 CONCLUSION
This thesis set out to test the following hypotheses
based on the UK pharmaceutical market :
HI Segmentation can be used to allocate sales effort.
H2 Such segmentation procedures can be implemented in 
practice.
H3 It is possible to define market segments on the 
basis of response to marketing stimuli.
H4 It is possible to define static segments which 
reflect dynamic behaviour.
H5 A model can be used to support the optimum 
allocation of the marketing budget across 
products, segments and promotional tools.
With respect to these hypotheses the findings are:
1. Hypothesis HI is accepted. As demonstrated in
chapters six and eight, segments in pharmaceutical 
markets can be used to direct the sales force 
effort more effectively.
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2. Hypothesis H2 is accepted. As discussed in 
chapter nine, with the help of comprehensive 
databases it is possible to implement segmentation 
procedures in practice.
3. Hypothesis H3 is rejected. With the use of the 
data available it could not be sufficiently proven 
that it is possible to define market segments on 
the basis of response to marketing stimuli 
(chapter five).
4. Hypothesis H4 is accepted. As demonstrated in 
chapter six it can be shown that segments 
identified on the basis of static information 
reflect dynamic behaviour. Thus, these static 
segments show a significant difference in response 
to marketing stimuli. Hence these segments 
represent a meaningful way of classifying the 
market.
5. Hypothesis H5 is accepted. As discussed in 
chapter eight a model is developed which can be 
used to support decision making in the allocation 
of the marketing budget to products, segments and 
promotional tools.
The work reported in this thesis spans a number of
areas in marketing theory, the ultimate objective being
to develop a model assisting in budget allocation 
decisions. This work is obviously closely related to 
research into decision support systems. A review of 
the literature on decision support systems with 
particular emphasis on marketing decision support 
systems was provided in chapter two. There it was 
concluded that the way the term DSS is used in this 
thesis would follow Stabell's (1987) distinction 
between the various DSS 'schools' and would be called 
the decision calculus approach. This approach to DSS 
research puts the focus closely on the development of 
models as the heart of a DSS.
With the objective of modelling budget allocation 
problems to products, segments and promotional tools, 
one important problem needs to be addressed first, the 
segmentation of the market in question. While the 
products and the promotional tools can be treated as 
given, segments are not necessarily easily defined. 
Chapter three set out to explain the background to this 
case, a Company operating in the UK pharmaceutical 
industry. It was concluded that segments in the GP 
market are not obvious, hence the need to undertake a 
segmentation study.
Chapter four provided an overview of the literature on 
segmentation research with the objective of identifying 
appropriate bases of segmenting the GP market.
Chapter five aimed to identify segments within the GP 
population on the basis of response to marketing 
stimuli. This is important because if segmentation is 
conducted with the ultimate objective of an optimal 
allocation of the marketing budget, then clearly the 
response to these very promotional tools is the best 
basis for segmentation. However, mainly due to 
limitations in the data, only two sets of 'snap shots' 
over time rather than time series data were available; 
segments identified to be responsive were too small to 
be of any significance.
As a separate finding, this chapter reported on 
evidence which indicates that promotional expenditure 
has a stronger role in maintaining an existing customer 
base rather than in gaining new customers.
Chapter six discussed two static approaches to 
segmenting the GP marketing. The macro analysis across 
doctors' prescribing pattern in all therapeutic classes 
for which data were available identified seven 
segments. It was concluded that these segments 
displayed a different degree of attractiveness for 
pharmaceutical companies. It is shown that these 
segments are meaningful because it could be proven that 
there is a significant difference in the response to 
marketing stimuli.
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The micro analysis, however, demonstrated how the 
market within a therapeutic class can be segmented. By 
applying this technique a useful insight for brand 
positioning can be gained.
Since the overall objective has been to identify 
segments in the GP population in a more general way, 
the seven segments identified in the macro analysis 
were used in the model building.
The foundation to the model was presented in chapter 
seven. Based on a review of the literature on 
marketing models, a gap in the literature was detected 
with respect to the allocation of marketing resources 
to segments. The application of subjective estimation 
was seen to be common in parameterising models which 
were closest to solving the problems discussed in this 
thesis. Subsequently, elements of subjective 
estimation were outlined.
Chapter eight examined the application of a model. The 
model's specification was outlined and its 
parameterisation explained. The various parameters 
were determined, particularly with the help of 
subjective estimation conducted by marketing managers. 
Subsequently the optimisation procedure was outlined 
and the results explained.
An increase in gross profit in excess of fifty percent 
was feasible when the fixed budget was re-allocated to 
the most promising set of products, segments and 
promotional tools. This re-allocation of the budget 
was primarily achieved at the expense of expenditure on 
the sales force, which was reduced significantly. When 
it is accepted that in the short term no significant 
changes in sales force expenditure can be undertaken, 
the model is flexible to allow for an additional 
constraint in the form of a fixed proportion of current 
expenditure. Even a re-allocation of the budget with 
80% of sales force expenditures being fixed achieved an 
increase in gross profit in excess of 50%.
The implementation of the various analyses has been 
discussed in chapter nine. There it was concluded that 
the segmentation study was welcomed as an additional 
benefit to the introduction of a new database targeting 
system. For the allocation model, however, it is too 
early to comment. Change in key managerial positions 
has not necessarily eased the implementation of the new 
decision support system.
Limitations and Future Research
287
As far as the segmentation study is concerned, the 
methodology employed has proven to be successful.
Although the definition ot static segments eases 
implementation because it is easier and quicker to 
conduct, response to marketing stimuli remains a key 
issue in segmentation research. In this thesis it is 
shown that the static segments identified displayed 
differences in response to marketing stimuli, thus a 
balance of ease of use and utility is achieved.
However, segmentation on the basis of response should 
be tried directly. With the database used it should 
even be possible to conduct this more successfully than 
it was possible in this analysis. In the future, the 
database will be more frequently updated, which means 
that more data over a longer period of time will be 
available. Although it will never be as accurate as 
times series data, an analysis of change in preference 
over time relative to promotional spending should be 
more accurate once, say, four responses to the 
questionnaire are available compared to two in this 
case.
The segmentation study itself has identified segments 
which warrant further research. The group of 'Young 
Conservatives' are a large and important group of 
doctors for the future. Pharmaceutical companies need 
to understand better what doctors in this segment want 
and how they can be approached. Additional market 
research could also produce some important insights
into the prescribing behaviour of doctors in the 
currently highly attractive segments of 'Early 
Majority' and 'High Energy'. These doctors account for 
a large number of prescriptions and are very attractive 
targets for pharmaceutical companies. For example it 
would be worth monitoring their prescribing behaviour 
over time to test hypotheses with respect to their 
innovativeness and brand loyalty.
In addition, the stability of segments over time has to 
be established. Obviously, the accuracy of the 
allocation model is dependent on the validity of the 
segments identified. However, the model is adaptable 
to cater for any number and types of segments which may 
be identified in the future as long as the response to 
promotional expenditure is determined for the changing 
or evolving segments.
The results of the optimisation procedure indicate that 
considerable increases in expenditures on direct mail 
and advertising at the expense of sales force 
expenditure would lead to significant increases in 
gross profits. It has to be established whether the 
effectiveness of direct mail and advertising has not 
been exaggerated when estimating the response to 
expenditure.
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The effectiveness of relevant promotional tools has to 
be investigated further in particular in the light of 
the findings reported in chapter five. There, some 
evidence for a defensive role of promotional 
expenditure was reported. It could not be established 
that promotional expenditure helped significantly in 
gaining new customers.
Analysing the response to promotional expenditure using 
time series data and econometric models would help 
gaining a better understanding of the relative 
importance of a promotional tool. This knowledge could 
be used as an input in re-estimating the response to 
promotional expenditure. By increasing the quality of 
the estimates it is expected to improve the quality of 
output of the budget allocation model.
The limitations of the model at the heart of the 
decision support system are best discussed against the 
criteria set by Little (1970) as outlined in chapter 
two.
He postulated that a OSS should be simple, robust, easy 
to control, adaptive, as complete as possible and easy 
to communicate with. These aspects will be discussed
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in turn:
Simple: the basic structure of a model needs to be easy 
to understand. The basic structure of the model 
developed here is not too complex. However, simplicity 
is obviously hampered by the desire to model complex 
interaction effects. Hence the model can be judged as 
being simple considering the complexities modelled.
Robust: absurd answers, such as a market share in 
excess of one hundred percent are not possible in this 
model. It can be judged to be robust.
Easy to Control: it should not be too difficult to 
understand the kind of input data required. However, 
when re-calibrating the model, an experienced outside 
communicator should be present.
Adaptive: the model is within reason adaptable to new 
information. For example, new knowledge about the size 
of the budget available, the degree of flexibility in 
terms in change compared with previous expenditure, or 
limits on market shares achievable can be incorporated 
fairly easily. The re-estimation of response to 
marketing stimuli is also possible but requires 
substantially more effort and time.
Work recently reported by Fraser and Hite (1988) could 
provide an interesting starting point for integrating 
information from experience with information from
models in what they labelled 'an adaptive utility 
approach'.
Completeness: this criterion examines whether important 
phenomena are included in the model. From a list of 
criteria compiled for marketing mix models (Lilien and 
Kotler 1983 p. 663) some are applicable in this case.
The most obvious criterion is interaction between the 
promotional tools. This aspect has been tackled 
satisfactorily. However, the model does not explicitly 
incorporate competitive effects or lag-effects of 
expenditure. Competitive effects are indirectly 
included since the judgemental determination of 
response curves to promotional expenditure inevitably 
takes competitors' moves into account.
Lag-effects are currently not included, but this is an 
area where future research could quite easily fill the 
gap. This is primarily important once the 
implementation is progressed and the desire for an 
increase in sophistication is present.
Another area where future research could be beneficial 
is the aspect of incorporating various levels of 
effectiveness for expenditures.
2 9 2
The model is currently complete in incorporating vital 
phenomena. There is, however, room for developing it 
further to include lag-effects and different levels of 
effectiveness of expenditure.
Communication
Following the procedure used in STRATPORT (Larreche and 
Srinivasan 1981) it is attempted to combine subjective 
estimation and optimisation. The optimisation routine, 
however, is run on a mainframe computer. This 
prohibits the use by management as explained in chapter 
two. However, the model is easily transferable to 
Lotus 1-2-3. This obviously will not allow 
optimisation procedures, but will allow the test of 
various What if? scenarios.
The use of the model could thus be in two steps: 
establishing the optimum solution on the mainframe 
computer, then taking the results for What If? tests on 
to Lotus 1-2-3 to examine for the sensitivity of the 
findings. From an implementation point of view this 
facility is obviously paramount in achieving successful 
adoption (C.F. chapter two). Only this facility will 
actually bridge the gap between the user and the 
developer and should avoid the pitfalls of early 
operational research models which tended to neglect 
this issue. This aspect of the implementation takes a
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301
PROGRAM MAIN
ALLOCATION OPTIMIZATION 302
MAIN PROGRAM
C0M40N /MYOATA/ GM(S). SIZE(5.6), SH'5,6), SMPSI5.6), SNOW(5,6),
• RMDIUM(5,6.3),ALPHAO(5, 6. 3) , ALPHA1 (5, 6. 3 ) , ALPHA2(5,6,3),
• M I S , «.91, SMPSMI5.6, 3) .
• MAXPRD,MAXSEG. MAXMEC 
C0f*4ON /MINIM/ BESTIT,ICOU
COi*K>N /BSTCOM/ FACTOR.FACT1,FACT2.FACT3,XXSA7E(65I,KMAX 
REAL OB JF
INTEGER I. ¡FAIL. ITMAX, J, N, KMAX,
• NIN, NOUT, CMD, IWORKU000),
• LIWORK,LWORK
REAL X (6,6,3) , XX (65) , YY(65>, WORK(SOOO)
EXTERNAL CMD
SET LIMITS TO THE PROBLEM
MAXPRD-5
MAXSEG—6
MAXMED—3
SET FILE 20 FOR RESULTS 
I-CMD(•FILEDEF 20 DISK 
GET LOWER BOUND FACTOR 
WRITE(6,4010)
READ(5.*) FACT)
GET LONER BOUND FACTOR 
WRITE(6,4020)
READ(5.*) FACT2
GET LOWER BOUND FACTOR
WRITE(6,4030)
READ(5,* > FACT3
START1 RESULT A ( RECFM F LRECL 80') 
FOR ADVERTISING
FOR MAIL SHOT
FOR SALESMAN
GROSS MARGIN DATA IS IN A FILE CALLED GM DATA 
I-CMD('FILEDEF 1 DISK GM DATA')
READU.-) (GM (I) , I — 1, MAXPRD)
SH DATA IS IN A FILE CALLED SHAREM2 DATA 
I-CMD('FILEDEF 2 DISK SHAREM2 DATA')
DO 80 IPROD-1,MAXPRD
READ (2, • ) SH (I PROD, 1) , SHIIPROD.2), SH(IPROD,3>, SHUPROC.4),
• SH(IPROD,S), SH(IPROD,6)
CONTINUE
MARKET SIZE DATA IS IN A FILE CALLED SIZE DATA 
I-CMD('FILEDEF 3 DISK SIZE DATA')
DO 90 IPROD-1,MAXPRD
READ(3,•) SIZE(IPROD,1). SIZE(IPROD.2), SIZE(IPROD.3) .
• SIZE(IPROD,4), SIZE(IPROD,5). SIZE(IPROD,6)
CONTINUE
READ(3,«) ( (SIZE(I.J).I-1.MAXPRD).J-l.MAXSEG)
RESPONSE FUNCTION DATA IS IN A FILE CALLED ALP HA 1 DATA 
I-CMD('FILEDEF 4 DISK ALPHA1 DATA')
DO 130 IPROD-1,MAXPRD 
READ(4,1000)
1 M,ALPHA0(IPROD,1,1),ALPHA1(IPROD,1.1),
2 ALPHA2(IPROD,1,1),RR(IPROD,1,1)
DO 120 ISEG-1,MAXSEG
DO 110 IMED-2,MAXMED 
READ(4. 1000)
1 M,ALPHA0(IPROD,ISEG, IMED),ALPHA1(IPROD,ISEG.IMED) ,
2 ALPHA2(IPROD,ISEG, IMED) , RR (IPROD, ISEG,IMED)
WRITE(20,1000)
1 M,ALPHA0(IPROD,ISEG,IMED),ALPHA1(IPROD,ISEG,IMED) ,
2 ALPHA2(IPROD,ISEG, IMED),RR (IPROD. ISEG.IMED)
OPT00010 
OPT00020 
OPT00030 
QPT00040 
OPTC3C5C 
OPTG3060 
OPTC0C70 
OPTC0080 
OPTOo:90 
OPTCO100 
OPTCOUO 
OPTO o;20 
OPT00130 
OPTO014 0 
OPTCO150 
OPT00160
oPTeono
OPTO0180 
OPTO0190 
OPT00200 
OPT00210 
OPTC022C 
OPT00230 
OPT00240 
OPT00250 
OPTO0260 
OPT00270 
OPT00280 
OPTO0290 
OPT00300 
OPT00310 
OPT00320 
OPTOO 330 
OPT00340 
OPTOO350 
OPT00360 
OPT00370 
OPTOO 380 
OPTO0390 
OPT00400 
OPTO0410 
OPT00420 
OPT004 30 
OPT00440 
OPTO0450 
OPTO0460 
OPTO0470 
OPT0048C 
OPTO0490 
OPTOOSOO 
OPTOOS 10 
OPT00520 
OPT00530 
OPTOO540 
OPTOO550 
OPT00560 
OPT00570 
OPT00580 
OPTO0590 
OPT00600 
OPT00610 
OPT00620 
OPT0063C 
OPT0064C 
OPT0065C 
OPTO0660
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!220
240
250
c o nt inu e
CONTINUE
CONTINUE 303
CURRENT EXPENDITURE IS IN A FILE CALLEO START DATA 
I-CMDCFILEDET 10 DISK START DATA')
OO 240 IPROD-l.MAXPAD
HEAD (10. 85001 M,X(IPAOC. 1.1»
OO 220 IMED-2.MAXMEC
REAO(IO.aOOO) M,X(IPROO.1,IMED). X (IPROO,2,IMED). 
XCPROD. 3. IMED) . X ( I PROD, 4. IMED ) , X ( IPROO, 5. IMED I . 
X (IPROO,6,¡MED)
CONTINUE
CONTINUE
MAXIMUM SHARE OATA IS IN A FILE CALLED SMAX DATA 
I-CMC('FILEDEF 12 DISK SMAX DATA'I 
DO 250 IPROD-l.MAXPRD
READ (12,*I SMPS(IPROD,11, SMPS(IPROO.2), SMPS(IPROD,3). 
SMPS(IPROO,4 ) , SMPS(IPROO,5), SMPS(IPROO,6)
CONTINUE
C CURRENT MARKET SHARE DATA IS IN A FILE CALLEO SNOW DATA
I-CMDI'FILEOEF 13 DISK SNOW DATA'»
DO 260 IPROO«1,MAXPRD
READ (13,*) SNOW(IPROD.1), SNOW(IPROO.2), SNOW(IPROO,3),
• SNOW(IPROD,4), SNOW(IPROO,5). SNOW(IPROO.6)
260 CONTINUE
C READ(13,•) ((SNOW(I,J),1*1,MAXPRD), J-l.MAXSEG)
C
C SHARE ACHIEVABLE WITH MEDIUM IS IN A TILE CALLEO MEDSKM OATA
I-CMD ('FILEDEF 14 DISK MEOSHM DATA')
DO 280 IPROD-l.MAXPRD 
READ(14,1000)
1 M.SMPSMIIPROD,1.1)
00 270 ISEG-t. MAXSEG
OO 265 IIKD—2. MAXMED 
READ(14,1500)
1 M.SMPSM(IPROO.ISEG.IMED)
WRITE(20,1500)
1 M.SMPSM(IPROD,ISEC,IMEO)
265 CONTINUE
270 CONTINUE
280 CONTINUE 
K-0
DO 330 IPROD-l.MAXPRD 
K-K»l
XX(K)-X(IPROD, 1.1)
DO 320 ISEG-2,MAXSEG
00 310 IMED-2,MAXMED 
K-K*l
XX(K)-X(IPROO, ISEG. IMED)
310 CONTINUE
320 CONTINUE 
330 CONTINUE 
KMAX-K
C WRITE (20, *000) KMAX 
DO 410 I-1,KMAX 
XXSAVE(I)-XX 11>
410 CONTINUE 
NOUT-22
C CALL PROCEDURE - SPECIFICATION
C
CALL X04ABF(1, NOUT)
NCLIN-1
:r:;ro
OPT0C680 
3PT00690 
OPTCO’OO 
OPTOO’IO 
OPT00720 
OPT00730 
OPTO0740 
OPT00750 
OPTC0760 
OPT00770 
OPT00780 
OPTO 07 90 
OPT00800 
OPT00810 
OPT00820 
OPT00830 
OPT00840 
OPTO0850 
OPT00860 
OPT00870 
OPT00880 
OPTO0890 
OPTO0900 
OPT00910 
OPT00920 
OPT00930 
OPT00940 
OPT00950 
OPTO0960 
OPT00970 
OPT00980 
OPT00990 
OPTO 1000 
OPT01010 
OPTO 1020 
OPTO1030 
OPTO 1040 
OPTC1050 
OPTO 1060 
OPTO 1070 
OPTO 1080 
OPTO 1090 
OPTO 1100 
OPTO 1110 
OPTO 1120 
OPTO1130 
OPTO 114 0 
OPTO 1150 
OPTO 1160 
OPTO1170 
OPT01180 
OPTO 1190 
OPTO 1200 
OPT01210 
OPTO 1220 
OPTO 1230 
OPT01240 
OPTO 1250 
OPTO 1260 
OPTO 12*0 
OPTO 1280 
OPTO 1290 
OPTO 1300 
OPTO 1310 
OPTO 1320
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LWORK-500G
LIWORK-1000
304C SOLVE TNE PROBLEM
ITER-0
N-KMAX
CALL MRITXX(XX)
»99 CONTINUE
ITER-ITER*1 
WRITE<20.7000) ITER 
CALL CONVIN(XX,YY)
CALL RECONV(XX,YY)
CALL FUNCT1(N.YY.OBJT)
CALL CRRECT(N,YY,OBJFl 
XP(ITER.EQ .X) THEN 
WRITE»20,70501 OBJF 
END IF 
ICOU—0 
IFAIL-1
CALL E04CSF (N,YY. OBJF,IWORK.LIWORK,WORK. LWORK,IFAIL)
CALL RECONV(XX, YY)
WRITE(20.(0SO) IFAIL 
C IF(XFAXL.NE.0) GOTO 999
CALL CRRECT(N.YY.OBJF)
WRITE(20. 4110) FACT1 
WRITE(20. 4120) FACT2 
WRITE(20. 4130) FACT3 
WRITE(20.70(0) OBJF 
CALL WRITXX(XX)
STOP
20 WRITE(MOOT, 99997) IFAIL
C
1000 FORMAT(13X.A2.10X,F7.2,F9.5, F9.5, F9.2)
1S00 FORMAT(13X.A2,13X.F4.1)
2000 FORMAT(A2,F(.2,FS.3,F7.2,F11.2.2F10.2)
3000 FORMAT(A2,F(.2)
4010 FORMAT!' GIVE LOWER BOUND FACTOR FOR ADVERTISING ( 0 TO 1 )')
4020 FORMAT!' GIVE LONER BOUND FACTOR FOR MAIL SHOT ( 0 TO 1 )*)
4030 FORMAT!' GIVE LOWER BOUND FACTOR FOR SALES FORCE I 0 TO 1 )').
5000 FORMAT(A2,F(.2)
4110 FORMAT!' LOWER BOUND FACTOR FOR ADVERTISING IS '.F12.4)
4120 FORMAT(' LOWER BOUND FACTOR FOR MAIL SHOT IS '.F12.4)
4130 FORMAT!' LOWER BOUND FACTOR FOR SALES FORCE IS '.F12.4)
(000 FORMAT(A2,F6.2,F6.3,F7.2,F8.2,2F9.2)
(050 FORMAT!' IFAIL-'.13)
7000 FORMAT!' ITERATION',13)
7010 FORMAT!' '.I3.2FK.O
7050 FORMAT!' INITIAL SOLUTION '.F14.8)
70(0 FORMAT!' FINAL SOLUTION '.F14.8)
8000 FORMAT(A2,F8.4,F10.S,F10.5,F10.S,F10.4,F13.4)
8500 FORMAT(A2,F8.41
9000 FORMAT!' OPTIMISATION OVER ',13.' VARIABLES')
99996 FORMAT!' OPTIMISATION CRRECT')
99997 FORMAT!' OPTIMISATION FAILED IFAIL-',13)
C
END
C
SUBROUTINE CRRECTIN,YY.OBJF)
REAL YY(N).OBJF.SUM 
INTEGER N.I 
SUM-0.0 
DO 100 I-l.N
SUM-SUM*YY(I)«YY!!)
100 CONTINUE
WRITE(20,1000) N.SIM
OPTC133C 
OPTC134C 
OPTC135C 
OPTO 13(0 
OPTO 13’0 
OPTC138C 
OPTC139C 
OPTO 14CC 
OPTO 1410 
OPTO!42C 
OPTO 1430 
OPTO 1440 
OPTO 14 50 
OPTO 1480 
OPTO 1470 
OPTO 1480 
OPTO 1490 
OPTO 1500 
OPTOISIO 
OPTO 1520 
OPTOIS30 
OPTO 1540 
OPTO1550 
OPTO15(0 
OPTO1570 
OPTO1580 
OPTO1590 
OPTO 1(00 
OPTO 1(10 
OPTO 1(20 
OPTO 1630 
OPTO 1640 
OPTO1650 
OPTO1660 
OPTO1670 
OPTO1680 
OPTO1690 
OPTO1700 
OPTO 1710 
OPTO1720 
OPTG1730 
OPTO1740 
OPTO1750 
OPTO17(0. 
OPTO1770 
OPTO 1780 
OPTO 1790 
OPT01800 
OPTOISIO 
OPTO1820 
OPTO1830 
OPT01840 
OPTO1850 
OPTO1860 
OPTO1870 
OPTO 1880 
OPTO1890 
OPT0190C 
OPT01910 
OPTO1920 
OPTO 1930 
OPTO1940 
OPTO1950 
OPTO1960 
OPTO 1970 
OPTO1980
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I OBJF — OBJF* (SUM-1.0)**2 
RETURN
1000 FORMAT(' CRRECT '.X3.F12.6) 305
END
c
C CALL OPTIMIZATION SUBROUTINE 
C
SUBROUTINE FUNCT1 (N, TV. OBJFl
COMMON /MYDATA/ CM(5>, SIZE(5,6), SH(5.6>, SMPS<5,6>, SNOW<5,6>.
• RMDIUM(5.6. 3) . ALPHAO(5.6,3). ALPHA1(5.6.3). ALPHA2(5,6,3),
• RR(5,6,3l , SMPSMlS.6,3).
• MAXPRD.MAXSEG. MAXMED 
COMMON /MINIM/ BESTIT.ICOU 
INTEGER N
REAL YY(N). OBJF
REAL X(5.6,3),PROD.PRO. XXX, PR. PF,PI,PROFIT.XX(100) . SUM 
INTEGER I, J. K, P, S 
EXTERNAL F 
ICOU-ICOU*l
IF (ICOU.EQ.1) BESTIT-0 
C
C CREATE XX-ARRAY
C
CALL RECONV(XX,YY)
C
C CREATE X-ARRAY
C
K-0
DO 130 P-l.MAXPRD 
K-K'fl
X(P. 1, l)-XX(K)
DO 120 S-2,MAXSEG 
DO 110 1-2.MAXMED 
K-K*l
X(P, S, I)-XX(K)
110 CONTINUE
120 CONTINUE
130 CONTINUE
C
C CREATE OBJECTIVE FUNCTION
C
XXX-0
PF-0
PRO-1
DO 210 P-l.MAXPRD 
PI-0
DO 200 S-2,MAXSEG 
PROD-1.0
PROD-PROD*((SMPSMIP,1.1)/100-(F(P.1.1.X(P.1.1))/100))/
• ( (SMPSMiP. 1. D/100)- SNON(P.l) ) )
C PROD-PROD*((1.0-(F(P,1,i,X(P.1,1))/100))/SH(P. 1))
XXX- XXX*X(P,1.1)
DO 150 1-2,MAXMED
PROD-PROD*((SMPSM <P,S,I)/100-(F(P,S,X,X(P,S,X))/100))/
• ((SMPSM(P,S,I)/100)- SNOW(P.S)))
XXX- XXX*X(P,S.X)
150 CONTINUE
PI-PI* SIZE(P. S) * (SMPS(P.S)-(SMPS(P.S)-SNON(P.S))*PROD>
200 CONTINUE
PF-PF*PI*GM(P)
210 CONTINUE 
PROFIT-PF 
SUM-0.0 
DO 220 I-l.N
SUM-SUM*YY(I)*YY (I)
220 CONTINUE
OPT0199C 
OPTC2COO 
OPTC2013 
OPTC2C20 
OPT02C3C 
CPT0204C 
OPTC2050 
CPT02C60 
OPTC207C 
OPTC208C 
OPTO2090 
OPTC210C 
OPT02110 
OPTO2120 
OPTC2130 
OPT0214C 
OPTC2150 
OPTC2160 
OPTG2170 
OPTC2180 
OPT02190 
OPT02200 
OPT02210 
OPT02220 
OPT02230 
OPTO2240 
OPT02250 
OPT02260 
OPT02270 
OPT02280 
OPTO2290 
OPT02300 
OPT02310 
OPT02320 
OPT02330 
OPT02340 
OPT02350 
OPTO2360 
OPT02370 
OPT02380 
OPT02390 
OPT02400 
OPT02410 
OPT02420 
OPT02430 
OPT02440 
OPT024S0 
OPTO2460 
OPTO2470 
OPT02480 
OPTO2490 
OPT02500 
OPT02510 
OPT02520 
OPTO2530 
OPT02540 
OPT02550 
OPTO2560 
OPTO2570 
OPTC258C 
OPTO2590 
GPT0260C 
GPTG261C 
CPTC262C 
CPTC2630 
CPTC264C
Appendix 2 contd
C*.T— P *O r:> IS U M -1 .3 l»2  
IF(PROFIT.GT.BESTIT) then
c i f f - p r o f i t - b e s t i t  
: f i o i f f . 3 T . : . oo- 3 )  then 
BESTIT-PROFIT
WRITE(20.90011 ICOU.BESTIT,SUM 
ENOIF 
END IF 
RETURN
9001 FORMAT(' ITERATION '.IS.' PROFIT'.FIS.9.' SUM'.FI* 6)
9002 FORMAT(' '.6F11.8)
END
C
C GOMPERTZ FUNCTION
FUNCTION FIP.S.I.XI 
COMMON /MYDATA/ GM(5), SIZE(5.6», 
RMDIUM ( 5. 6. 3 ) , A LP HAO ( 5,6. 3 ) . 
' RRIS.6.3). SMPSMI5.6, 3) ,
MAXPRD, MAXSEG, MAXMED 
INTEGER P, S, I 
REAL X
XX-ALPHA2(P,S.II**X 
IF(XX.LE.0.0) THEN 
F-0.0
WRITE (20. *1 'XX LESS O'. F 
RETURN
SH (S. 6) . SMPS (5,6), SNOW (5,6), 
ALFHA1 (5, 6, 3), ALPHA! (5,6,3),
END IF
F-ALPHAO (P, S. I) • (ALPHAI (P.S. I) •• (- <ALPHA2 U-.S. I» •• (X*1000) ) ) )
RETURN
END
SUBROUTINE CONVIN(XX.YY)
COtMON /MYDATA/ GM(5>, SIZEI5.6), SH(S.S). SMPS(S.S). SNOW<5,6>.
• RMDIUM (5, 6,3), ALPHAO (5,6,3), ALPHA1 (5, 6, 3) . ALPHA2 ( 5, 6* 3 ) '
• RR (5, 6, 3) , SMPSM ( >,6,3),
• MAXPRD,MAXSEG.MAXMED 
/BSTCOM/ FACTOR. FACT1. FACT2. FACTS. XXSAVE (65) , KMAX
V-XX(K)-XXSAVE(K)*FACT1 
IF(V.LT.O) V-0 
YY(K)-SQRTIV) 
SUMF-SUMF-V 
DO 320 ISEC-2.MAXSEG 
DO 310 IMED-2,MAXMED K-KTl
IFdMED.EQ.2) V-V-XXSAVE (K) «FACT2 
IF(IMED.EQ.3) V-V-XXSAVE(K) TACT3 
IF(V.LT.O) V-0 
YY (K) «SORT (V)
SUMF-SUMF-V 
310 CONTINUE
320 CONTINUE 
330 CONTINUE
SQSUM-SQRT(SUMF)
DO 400 I — 1,KMAX
YY(I)-YY(I)/SQSUM 
400 CONTINUE
FACTOR-SUMF
RETURN
END
:p t :2«50 
OPTO2660 
OPT0267J 
OPTC268G 
OPTO 2 6 90 
OPT02-33
opto 2 no
OPT02-29 
OPT02,30 
OPT02T40 
OPT02-50 
OPT02'*6C 
OPT027T0 
OPT02780 
OPT02-»90 
OPT02800 
, OPT02810
. OPTO2820 
GPT02830 
OPTC2840 
OPT02850 
OPTO2860 
OPT02870 
OPT02880 
OPTO 2 8 90 
OPT02 900 
OPT02910 
OPT02920 
OPT02930 
OPTO2940 
OPT02950 
OPTO2960 
OPT02970 
OPTO2980 
OPTO2990 
OPTO3000 
OPTO3010 
OPTO 3020 
OPTO3030 
OPT03040 
OPT03050 
OPTO3060 
OPT03070 
OPTO 3080 
OPTO3090 
OPTO3100 
OPTO 3110 
OPTO3l20 
OPTO3l30 
OPTO3140 
OPTO3150 
OPTO3160 
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SUBROUTINE AECOMV (XX. TYI
CCfBKON /MYCATA/ 3M(5). S I U lS .i t .  3 H l5 .il . 3MPSlS.il, SNGWi5.il. 
RMC ! UH ( 5 , 4, 31 . ALP MAC (5 ,6 ,3 1 . ALPHA1 (S. 4. 3) . ALPHA2 < 5. 4. J). 
RA IS. 4, 31 . SMPSMiS.4. 3).
MAXPRD. MAXSEG. MAXMEC
:S(*ION / BS7C0M/ FACTOR. FACT1, FACT2. FACTS. XXSAVE (45> . KMAX 
BEAL XXI•I . YY I •>
SUM-0.0
30 100 I - i  . KMAX
x x i i i - y y i d  *y y i :>
SUM-SUM-XX ( X )
CONTINUE
K-0
DO 310 IPRGC-i. MAXPRD 
K-K-l
XX IK)-XX (K)/ SUM*FACTOR-XXSAVE(K>*FACT1 
DO 3C0 : SEG-2, MAXSES 
DO 3X0 IMED-2. MAXMED 
K-K-l
XX (K) -XX(K)/ SUM*FACTOR
IF IIMED.EC■2) XX(K)-XX IK)-XXSAVE IK)*FACT2 
IFlIMED.EQ.3) XX(K)-XX IK)-XXSAVEIK)*FACT3 
310 CONTINUE
320 CONTINUE 
330 CONTINUE 
RETURN 
ENO
SUBROUTINE WRITXXIXX)
COMION /MYDATA/ GM(5), SIZEIS.i), SHIS.4 ). SMPSI5.4). SNOM(S.i),
• RMDIUM(5, 4.3), ALPHAO IS. 4. 3) . ALPHA1 IS. 4. 3) . ALPHA2 15,4. 3),
• RAIS.4 .3 ) .  SMPSM(5,4,3>,
-  MAXPRD.MAXSES. MAXMED
INTEGER MAXPRO,MAXSEG.MAXMED.P.S. I . K 
REAL X X (* ) ,X (S ,4 ,3 ) , TOTEXP 
TOTEXP-O.0 
K-0
00 130 P-1,MAXPRO 
K-K-l
X (P .l.ll-X X IK )
TOTEXP-TOTEXP-XXIK)
DO 10S 1—2. MAXMED 
XIP. 1. I) -0 .0  
105 CONTINUE
DO 120 S -2 . MAXSEG 
00 110 1 -2 ,MAXMED 
K-K-l
XIP.8 . Z)-XX IK)
XIP. 1 . I)-X IP , 1,1) -XXIK)
TOTEXP-TOTEXP-XXIK)
110 CONTINUE
120 CONTINUE
130 CONTINUE
WRITE(20,500) TOTEXP 
DO 230 P-1. MAXPRO 
WRITE(20.1000) P 
WRITE (20, 2000) 1. XIP. i . l l  
DO 220 1—2 . MAXMEC
WRITE(2 0 .2 0 0 0  I . (X(P ,S .I ) . S - l . MAXSEG)
220 CONTINUE
230 CONTINUE 
RETURN
500 FCnMATI' TOTAL EXPENDITURE '.F 1 2 .it  
1000 FORMAT!' PROOUCT ',131  
2000 FORMAT!' ’ .I3 .6 F 1 2.4 )
ENO
;?c:33;: 
OPT03320 
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0PT033Î0 
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OPTO3840 
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OPT0388C 
OPTO 3890 
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